Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 711
Healthy volunteers: no

Brief summary:
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: semaglutide intervention 2: liraglutide intervention 3: placebo
Intervention descriptions: intervention 1: Oral semaglutide once-daily. intervention 2: Subcutaneous (s.c.) injection once-daily. intervention 3: Placebo once-daily.

Protocol document:
Prot_000.pdf: 
Cover Page for Protocol 
 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT02863419 
Sponsor trial ID: 
NN9924-4224 
Official title of study: 
PIONEER 4 – vs. GLP-1 RA 
Efficacy and safety of oral semaglutide versus liraglutide and 
versus placebo in subjects with type 2 diabetes mellitus 
A 52-week randomised, double-blind, active- and placebo- 
controlled trial 
Document date: 
29 October 2018 
 


Link
Link
List of contents
Protocol ...............................................................................................................................................
Protocol amendment 1 .......................................................................................................................
CONFIDENTIAL
Date:
Novo Nordisk
Version:
Status:
Semaglutide
Trial ID: NN9924-4224
Clinical Trial Report
Appendix 16.1.1
29 October 2018
1.0
Final
16.1.1 Protocol and protocol amendments
CONFIDENTIAL
Redacted protocol 
Lncludes redaction of personal identifiable DQGFRPSDQ\
FRQILGHQWLDOinformation. 
. 


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
1 of 132
Protocol
Trial ID: NN9924-4224
PIONEER 4 – vs. GLP-1 RA
Efficacy and Safety of Oral Semaglutide versus Liraglutide 
and versus Placebo in Subjects with Type 2 Diabetes Mellitus
A 52-week randomised, double-blind, active- and placebo-controlled trial
Trial phase: 3a
Protocol originator
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
2 of 132
Table of Contents
Page
Table of Contents..............................................................................................................................................2
Table of Figures................................................................................................................................................7
Table of Tables..................................................................................................................................................7
List of abbreviations.........................................................................................................................................8
1
Summary..................................................................................................................................................11
Primary objective.........................................................................................................................11
Secondary objectives ...................................................................................................................11
Primary endpoint..........................................................................................................................11
Key secondary endpoints...........................................................................................11
2
Flow chart ................................................................................................................................................15
3
Background information and rationale for the trial............................................................................22
3.1
Background information..............................................................................................................22
3.1.1
Type 2 diabetes mellitus ............................................................................................22
3.1.2
Glucagon-like peptide-1 ............................................................................................22
3.1.3
Oral semaglutide........................................................................................................22
3.1.4
Nonclinical data.........................................................................................................23
3.1.4.1
Semaglutide.........................................................................................23
3.1.4.2
SNAC ..................................................................................................24
3.1.5
Clinical data for oral semaglutide..............................................................................25
3.1.5.1
Pharmacokinetics ................................................................................25
3.1.5.2
Efficacy ...............................................................................................26
3.1.5.3
Safety...................................................................................................26
3.1.6
Liraglutide..................................................................................................................27
3.2
Rationale for the trial...................................................................................................................27
4
Objectives and endpoints........................................................................................................................28
4.1
Objectives ....................................................................................................................................28
4.1.1
Primary objective.......................................................................................................28
4.1.2
Secondary objectives .................................................................................................28
4.2
Endpoints .....................................................................................................................................28
4.2.1
Primary endpoint........................................................................................................28
4.2.2
Secondary endpoints..................................................................................................28
4.2.2.1
Confirmatory secondary endpoints .....................................................28
4.2.2.2
Supportive secondary endpoints..........................................................28
5
Trial design ..............................................................................................................................................31
5.1
Type of trial .................................................................................................................................31
5.2
Rationale for trial design..............................................................................................................31
5.3
Treatment of subjects...................................................................................................................33
5.3.1
Dosing instructions ....................................................................................................35
5.3.2
Background medication.............................................................................................35
5.4
Treatment after discontinuation of trial product ..........................................................................35
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
3 of 132
5.5
Rationale for treatment ................................................................................................................36
6
Trial population.......................................................................................................................................37
6.1
Number of subjects......................................................................................................................37
6.2
Inclusion criteria ..........................................................................................................................37
6.3
Exclusion criteria.........................................................................................................................37
6.4
Rescue criteria..............................................................................................................................38
6.5
Criteria for premature discontinuation of trial product................................................................39
6.6
Withdrawal from trial ..................................................................................................................39
6.7
Subject replacement.....................................................................................................................39
6.8
Rationale for trial population.......................................................................................................39
7
Milestones.................................................................................................................................................41
8
Methods and assessments .......................................................................................................................42
8.1
Visit procedures...........................................................................................................................42
8.1.1
Screening, visit 1........................................................................................................42
8.1.2
Fasting visits ..............................................................................................................43
8.1.3
Randomisation and trial product administration........................................................43
8.1.4
Phone contacts ...........................................................................................................44
8.1.5
End-of-treatment (visit 13) and Follow-up (visit 14).................................................44
8.1.6
Premature discontinuation of trial product and Follow-up (visits 13A and 14A)......44
8.1.7
Withdrawals...............................................................................................................45
8.1.8
Investigator assessments............................................................................................45
8.2
Subject related information/assessments .....................................................................................46
8.2.1
Demography...............................................................................................................46
8.2.2
Diabetes history and diabetes complications .............................................................46
8.2.3
Concomitant illness and medical history...................................................................46
8.2.4
Concomitant medication............................................................................................47
8.2.5
Childbearing potential................................................................................................48
8.2.6
Tobacco use ...............................................................................................................48
8.3
Efficacy assessments....................................................................................................................48
8.3.1
Laboratory assessments for efficacy..........................................................................48
8.3.1.1
Fasting plasma glucose........................................................................49
8.3.2
Self-measured plasma glucose...................................................................................49
8.3.3
Body weight and height .............................................................................................50
8.3.4
Waist circumference ..................................................................................................50
8.3.5
Patient reported outcomes questionnaires..................................................................51
8.4
Safety assessments.......................................................................................................................51
8.4.1
Adverse events...........................................................................................................51
8.4.1.1
Medication error..................................................................................51
8.4.1.2
Adverse events requiring additional data collection ...........................52
8.4.2
Physical examination.................................................................................................53
8.4.3
Vital signs ..................................................................................................................53
8.4.4
Eye examination ........................................................................................................53
8.4.5
Electrocardiogram (12-lead)......................................................................................54
8.4.6
Laboratory assessments for safety .............................................................................55
8.4.7
Pregnancy testing.......................................................................................................56
8.4.8
Anti-semaglutide antibodies ......................................................................................56
8.4.9
Hypoglycaemic episodes ...........................................................................................56
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
4 of 132
8.5
Laboratory assessments ...............................................................................................................59
8.6
Other assessments........................................................................................................................60
8.6.1
Subject diary ..............................................................................................................60
8.6.2
Training in the injection pen......................................................................................60
8.7
Subject compliance......................................................................................................................60
9
Trial supplies ...........................................................................................................................................62
9.1
Trial products...............................................................................................................................62
9.2
Labelling......................................................................................................................................63
9.3
Storage .........................................................................................................................................64
9.4
Drug accountability and destruction............................................................................................65
9.5
Auxiliary supplies........................................................................................................................65
10 Interactive voice/web response system ..................................................................................................66
11 Randomisation procedure and breaking of blinded codes..................................................................67
11.1
Breaking of blinded codes ...........................................................................................................67
12 Adverse events, technical complaints and pregnancies .......................................................................68
12.1
Definitions ...................................................................................................................................68
12.1.1
Adverse event ............................................................................................................68
12.1.2
Serious adverse event.................................................................................................69
12.1.3
Non-serious adverse event.........................................................................................70
12.1.4
Medication errors.......................................................................................................71
12.1.5
Adverse events requiring additional data collection..................................................71
12.1.6
Technical complaints.................................................................................................72
12.2
Reporting of adverse events.........................................................................................................73
12.3
Follow-up of adverse events........................................................................................................76
12.4
Technical complaints and technical complaint samples ..............................................................77
12.4.1
Reporting of technical complaints .............................................................................77
12.4.2
Collection, storage and shipment of technical complaint samples ............................77
12.5
Pregnancies in female subjects ....................................................................................................78
12.5.1
Pregnancies in female subjects ..................................................................................78
12.6
Precautions and/or overdose ........................................................................................................79
12.7
Committees related to safety........................................................................................................80
12.7.1
Novo Nordisk safety committee ................................................................................80
12.7.2
Event adjudication committee....................................................................................80
13 Case report forms....................................................................................................................................85
13.1
Corrections to case report forms..................................................................................................85
13.2
Case report form flow..................................................................................................................85
14 Monitoring procedures ...........................................................................................................................87
15 Data management....................................................................................................................................89
16 Computerised systems.............................................................................................................................90
17 Statistical considerations ........................................................................................................................91
17.1
Sample size calculation................................................................................................................93
17.2
Definition of analysis sets............................................................................................................96
17.3
Primary endpoint..........................................................................................................................99
17.3.1
Primary analysis for the primary estimand ................................................................99
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
5 of 132
17.3.2
Primary analysis for the secondary estimand...........................................................100
17.3.3
Sensitivity analyses..................................................................................................101
17.3.3.1
Pattern mixture models......................................................................102
17.3.3.2
Other sensitivity analyses..................................................................103
17.3.3.3
Assessment of sensitivity analyses....................................................103
17.4
Secondary endpoints..................................................................................................................103
17.4.1
Confirmatory secondary endpoints..........................................................................103
17.4.2
Supportive secondary endpoints ..............................................................................104
17.4.2.1
Efficacy endpoints.............................................................................104
17.4.2.2
Continuous efficacy endpoints..........................................................104
17.4.2.3
Safety endpoints................................................................................106
17.5
Interim analysis........................................................................................................................110
17.6
Health economics and/or patient reported outcomes (PROs) ....................................................111
18 Ethics......................................................................................................................................................112
18.1
Benefit-risk assessment of the trial............................................................................................112
18.1.1
Risks and precautions ..............................................................................................112
18.1.1.1
Liraglutide.........................................................................................114
18.1.1.2
Placebo ..............................................................................................114
18.1.2
Benefits....................................................................................................................115
18.1.3
Risk and benefit conclusion.....................................................................................115
18.2
Informed consent .......................................................................................................................115
18.3
Data handling.............................................................................................................................116
18.4
Information to subjects during trial............................................................................................116
18.5
Premature termination of the trial and/or trial site.....................................................................116
19 Protocol compliance..............................................................................................................................118
19.1
Protocol deviations ....................................................................................................................118
19.2
Prevention of missing data.........................................................................................................118
20 Audits and inspections ..........................................................................................................................119
21 Critical documents ................................................................................................................................120
22 Responsibilities......................................................................................................................................122
23 Reports and publications......................................................................................................................123
23.1
Communication of results..........................................................................................................123
23.1.1
Authorship ...............................................................................................................124
23.1.2
Site-specific publication(s) by investigator(s) .........................................................124
23.2
Investigator access to data and review of results.......................................................................124
24 Retention of clinical trial documentation and human biosamples....................................................125
24.1
Retention of clinical trial documentation...................................................................................125
24.2
Retention of human biosamples.................................................................................................125
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............127
26 Indemnity statement .............................................................................................................................128
27 References..............................................................................................................................................129
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
6 of 132
Attachment I – Global list of key staff and relevant departments and suppliers
Attachment II – Country list of key staff and relevant departments
Appendix A – Monitoring of Calcitonin
Appendix B – Adverse events requiring additional data collection
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
7 of 132
Table of Figures
Page
Figure 5–1
Trial design.............................................................................................................................31
Figure 12–1
Reporting of AEs....................................................................................................................75
Figure 17–1
Graphical illustration of the closed testing procedure ............................................................96
Figure 17–2 
ADA classification of hypoglycaemia..................................................................................110
Table of Tables
Page
Table 5–1
Treatment of subjects..............................................................................................................34
Table 9–1
Investigational medicinal products.........................................................................................62
Table 9–2
Storage conditions for investigational medicinal products.....................................................64
Table 12–1
Adverse events requiring completion of specific event forms and/or are subject to event 
adjudication ............................................................................................................................72
Table 12–2
Adverse events for adjudication .............................................................................................82
Table 17–1
Assumptions used in the sample size calculation...................................................................95
Table 17–2
Calculated powers for individual hypotheses.........................................................................95
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
8 of 132
List of abbreviations
AACE
American Association of Clinical Endocrinologists
ADA
American Diabetes Association
AE
adverse event
ALP
Alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
Analysis of covariance
AST
aspartate aminotransferase
AUC
Area under the curve
BG
blood glucose
BG meter
blood glucose meter
BMI
body mass index
CLAE
clinical laboratory adverse event
CK
creatine kinase
CKD-EPI
Chronic Kidney Disease Epidemiology collaboration
CRF
case report form
CRO
contract research organisation
CVD
cardiovascular disease
DFU
direction for use
DPP-4
dipeptidyl peptidase-4
DTSQ
diabetes treatment satisfaction questionnaire
DUN
dispensing unit number
EAC
event adjudication committee
ECG
electrocardiogram
eCRF
electronic case report form
EDC
electronic data capture
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EOT
end of treatment
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
9 of 132
FAS
full analysis set
FDA
U.S. Food and Drug Administration
FDAAA
U.S. Food and Drug Administration Amendment Act
FPG
fasting plasma glucose
FSFV
first subject first visit
GCP
Good Clinical Practice
GLP-1
glucagon-like peptide-1
GLP-1 RA
glucagon-like peptide-1 receptor agonist
HbA1c
glycosylated haemoglobin
HDL
high density lipoprotein
HOMA-B
homeostatic model assessment index of beta-cell 
function
HOMA-IR
homeostatic model assessment index of insulin 
resistance
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation
ICMJE
International Committee of Medical Journal Editors
IEC
independent ethics committee
IMP
investigational medicinal product
IRB
institutional review board
IWRS
interactive web response system
LDL
low density lipoprotein
LLoQ
lower limit of quantification 
LSFV
last subject first visit
LSLV
last subject last visit
MAR
missing at random
MedDRA
Medical Dictionary for Regulatory Activities
MEN 2
Multiple Endocrine Neoplasia Type 2
MI
myocardial infarction
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
10 of 132
MTC
Medullary Thyroid Carcinoma
NIMP
non-investigational medicinal product
NYHA
New York Heart Association
OAD
oral antidiabetic drug
PG
plasma glucose
PK
pharmacokinetics
PP
per protocol
PRO
patient reported outcome
SAE
serious adverse event
SAP
statistical analysis plan
s.c.
subcutaneous(ly)
SGLT-2
sodium-glucose co-transporter-2
SIF
safety information form
SMPG
self-measured plasma glucose
SmPC
summary of product characteristics
SNAC
sodium N-[8-(2-hydroxybenzoyl) amino] caprylate
STEMI
ST-elevation acute myocardial infarction
SUSAR
suspected unexpected serious adverse reaction
T2DM
type 2 diabetes mellitus
TEAE
treatment-emergent adverse events
TIA
transient ischaemic attack
TMM
Trial Materials Manual
UNL
Upper Normal Limit
UTN
Universal Trial Number
VLDL
very low density lipoprotein
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
11 of 132
1
Summary
Objective(s) and endpoint(s):
Primary objective
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on glycaemic control in subjects with type 2 diabetes mellitus (T2DM).
Secondary objectives
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on body weight in subjects with T2DM.
To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus 1.8 
mg liraglutide subcutaneous and versus placebo, all in combination with metformin with or without 
a SGLT-2 inhibitor, in subjects with T2DM.
Primary endpoint
Change from baseline to week 26 in HbA1c
Key secondary endpoints
Change from baseline to week 52 in HbA1c
Change from baseline to week 26 and week 52 in:
!
Body weight (kg)
!
Fasting plasma glucose
If a subject after week 26 and week 52 achieves (yes/no):
!
HbA1c < 7.0 % (53 mmol/mol) American Diabetes Association target
Number of treatment-emergent adverse events during exposure to trial product, assessed up to 
approximately 57 weeks.
Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic 
episodes during exposure to trial product, assessed up to approximately 57 weeks.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
12 of 132
Trial design:
This is a 52-week, randomised, double-blind, double-dummy, active- and placebo-controlled, 
parallel-group, multicentre, multinational trial with 3 arms comparing the efficacy and safety of 
once-daily dosing of oral semaglutide vs. liraglutide and vs. placebo in subjects with T2DM.
Subjects will be randomised in a 2:2:1 manner to receive one of the following treatments:
!
14 mg oral semaglutide once-daily
!
1.8 mg liraglutide subcutaneous (s.c.) injection once-daily
!
placebo once-daily 
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks. 
Trial population:
Number of subjects planned to be randomised: 690
Inclusion criteria:
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 90 days prior to day of screening.
4. HbA1c of 7.0–9.5 % (53–80.3 mmol/mol) (both inclusive).
5. Stable daily dose of metformin (≥1500 mg or maximum tolerated dose as documented in the 
subject medical record) alone or in combination with a stable daily dose of a SGLT-2 inhibitor 
for at least 90 days prior to day of screening (fixed-dose combinations are allowed).
Key exclusion criteria:
1. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by local regulation or practice). 
For certain specific countries: Additional specific requirements apply
2. Any disorder, which in the investigator’s opinion might jeopardise subject’s safety or 
compliance with the protocol.
3. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).
4. History of pancreatitis (acute or chronic).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
13 of 132
5. History of major surgical procedures involving the stomach and potentially affecting 
absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric 
bypass surgery).
6. Any of the following: myocardial infarction (MI), stroke or hospitalisation for unstable 
angina or transient ischaemic attack within the past 180 days prior to the day of screening. 
7. Subjects presently classified as being in New York Heart Association (NYHA) Class IV.
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening.
9. Subjects with ALT > 2.5 × upper normal limit (UNL).
10. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) < 60 
mL/min/1.73 m2 as per Chronic Kidney Disease Epidemiology Collaboration formula 
(CKD-EPI).
11. Treatment with any medication for the indication of diabetes or obesity other than stated in 
the inclusion criteria in a period of 90 days before the day of screening. An exception is 
short-term insulin treatment for acute illness for a total of ≤14 days.
12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus 
photography or dilated fundoscopy performed within 90 days prior to randomisation.
13. History or presence of malignant neoplasms within the last 5 years (except basal and 
squamous cell skin cancer and carcinoma in situ).
14. History of diabetic ketoacidosis.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
14 of 132
Key assessments:
Efficacy
!
HbA1c
!
FPG
!
Body weight
Safety
!
Adverse events
!
Hypoglycaemic episodes
Trial products:
Investigational medicinal products:
Test products:
!
Semaglutide 3 mg, 7 mg and 14 mg, tablets
!
Semaglutide placebo, 0 mg, tablets
Reference therapies:
!
Liraglutide, 0.6 mg (0.1 mL), 1.2 mg (0.2 mL), 1.8 mg (0.3 mL), solution for injections 
(strength: 6.0 mg/mL, pen-injector) 
!
Liraglutide placebo, 0.1 mL, 0.2 mL, 0.3 mL, solution for injections (strength: 0.0 mg/mL, pen-
injector)
The subject’s de facto cost of SGLT-2 inhibitor and metformin (mono- or fixed-dose combination 
products) will be reimbursed in accordance with local legislation and Ethics Committee approval.
CONFIDENTIAL


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
15 of 132
2
Flow chart
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
SUBJECT RELATED
INFO/ASSESSMENTS
Informed consent
x
In/exclusion criteria
x
x
Concomitant medication
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Demography
x
Tobacco use
x
Concomitant illness and Medical 
x


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
16 of 132
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
history
Diagnosis of diabetes/diabetes 
complications
x
History of cardiovascular disease 
x
History of gallbladder disease
x
History of gastrointestinal disease
x
Randomisation
x
Criteria for premature 
discontinuation of trial product
x
x
x
x
x
x
x
x
x
x


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
17 of 132
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
EFFICACY
HbA1c
x
x
x
x
x
x
x
x
x
x
x
x
Fasting plasma glucose
xi
x
x
x
x
x
x
x
x
Lipids
x
x
x
x
x
Height
x
Body weight
x
x
x
x
x
x
x
x
x
x
x
Waist circumference
x
x
x
x
x
x
7-point profile
x
x
x
x


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
18 of 132
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
PRO questionnaire
x
x
x
x
SAFETY
Eye examination
xd
Physical examination
x
x
x
ECG
x
x
x
x
x
x
Vital signs
x
x
x
x
x
x
x
x
x
x
x
x
x
Pregnancy test
xe
x
x
x
x
x
x
x
x
x
x
x
x
x
Calcitonin
x
x
x
x
x
x
x
x
Biochemistry
xf
x
x
x
x
x
x
x
x
x
x


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
19 of 132
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
Haematology
x
x
x
x
x
x
x
x
x
x
Antibodies
xg
x
x
x
x
x
x
x
x
x
Adverse events
xh   
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Hypoglycaemic episodes
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Technical complaints
x
x
x
x
x
x
x
x
x
x
x
x
TRIAL MATERIAL
IWRS call
x
x
x
x
x
x
x
x
x
x
x
x
Drug accountability
x
x
x
x
x
x
x
x
x
x
x
Dispensing visit
x
x
x
x
x
x
x
x
x


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
20 of 132
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
REMINDERS
Dispense and/or collect diary
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Attend visit fasting
xi
x
x
x
x
x
x
x
x
Handout and instruct in BG meter 
use
x
Handout ID card
x
Training in trial products, dosing 
instructions and pen handling
xj
x
x
x
x
x
x
x
x
x
x


Protocol
UTN: U1111-1176-6029 
Date:
02 March 2016
Status:
Final
Novo Nordisk
Trial ID: NN9924-4224
EudraCT no.: 2015-005210-30
Version:
1.0
Page:
21 of 132
Footer
Description
xa
Subject can be randomised as soon as all inclusion and exclusion criteria are confirmed. The screening assessment must not exceed 2 
weeks prior to randomisation (V2).
xb
Subjects, who have discontinued trial product prematurely, are not required to attend V14 (Follow-up).
xc
V13A and V14A are only applicable for subjects who have discontinued trial product prematurely
xd
Dilated fundoscopy/fundus photography performed within 90 days prior to randomisation is acceptable if results are available for
evaluation at V2, unless worsening of visual function since last examination.
xe
For women of child-bearing potential: Urine pregnancy test should also be performed at any time during the trial if a menstrual period 
is missed, and/or according to local regulations/law.
xf
At V1, only ALT, creatinine and eGFR will be assessed as part of Biochemistry.
xg
At randomisation, the antibody sampling must be done pre-dose. No antibody sampling should be done for visits occurring after V14A 
(subjects who have discontinued trial product prematurely).
xh
Adverse events reporting includes adverse events from the first trial-related activity after the subject has signed the informed consent at
V1, however, pre-existing conditions identified as a result of the screening procedures should be reported as medical history.
xi
Fasting for blood sampling is defined as no food or liquid within the last 8 hours prior to blood sampling, however, water is allowed up 
until 2 hours prior to blood sampling. Trial product must be taken after blood sampling. Other oral medication can be taken 30 minutes 
after trial product. Injectable medications can be administered after blood sampling.
xj
The investigator must document that direction for use is given to the subject verbally and in writing at the first dispensing visit (V2) 
and at subsequent visits when judged necessary by the investigator. The subjects must be trained in how to handle the injection pen 
when handed out the first time and training must be repeated at regular intervals. The investigator must document that subjects are 
instructed in the dosing requirements at every dispensing visit.


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
22 of 132
3
Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP)1 and applicable regulatory requirements, and in 
accordance with the Declaration of Helsinki2.
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1
Background information
3.1.1
Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is a progressive, metabolic disease primarily characterised by 
abnormal glucose metabolism. The pathogenesis is heterogeneous involving environmental, 
lifestyle and genetic factors leading to chronic hyperglycaemia caused by peripheral tissue insulin 
resistance, impaired insulin secretion due to abnormal beta-cell function and abnormal glucose 
metabolism in the liver3.
Optimal glycaemic control is the treatment goal in subjects with T2DM in order to prevent long-
term complications associated with chronic hyperglycaemia4. Despite the availability of several 
anti-diabetic drugs, a significant proportion of subjects with T2DM do not achieve the 
recommended targets for glycaemic control5,6.
3.1.2
Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone with a glucose-dependent stimulatory 
effect on insulin and inhibitory effect on glucagon secretion from the pancreatic islets7,8. Subjects 
with T2DM have a decreased incretin effect9-12. However, the insulinotropic action of GLP-1 and 
thus, the ability to lower BG levels, is preserved when GLP-1 is administered at supraphysiological 
levels13. In addition, supraphysiological levels of GLP-1 induce reduction in body weight14. GLP-1 
is a physiological regulator of appetite and food intake and GLP-1 receptors are present in several 
areas of the brain involved in appetite regulation15,16. Physiologically, GLP-1 also has a pronounced 
inhibitory effect on gastric emptying; however this effect seems to diminish upon chronic 
exposure14-16. These mechanisms of action make glucagon-like peptide-1 receptor agonists (GLP-1
RAs) an attractive pharmacological treatment for T2DM17-19.
3.1.3
Oral semaglutide  
Semaglutide is a long-acting GLP-1 RA structurally similar to liraglutide (Victoza®), a once-daily 
GLP-1 RA developed by Novo Nordisk and approved worldwide for the treatment of T2DM. 
Compared to human native GLP-1, which has a short half-life, the semaglutide molecule has three 
minor but important modifications ensuring protraction of its action: amino acid substitutions at 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
23 of 132
position 8 (alanine to alpha-aminoisobutyric acid, a synthetic amino acid) and position 34 (lysine to 
arginine) and acylation of the peptide backbone with a spacer and C-18 fatty di-acid chain to lysine 
in position 2620. The fatty di-acid side chain and the spacer mediate strong binding to albumin, 
thereby reducing renal clearance. The amino acid substitution at position 8 makes semaglutide less 
susceptible to degradation by dipeptidyl peptidase-4 (DPP-4). The change in position 34 from a 
lysine to an arginine is included to have only one lysine in the sequence whereto a spacer can be 
attached.
Semaglutide is in development for oral once-daily treatment of T2DM. As the bioavailability of 
GLP-1 RAs is low when administered orally, semaglutide has been co-formulated with the 
absorption-enhancing excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) to 
increase the bioavailability of semaglutide. The absorption-enhancing properties of SNAC co-
formulation are based on the 
 concept developed by 
SNAC facilitates the absorption of semaglutide in a strictly time- and size-dependent manner, 
primarily via the transcellular route. The available data for semaglutide co-formulated with SNAC 
support that the absorption takes place in the stomach in a localised, buffered environment in close 
proximity to the tablet erosion. The absorption process is hampered if dosed with food, liquid or in 
the presence of significant stomach content. 
The absorption enhancement requires co-formulation between semaglutide and SNAC. Throughout 
this document “oral semaglutide” will refer to the drug product, that is, semaglutide co-formulated 
with 300 mg SNAC. 
3.1.4
Nonclinical data
3.1.4.1
Semaglutide
The nonclinical programme for semaglutide was designed according to the ICH M3 guideline to 
support the clinical development21. The standard nonclinical data package required to support phase 
3 clinical trials has been completed. In addition, 2-year carcinogenicity studies and a pre- and 
postnatal development toxicity study have been completed. Semaglutide was generally well 
tolerated in animals (mice, rats and cynomolgus monkeys). Two potential safety issues have been 
identified and these are detailed below.
Thyroid C-cell tumours in rodents
Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were 
observed in 2-year carcinogenicity studies with semaglutide; thyroid hyperplasia was preceded by 
an increase in serum calcitonin. C-cell changes have not been observed in long-term studies in non-
human primate. The observed pattern of effects in mice and rats and lack of these effects in the non-
human primate and in man suggest that the mechanism by which semaglutide acts on the thyroid C-
cells in rodents is the same as has been demonstrated for other GLP-1 RAs, including liraglutide. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
24 of 132
According to this mechanism, C-cell hyperplasia is mediated by the GLP-1 receptor and is not 
associated with RET (re-arranged during transfection) gene activation and rodents appear to be 
particularly sensitive, whereas humans are not. The relevance for human subjects is currently 
unknown, but considered to be low22.
Embryo−foetal development toxicity
Semaglutide caused embryo-foetal development toxicity in the rat through a GLP-1 receptor 
mediated effect on the inverted yolk sac placenta leading to impaired nutrient supply to the 
developing embryo. Primates do not have an inverted yolk sac placenta which makes this 
mechanism unlikely to be of relevance to humans and cynomolgus monkeys. In the developmental 
toxicity studies in cynomolgus monkey, a marked maternal body weight loss associated with the 
pharmacological effect of semaglutide coincided with increased early foetal loss; however, there 
was no indication of a teratogenic potential of semaglutide in this species.
A review of the results from the nonclinical studies can be found in the investigator’s brochure (IB) 
for semaglutide (subcutaneous administration), edition 1023 and the IB for oral administration of 
semaglutide (NN9924), edition 624, or any updates of these documents.
3.1.4.2
SNAC
SNAC was developed as an absorption-enhancing excipient for the oral route of administration. The 
nonclinical programme to support clinical phase 3 development and marketing authorisation 
application submission has been conducted including a 26-week carcinogenicity study in transgenic 
rasH2 mice and a 2-year carcinogenicity study in Sprague-Dawley rats.
 
 
 
 
 
Measurements of lactate levels have 
been included at selected time points around peak concentrations of SNAC in two of the phase 3a 
trials in the PIONEER programme (PIONEER 1 and 2) with the intention to document that SNAC 
does not impair cellular respiration in humans. In addition, events of lactic acidosis must be 
reported as an AE requiring additional data collection, please refer to Section 8.4.1.2, Section 12.1.5
and appendix B.   
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
25 of 132
The carcinogenicity studies demonstrated that SNAC was not carcinogenic to the transgenic rasH2 
mouse or the Sprague-Dawley rat. The doses tested covered total exposures of SNAC in plasma (in 
terms of AUC) of 2-fold in the mouse and up to 44-fold in the rat when compared to the mean total
exposure of SNAC in humans following a clinical dose of 300 mg SNAC/day.
A review of the SNAC results from the nonclinical studies can be found in the Investigator’s 
Brochure (IB) for oral administration of semaglutide (NN9924), edition 624, or any updates hereof.
3.1.5
Clinical data for oral semaglutide
A comprehensive clinical pharmacology programme including 12 trials has been completed, as well 
as a 26-week phase 2 dose-finding trial involving more than 600 subjects with T2DM.
For details on the individual trials, please see the IB for oral administration of semaglutide 
(NN9924) edition 624, or any updates hereof.
3.1.5.1
Pharmacokinetics
In the multiple-dose trial (NN9924-3991), oral semaglutide has demonstrated a long mean terminal 
half-life (t½) ranging from 153 to 161 hours (~1 week) and a median time to reach maximum 
observed concentration (tmax) ranging from 1 to 2 hours in healthy subjects.
In multiple-dose pharmacokinetics (PK) trials, the exposure to oral semaglutide increased with 
increasing dose. Overall, the pharmacokinetic properties of semaglutide appeared similar in healthy 
subjects and in subjects with T2DM.
Exposure to semaglutide exhibits a substantially greater dose-to-dose variation following oral 
administration compared to subcutaneous (s.c.) administration. However, when administered orally 
once-daily the PK properties of semaglutide, i.e. low clearance and long half-life, will limit the 
variation in exposure at steady state.
Data obtained following investigation of different dosing conditions for oral semaglutide have 
demonstrated that subjects should take the oral semaglutide tablet in the morning in a fasting state 
and at least 30 minutes before the first meal of the day. 
 
 
 
 
 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
26 of 132
 
 
 
In subjects with mild to severe hepatic impairment, the exposure to semaglutide appeared to be 
unaffected by the degree of hepatic impairment, whereas the exposure to SNAC (in terms of both 
AUC and Cmax) was increased for subjects with hepatic impairment as compared to subjects with 
normal hepatic function.
All tablets of oral semaglutide contain 300 mg of SNAC regardless of the semaglutide dose. SNAC 
is rapidly absorbed with a median tmax ranging from 0.35−0.5 hours in healthy subjects and from 
0.52−1.43 hours in subjects with T2DM. It is extensively metabolised and no accumulation of 
SNAC has been observed in clinical trials.
3.1.5.2
Efficacy
The efficacy of oral semaglutide in adult subjects with T2DM was investigated in a 26-week phase 
2 dose-finding trial (NN9924-3790). In this trial, placebo or one of the following doses of oral 
semaglutide were administered once daily: 2.5, 5, 10, 20 and 40 mg.
Results from the trial showed that oral semaglutide effectively lowered glycosylated haemoglobin 
(HbA1c) and body weight. Placebo-adjusted reductions in HbA1c were dose-dependent and clinically 
relevant for all oral semaglutide treatment arms at week 26 (range: −0.40 % to −1.59 %). Placebo-
adjusted reductions in body weight were dose-dependent and statistically significant for oral 
semaglutide treatment doses of 10 mg and above at week 26 (range: −3.61 kg to −6.98 kg).
3.1.5.3
Safety
In the clinical trials completed so far, no unexpected safety findings have been identified for oral 
semaglutide administered up to 40 mg once daily. Consistent with other GLP-1 RAs, commonly 
reported adverse events (AEs) included nausea and vomiting, most of which were mild to moderate 
in severity. In line with findings for other GLP-1 RAs, an increase in heart rate and serum levels of 
lipase and amylase has also been observed in subjects exposed to oral semaglutide.
In addition to the 13 completed clinical trials with oral semaglutide, SNAC has been investigated in 
the programme of orally administrated heparin in combination with SNAC (heparin/SNAC). The 
heparin/SNAC programme 
 included 29 phase 1 trials (SNAC doses 
ranged from 0.172–10.5 g). In three of these trials, SNAC alone was investigated (to a maximum 
dose of 10.5 g). The trials covered formulation development, food effect, hepatic and renal 
impairment, age effect and drug-drug interaction. The programme also included a total of three 
phase 2 and 3 trials in which the effects of orally delivered heparin solution (with >1.5 g SNAC 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
27 of 132
three times a day) was investigated. The overall safety profile of oral semaglutide and 
heparin/SNAC indicates that SNAC is safe and well-tolerated. 
For further details, please see the IB for oral administration of semaglutide (NN9924) edition 624, or 
any updates hereof.
3.1.6
Liraglutide
The selected active comparator in this trial is liraglutide, an injectable GLP-1 RA approved for 
once-daily administration. Liraglutide was developed by Novo Nordisk and approved in 2009 in the 
EU, in 2010 in Japan, and in 2010 in the US under the trade name Victoza® to improve glycaemic 
control in adults with T2DM.
For further details, please see the current approved label for Victoza®25,26.
For an assessment of benefits and risks of the trial, see Section 18.1.
3.2
Rationale for the trial
Many patients with T2DM are not in glycaemic control with the currently marketed oral anti-
diabetic drugs (OADs). Nevertheless, treatment with more efficacious injectable therapies such as 
GLP-1 RAs and insulin are rarely added during the early stages of the disease. Oral semaglutide is 
the first GLP-1 RA in development in a tablet formulation and it has the potential of becoming a 
new attractive treatment option early in the treatment cascade due to its effects on both 
hyperglycaemia and body weight. 
The purpose of the present trial is to compare oral semaglutide with liraglutide, a well-established, 
injectable GLP-1 RA, in terms of glycaemic control, weight loss and other efficacy and safety 
parameters in subjects with T2DM inadequately controlled on metformin only or metformin in 
combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor or a fixed-dose
combination of metformin and SGLT-2 inhibitor.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
28 of 132
4
Objectives and endpoints
4.1
Objectives
4.1.1
Primary objective
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on glycaemic control in subjects with type 2 diabetes mellitus (T2DM).
4.1.2
Secondary objectives
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on body weight in subjects with T2DM.
To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus 1.8 
mg liraglutide subcutaneous and versus placebo, all in combination with metformin with or without 
a SGLT-2 inhibitor, in subjects with T2DM.
4.2
Endpoints
The confirmatory endpoints are evaluated as a change from baseline to week 26. There will not be 
an interim analysis at week 26, the evaluation will take place after completion of the trial. 
4.2.1
Primary endpoint
Change from baseline to week 26 in HbA1c
4.2.2
Secondary endpoints
4.2.2.1
Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) 
4.2.2.2
Supportive secondary endpoints
Supportive secondary efficacy endpoints
Change from baseline to week 52 in: 
!
HbA1c*
!
Body weight (kg)*
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
29 of 132
Change from baseline to week 26 and week 52 in:
!
Fasting plasma glucose (FPG)*
!
7-point self-measured plasma glucose (SMPG) profile
–
Mean 7-point profile
–
Mean postprandial increment (during all meals)
!
Body weight (%)
!
Body mass index (BMI)
!
Waist circumference
!
Fasting lipid profile (total cholesterol, low density lipoprotein [LDL] cholesterol, very low 
density lipoprotein [VLDL] cholesterol, high density lipoprotein [HDL] cholesterol, 
triglycerides, free fatty acids)
!
Patient reported outcomes 
–
Diabetes Treatment Satisfaction Questionnaire (DTSQs)
If a subject after week 26 and week 52 achieves (yes/no):
!
HbA1c < 7.0 % (53 mmol/mol) American Diabetes Association (ADA) target*
!
HbA1c ≤6.5 % (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) 
target
!
HbA1c reduction ≥1 % (10.9 mmol/mol)
!
Weight loss ≥3 % 
!
Weight loss ≥5 % 
!
Weight loss ≥10 % 
!
HbA1c < 7.0 % (53 mmol/mol) without  hypoglycaemia (treatment-emergent severe or BG-
confirmed symptomatic hypoglyceamia) and no weight gain
!
HbA1c reduction ≥1 % (10.9 mmol/mol) and weight loss ≥3 %
Time to event
!
Time to rescue medication
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
30 of 132
Supportive secondary safety endpoints
!
Number of treatment-emergent adverse events (TEAEs) during exposure to trial product, 
assessed up to approximately 57 weeks*
!
Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic 
episodes during exposure to trial product, assessed up to approximately 57 weeks*
!
Treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic episodes 
during exposure to trial product, assessed up to approximately 57 weeks (yes/no)
Change from baseline to week 26 and week 52 in:
!
Haematology
!
Biochemistry
!
Calcitonin
!
Pulse
!
Systolic blood pressure
!
Diastolic blood pressure
!
Electrocardiogram (ECG) category
!
Physical examination (week 52 only)
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!
Anti-semaglutide binding antibodies
!
Anti-semaglutide neutralising antibodies 
!
Anti-semaglutide binding antibodies cross-reacting with native GLP-1
!
Anti-semaglutide neutralising antibodies cross-reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 57 weeks:
!
Anti-semaglutide binding antibody levels
* Key supportive secondary endpoints prospectively selected for disclosure (e.g. clinicaltrials.gov 
and EudraCT)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
31 of 132
5
Trial design
5.1
Type of trial
This is a 52-week, randomised, double-blind, double-dummy, active- and placebo-controlled, 
parallel-group, multicentre, multinational trial with 3 arms comparing the efficacy and safety of 
once-daily dosing of oral semaglutide vs. liraglutide and vs. placebo in subjects with T2DM.
Subjects will be randomised in a 2:2:1 manner to receive one of the following treatments:
!
14 mg oral semaglutide once-daily
!
1.8 mg liraglutide subcutaneous (s.c.) injection once-daily
!
placebo once-daily 
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks. 
A schematic diagram of the trial design is shown in Figure 5–1.
Figure 5–1
Trial design
5.2
Rationale for trial design
The trial has been designed as a parallel-group, 3-armed trial to secure a direct comparison between 
oral semaglutide and the active comparator liraglutide and to demonstrate glycaemic effect of oral 
semaglutide compared to placebo. Subjects will be randomised between the three treatment arms 
and the trial will be double-blinded to minimise bias. The randomisation will be stratified based on 
anti-diabetic background medication at screening (metformin only/metformin in combination with a 
SGLT-2 inhibitor) and descent (Japanese subjects/non-Japanese subjects) to ensure a 2:2:1 
distribution of the three treatment arms within each stratum. The aim is to randomise a minimum of 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
32 of 132
125 subjects on a background medication including a SGLT-2 inhibitor, and a minimum of 75 
Japanese subjects out of the planned total number of subjects (690).
Semaglutide will be administered orally and liraglutide as s.c. injections. To maintain the blinding 
of the trial, a double dummy design will be applied. Accordingly, all subjects randomised to oral 
semaglutide will also receive liraglutide placebo injections, subjects randomised to liraglutide will 
also receive semaglutide placebo tablets and subjects randomised to placebo will receive both 
semaglutide placebo tablets and liraglutide placebo injections. 
There will be strict glycaemic rescue criteria in place to ensure acceptable glycaemic control during 
the trial for all treatment arms, including the placebo arm. 
The treatment duration will be 52 weeks to ensure adequate time to compare the full effect and 
sustainability of the treatments on glycaemic control and body weight.
The confirmatory endpoints will be defined after 26 weeks of treatment where the extent of missing 
data, use of rescue medication or premature treatment discontinuation is expected to be limited. 
This allows for a robust estimation of the effect of oral semaglutide on HbA1c and body weight that 
is considered adequate and meaningful. There will not be an interim analysis at week 26. The 
subjects will sign up for 52 weeks when they sign the informed consent.
The follow-up period is 5 weeks to allow for wash-out of semaglutide and to prevent interference in 
the antibody assay.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
33 of 132
5.3
Treatment of subjects
Treatment of subjects is summarised in Table 5–1.
Oral semaglutide treatment
Oral semaglutide is a long-acting GLP-1 RA to be administered orally once-daily. Subjects 
randomised to oral semaglutide will initiate treatment with 3 mg oral semaglutide once-daily and 
follow a fixed 4-week dose escalation regimen until reaching the maximum maintenance dose of 14 
mg oral semaglutide once-daily, as illustrated in Table 5–1. To mitigate the risk of gastrointestinal 
AEs, it is important to follow the fixed 4-week dose-escalation intervals. The dose must not be 
changed during the course of the trial once the 14 mg dose of oral semaglutide has been reached.
Liraglutide treatment
Treatment with liraglutide injections will be initiated at 0.6 mg once-daily. The dose will be 
escalated weekly in a fixed manner, initially to 1.2 mg once-daily and then to the recommended 
maximum dose of 1.8 mg once-daily according to the approved label in T2DM25,26. 
At the planned phone contact (P3) (see Section 2), the investigator should follow-up on compliance 
and potential technical issues regarding the dose escalation that was done by the subject after the 
first week of treatment. At P3, the subject will be instructed to dose escalate to 1.8 mg once-daily.
It is important to follow the weekly dose escalation. The dose must not be changed during the 
course of the trial once the 1.8 mg maintenance dose of liraglutide has been reached.
Placebo treatment
Treatment with semaglutide placebo tablets and liraglutide placebo injections will follow the same 
rules as outlined for the respective active treatments above. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
34 of 132
Table 5–1
Treatment of subjects
Trial periods
Screening 
Treatment 
period 1
Treatment 
period 2
Treatment 
period 3
Follow-up 
First visit in each period
V1
V2
V4
V6
V14
Duration of each period
2 weeks
4 weeks
4 weeks
44 weeks
5 weeks
Treatment arm
N
Oral semaglutide
276
Screening
3 mg oral 
semaglutide
tablet
+ liraglutide 
placebo 
injection 0.1 mL
with weekly 
volume-
matched 
escalation to 0.2 
mL and 0.3 mL
7 mg oral 
semaglutide 
tablet
+ liraglutide 
placebo 
injection 0.3 mL
14 mg oral 
semaglutide
tablet
+ liraglutide 
placebo 
injection 0.3 mL
Follow-up
Liraglutide
276
Screening
0.6 mg (0.1 mL) 
liraglutide  
injection (with 
weekly 
escalation
to 1.2 mg (0.2 
mL) and
1.8 mg (0.3 mL)
+ semaglutide 
placebo 
matching tablet 
1.8 mg (0.3 mL) 
liraglutide  
injection 
+ 7 mg oral 
semaglutide 
placebo 
matching tablet 
1.8 mg (0.3 mL) 
liraglutide   
injection
+ 14 mg oral 
semaglutide 
placebo 
matching tablet
Follow-up
Placebo
138
Screening
3 mg oral
semaglutide 
placebo 
matching tablet
+ liraglutide 
placebo 
injection 0.1 mL
with weekly 
volume-
matched 
escalation to 0.2 
mL and 0.3 mL
7 mg oral
semaglutide 
placebo 
matching tablet
+ liraglutide 
placebo 
injection 0.3 mL 
14 mg oral
semaglutide 
placebo 
matching tablet
+ liraglutide 
placebo 
injection 0.3 mL
Follow-up
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
35 of 132
The following trial products will be supplied by Novo Nordisk A/S, Denmark: 
!
Semaglutide 3 mg, 7 mg and 14 mg, tablets
!
Semaglutide placebo, 0 mg, tablets
!
Liraglutide, 0.6 mg (0.1 mL), 1.2 mg (0.2 mL), 1.8 mg (0.3 mL), solution for injections 
(strength: 6.0 mg/mL, pen-injector) 
!
Liraglutide placebo, 0.1 mL, 0.2 mL, 0.3 mL, solution for injections (strength: 0.0 mg/mL, pen-
injector)
5.3.1
Dosing instructions
Oral semaglutide/semaglutide placebo
Absorption of oral semaglutide is significantly affected by food and fluid in the stomach, hence 
dosing should be once-daily in the morning in a fasting state and at least 30 minutes before the first 
meal of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/4 
fluid oz). The tablets must be swallowed whole by the subject and must not be broken or chewed. 
(Table 9–2). Furthermore, other oral medication can be taken 30 minutes after administration of the 
oral trial product.
Liraglutide/liraglutide placebo
Liraglutide/liraglutide placebo should be administered once-daily as subcutaneous injection (under 
the skin) in the abdomen, thigh or upper arm. It is given independent of meals and preferably at the 
same time each day.
5.3.2
Background medication
After signing the informed consent, subjects must continue their anti-diabetic background 
medication (metformin or metformin+SGLT-2 inhibitor) throughout the entire trial. The 
background medication must be maintained at the same dose level as given at trial entrance and 
with the same frequency during the entire treatment period unless rescue medication is needed or a 
safety concern related to the background medication arises.
In addition, all background medication:
!
is considered to be non-investigational medicinal product (NIMP)
!
will not be provided by Novo Nordisk A/S, except if required by local regulations
!
should be used in accordance with standard of care and current approved label in the individual 
country 
!
should not exceed the maximum approved dose in the individual country
5.4
Treatment after discontinuation of trial product
When discontinuing trial products, either at the scheduled end of treatment visit (see Section 8.1.5) 
or if trial product is discontinued prematurely (see Section 8.1.6), the subject should be switched to 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
36 of 132
a suitable marketed product at the discretion of the investigator. After discontinuation of trial 
products, GLP-1 RAs are not allowed before completion of the follow-up visit 5 weeks after the last 
date on trial products (to avoid interference with the antibody assay for oral semaglutide).
Throughout the protocol, last date on trial product is defined as date of the subject’s last dosage of 
trial product.
As this trial is a phase 3a trial, oral semaglutide will not be available for prescription until after 
marketing authorisation.
5.5
Rationale for treatment
For oral semaglutide, the three dose levels (3, 7 and 14 mg), treatment initiation with the lowest 
dose and the 4-week dose escalation steps have been chosen based on data from the phase 2 dose-
finding trial. This regime is expected to have the optimal benefit-risk profile for further 
development for treatment of T2DM in the PIONEER programme. 
Liraglutide has been chosen as active comparator since it is a well-established injectable GLP-1 RA 
suitable for once-daily dosing. Treatment will be initiated at 0.6 mg once-daily in accordance with 
the current, approved label. 
Both oral semaglutide and liraglutide will be dose escalated to their highest respective maintenance 
doses to investigate and compare the maximum efficacy of the two drugs when added to metformin 
only or metformin in combination with a SGLT-2 inhibitor. 
The duration of randomised treatments is considered adequate to collect sufficient data on efficacy 
and safety in accordance with the trial objectives.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
37 of 132
6
Trial population
6.1
Number of subjects 
Number of subjects planned to be screened: 1150
Number of subjects planned to be randomised: 690
For Japan only: Approximately 75 subjects planned to be randomised/started on trial product(s).
Number of subjects expected to complete the trial on or off trial product: 621 
6.2
Inclusion criteria
For an eligible subject, all inclusion criteria must be answered “yes”.
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 90 days prior to day of screening.
4. HbA1c of 7.0–9.5 % (53-80.3 mmol/mol) (both inclusive).
5. Stable daily dose of metformin (≥1500 mg or maximum tolerated dose as documented in the 
subject medical record) alone or in combination with a stable daily dose of a SGLT-2 inhibitor 
(all doses approved as maintenance therapy) ≥90 days prior to the day of screening.
6.3
Exclusion criteria
For an eligible subject, all exclusion criteria must be answered “no”. 
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as 
required by local regulation or practice).
For Germany only: Only highly effective methods of birth control are accepted (i.e. one that 
results in less than 1% per year failure rate when used consistently and correctly such as 
implants, injectables, combined oral contraceptives, some intrauterine device), or sexual 
abstinence or vasectomised partner.
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by the partner), intrauterine device, sponge, spermicide or oral contraceptives.
4. Receipt of any investigational medicinal product within 90 days before screening.
5. Any disorder, which in the investigator’s opinion might jeopardise subject’s safety or 
compliance with the protocol.
6. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
38 of 132
7. History of pancreatitis (acute or chronic).
8. History of major surgical procedures involving the stomach and potentially affecting absorption 
of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
9. Any of the following: myocardial infarction (MI), stroke or hospitalisation for unstable angina 
or transient ischaemic attack within the past 180 days prior to the day of screening. 
10. Subjects presently classified as being in New York Heart Association (NYHA) Class IV.
11. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
12. Subjects with ALT > 2.5 × upper normal limit (UNL).
13. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 
m2 as per Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).
14. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of 90 days before the day of screening. An exception is short-term 
insulin treatment for acute illness for a total of ≤14 days.
15. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus 
photography or dilated fundoscopy performed within 90 days prior to randomisation.
16. History or presence of malignant neoplasms within the last 5 years (except basal and squamous 
cell skin cancer and carcinoma in situ).
17. History of diabetic ketoacidosis.
6.4
Rescue criteria
Subjects with persistent and unacceptable hyperglycaemia should be offered treatment 
intensification. To allow time for dose escalation to maximum dose and to observe the expected 
effect of treatment on glycaemic parameters, rescue criteria will be applied at week 8 and onwards. 
If any of the FPG values (including fasting SMPG) exceed the limits outlined below and no 
intercurrent cause of the hyperglycaemia can be identified, a confirmatory FPG (at central 
laboratory) should be obtained by calling the subject for a re-test. If the confirmatory FPG also 
exceeds the value described below, the subject should be offered rescue medication (i.e. 
intensification of anti-diabetic background medication and/or initiation of new anti-diabetic 
medication):
!
13.3 mmol/L (240 mg/dL) from week 8 to end of week 13
!
11.1 mmol/L (200 mg/dL) from week 14 to end of treatment
In addition, subject should be offered rescue medication if:
!
HbA1c (at central laboratory) >8.5 % (69.4 mmol/mol) from week 26 to end of treatment.
It is important for trial integrity that only subjects actually needing treatment intensification (as 
defined above) are started on rescue medication. Subjects that are started on rescue medication 
should continue to follow the protocol-specified visit schedule. Rescue medication should be 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
39 of 132
prescribed at the investigator’s discretion as add-on to randomised treatment and according to 
ADA/European Association for the Study of Diabetes guidelines27 and28 (excluding GLP-1 RAs,
DPP-4 inhibitors and amylin analogues). Rescue medication and any changes hereto should be 
captured on the concomitant medication form in the electronic case report form (eCRF), see Section 
8.2.4. Rescue medication is considered to be NIMP and will not be provided by Novo Nordisk.
6.5
Criteria for premature discontinuation of trial product 
All efforts should be made to keep the subject on trial product. However, the subject may be 
prematurely discontinued from trial product at the discretion of the investigator due to a safety 
concern related to trial product or unacceptable intolerability. 
The subject must be prematurely discontinued from trial product, if the following applies:
1. Safety concern related to trial product or unacceptable intolerability
2. Inclusion in the trial in violation of the inclusion and/or exclusion criteria
3. Pregnancy
4. Intention of becoming pregnant
5. Simultaneous participation in another clinical trial of an approved or non-approved  
investigational medicinal product (IMP)
6. Calcitonin ≥ 100 ng/L
If a criterion for premature discontinuation of trial product is met, trial product should not be re-
initiated but subjects should continue with the scheduled site contacts.
See Section 8.1.5 for procedures to be performed for subjects discontinuing trial product 
prematurely.
6.6
Withdrawal from trial
The subject may withdraw consent at will at any time. The subject’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered as 
withdrawn from trial.
See Section 8.1.6 for procedures to be performed for subjects withdrawing consent.
6.7
Subject replacement
Subjects who withdraw consent or discontinue trial product prematurely will not be replaced.
6.8
Rationale for trial population 
The trial population will include subjects with T2DM treated with stable doses of metformin only or 
metformin in combination with a SGLT-2 inhibitor for at least 90 days prior to screening as changes 
in the background medication shortly before trial participation may potentially impact data
interpretation. The HbA1c limits 7.0–9.5 % (53–80.3 mmol/mol) have been chosen to include 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
40 of 132
subjects needing intensification of their anti-diabetic medication. The upper limit will secure that 
subjects with severely dysregulated T2DM are not enrolled in this placebo-controlled trial. In 
addition, FPG and HbA1c will be monitored throughout the trial and rescue medication should be 
initiated in subjects with persistent, unacceptable hyperglycaemia. No BMI or blood pressure 
restrictions will be applied. Subjects with liver test abnormalities (ALT > 2.5 × UNL) will be 
excluded to avoid potential confounding of liver safety assessments. In addition, subjects with 
moderate, severe or end-stage renal impairment will be excluded due to restrictions in the labels of 
the allowed background medication. As SGLT-2 inhibitors have been associated with euglycaemic 
diabetic ketoacidosis, subjects with a history of diabetic ketoacidosis will also be excluded from this 
trial. Overall, the eligibility criteria allow for enrolment of a relatively broad trial population 
resembling the target population in common practice. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
41 of 132
7
Milestones
Planned duration of recruitment period
First Subject First Visit (FSFV) – Last Subject First Visit (LSFV): 26 weeks
Planned FSFV:
10-Aug-2016
Planned Last Subject Last Visit (LSLV):
03-Apr-2018
End of trial is defined as LSLV.
Recruitment:
The screening and randomisation rate will be followed closely via the IWRS in order to estimate 
when to stop screening. All investigators will be notified immediately when the recruitment period 
ends, after which no further subjects may be screened and the IWRS will be closed for further 
screening.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov, novonordisk-trials.com and the 
Clinical Trials Information JapicCTI site clinicaltrials.jp. According to the Novo Nordisk Code of 
Conduct for Clinical Trial Disclosure29, it will also be disclosed according to other applicable 
requirements such as those of the International Committee of Medical Journal Editors (ICMJE)30,
the U.S. Food and Drug Administration Amendment Act (FDAAA)31, European Commission 
Requirements32,33 and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact at these web sites, Novo Nordisk A/S may 
disclose the investigator’s contact details to the subject. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
42 of 132
8
Methods and assessments
8.1
Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2). Informed consent must be obtained before any trial related activity, see 
Section 18.1.2.
Refer to flowchart (Section 2) for number and timing of visits and specific assessments to be 
performed. 
Each subject will attend 12 site visits and 2 phone visits. It is the responsibility of the investigator to 
ensure that all site visits occur according to the flow chart.
Planned visits can be conducted and re-scheduled within the allowed visit window. If a visit is 
missed and it is not possible to re-schedule, every effort should be made to ensure information is 
collected at a telephone contact (within the visit window) and entered into the eCRF. Subjects will 
be invited for the next scheduled visit according to the visit schedule.
The investigator must keep a log of staff and a delegation of task(s) list at site. Investigator must 
sign the log of staff and the delegation of task(s) at site prior to the delegation of tasks.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log. 
8.1.1
Screening, visit 1
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
A screening session must be made in the IWRS. Each subject will be assigned a unique 6-digit 
subject number which will remain the same throughout the trial.
Once all data relating to V1 have been obtained, these must be reviewed, dated and signed by the 
investigator and/or documented in medical records to assess that the subject is eligible to continue 
in the trial.
Screening failures: For screening failures the screening failure form in the eCRF must be 
completed with the reason for not continuing in the trial. Serious adverse events (SAEs) from 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
43 of 132
screening failures must be transcribed by the investigator into the eCRF. Follow-up on SAEs must 
be carried out according to Section 12.
A screening failure session must be made in the IWRS. The case book must be signed.
Re-screening is NOT allowed if the subject has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the subject has failed one of the inclusion or exclusion criteria related to 
laboratory parameters. However, in case laboratory samples are lost (e.g. haemolysed/displaced), 
re-sampling is allowed.
8.1.2
Fasting visits
The subjects must attend several visits in a fasting state (see Section 2).
Fasting for blood sampling is defined as no food or liquid within the last 8 hours prior to blood 
sampling, however water is allowed up until 2 hours prior to blood sampling.
Trial product must be taken after blood sampling (see Section 5.3.1 for dosing instructions). Other 
oral medication can be taken 30 minutes after trial product. Injectable medications can be 
administered after blood sampling. In case a subject attends a fasting visit in a non-fasting state, all 
non-fasting measurements should be performed. The subject should return to the site in a fasting 
state to have the fasting blood samples done within the visit window for the relevant visit.
Fasting samples:
!
fasting plasma glucose (FPG)
!
fasting lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, very low 
density lipoprotein (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, free fatty acids)
8.1.3
Randomisation and trial product administration
Eligible subjects will be randomised into one of three treatment arms. The randomisation session 
must be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial 
product to be dispensed to the subject.
All V2 assessments must be performed before administration of first dose of trial product.
Trial products (see Section 9) will be dispensed to the subject by the site, hospital pharmacy or 
equivalent at each site visit during the trial from randomisation to last visit before the End-of-
treatment visit (see Section 2). The investigator must document that subjects are trained in the 
dosing instructions at every dispensing visit, please see Section 5.3.1.
Date of first administration of trial product will be captured in the eCRF.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
44 of 132
8.1.4
Phone contacts
The phone contacts should be conducted as outlined in the flowchart (see Section 2).
At V2, the investigator should instruct the subject to dose escalate liraglutide/liraglutide placebo to 
1.2 mg once-daily after the first week of treatment. At the planned phone contact (P3), the 
investigator should follow-up on compliance and potential technical issues regarding the dose 
escalation that was done by subject after the first week of treatment. At P3, the subject will be 
instructed to dose escalate to 1.8 mg once-daily.
8.1.5
End-of-treatment (visit 13) and Follow-up (visit 14)
Subjects, who stay on trial product throughout the trial, must attend the End-of-treatment visit 
(V13) 52 weeks after randomisation and the Follow-up visit (V14) 5 weeks after the last date on 
trial product (+3 days visit window). A completion call must be performed in the IWRS after 
completion of V13 (see Section 10).
In case the subject cannot be reached (by clinic visit or phone contact) at the scheduled V14, the site 
should consult the contacts provided by the subject (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow up and this should 
be specified in the end-of-trial form.
8.1.6
Premature discontinuation of trial product and Follow-up (visits 13A and 14A)
Subjects who discontinue trial product prematurely should attend V13A scheduled to take place on 
the day of discontinuation of trial product (+ 3 days visit window). V14A should be scheduled 5 
weeks (+3 days visit window) after the last date on trial product. The primary reason for premature 
discontinuation of trial product must be specified in the end-of-trial form in the eCRF, and final 
drug accountability must be made. A treatment discontinuation session must be performed in the 
IWRS at V13A (see Section 10).
If premature discontinuation of trial product is decided during a scheduled visit, the visit will be 
converted into a V13A and trial procedures must be performed accordingly.
Subjects should continue with the originally scheduled site contacts after V13A and up to and 
including V13. If necessary, in order to retain the subject in the trial, site visits can be replaced by 
phone contacts after V14A. However, if a subject is unable or unwilling to attend all subsequent 
visit(s), the investigator should at least aim to have the subject attend V9 (week 26) and the End-of-
treatment visit (V13) as these visits should be performed for all subjects, if at all possible (except 
subjects who withdraw informed consent, see Section 8.1.7). 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
45 of 132
Subjects, who only agree to attend or provide health status at the planned V12, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by clinic visit or phone 
contact) at the scheduled V12, the site should consult the contacts provided by the subject (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow-up and this should be specified in the end of trial form. 
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact with the site in relation to the trial 
should be considered as withdrawn from the trial (for withdrawal procedures see Section 8.1.7).  
8.1.7
Withdrawals
If a subject considers withdrawing from the trial, the investigator must aim to undertake procedures 
for V13A as soon as possible and V14A should be scheduled 5 weeks (+3 days visit window) after 
the last date on trial product, if the subject agrees to it.
The end-of-trial form must be completed and final drug accountability must be performed even if 
the subject is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS (see Section 10). The case book must be signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subject’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the end-of-trial form in the eCRF.
8.1.8
Investigator assessments
Review of diaries, Patient Reported Outcomes (PROs), laboratory reports, ECGs and 
fundoscopy/fundus photography must be documented either on the documents or in the subject’s 
medical record.
If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
The documents must be retained at the site as source documentation.
For ECGs, physical examinations and eye examinations, the evaluations must follow the categories:
!
Normal
!
Abnormal
–
Was the result clinically significant? (yes/no)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
46 of 132
The evaluation should be based on investigator’s judgement.
For laboratory report values outside the reference range, the investigator must specify whether the 
value is clinically significant or not clinically significant. All laboratory printouts must be signed 
and dated by the investigator prior to the following visit. The signed laboratory report is retained at 
the site as source documentation.
In case of abnormal clinically significant findings found as a result of screening procedures 
conducted at V1 or assessments revealing baseline conditions at V2, the investigator must state a 
comment in the subject’s medical record and record this in the medical history/concomitant illness 
form in the eCRF. 
The Investigator or his/her delegate must collect and review the PROs and diaries for completeness 
and to ensure that AEs are reported. 
8.2
Subject related information/assessments
8.2.1
Demography
Demography will be recorded in the eCRF at screening and consists of:
!
Date of birth (according to local regulation)
!
Sex
!
Ethnicity (according to local regulation)
!
Race (according to local regulation)
8.2.2
Diabetes history and diabetes complications
Diabetes history and diabetes complications will be recorded on a disease specific form at screening 
and consists of:
!
Date of diagnosis of type 2 diabetes
!
Information regarding diabetes complications including date of onset
o
Diabetic retinopathy
o
Diabetic neuropathy
o
Diabetic nephropathy
Please note that macroangiopathy (including peripheral arterial disease) should be reported on the
disease specific form History of cardiovascular disease (see Section 8.2.3).
8.2.3
Concomitant illness and medical history
A concomitant illness is any illness that is present at the start of the trial (V1) or found as a result 
of a screening procedure or other trial procedures performed before exposure to trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
47 of 132
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history as judged by the investigator should be reported.
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
The following must be recorded in the eCRF on the disease specific forms only, i.e. not on the 
medical history/concomitant illness form:
!
History of cardiovascular disease (CVD) (e.g. ischaemic heart disease, MI, heart failure incl. 
NYHA class, hypertension, stroke, peripheral arterial disease)
!
History of gallbladder disease (e.g. gallstone, cholecystitis, cholecystectomy)
!
History of gastrointestinal disease (e.g. gastroesophageal reflux disease, ulcer disease, chronic 
gastritis)
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE (see Section 12).
It must be possible to verify the subject’s medical history in source documents such as subject’s 
medical record. If a subject is not from the investigators own practice, the investigator must make 
reasonable effort to obtain a copy of subject’s medical record from relevant party, e.g. primary 
physician. The investigator must document any attempt to obtain external medical information by 
noting the date(s) when information was requested and who has been contacted.
8.2.4
Concomitant medication
A concomitant medication is any medication, other than the trial products, which is taken during 
the trial, including the screening and follow-up periods.
Details of any concomitant medication must be recorded at the first visit. Changes in concomitant 
medication must be recorded at each visit as they occur. 
The information collected for each concomitant medication includes
!
trade name or generic name
!
indication
!
start date and stop date or continuation
!
only applicable for anti-diabetic medication: start date of current dose and total daily dose
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subject’s eligibility to continue in the trial, the monitor must be informed.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
48 of 132
8.2.5
Childbearing potential
It must be recorded in the eCRF whether female subjects are of childbearing potential. 
Pregnancy testing must be performed on female subjects of childbearing potential as described in 
Section 8.4.7 (pregnancy testing). Female subjects of childbearing potential must be instructed to 
use an adequate contraceptive method throughout the trial and until 5 weeks after end of treatment.
For Germany only: Only highly effective methods of birth control are accepted (i.e. one that results 
in less than 1% per year failure rate when used consistently and correctly such as implants, 
injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or 
vasectomised partner.
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by the partner), intrauterine device, sponge, spermicide or oral contraceptives.
Female of non-childbearing potential is defined as:
!
Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal ligation 
!
Postmenopausal defined as no menses for 12 months without an alternative medical cause
!
Other medical reasons preventing childbearing potential
8.2.6
Tobacco use
Details of tobacco use must be recorded at V1. Smoking is defined as smoking at least one cigarette 
or equivalent daily.
Smoking status:
!
Never smoked
!
Previous smoker, smoking stop date
!
Current smoker
8.3
Efficacy assessments
8.3.1
Laboratory assessments for efficacy
For overall laboratory process see Section 8.5. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
49 of 132
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following efficacy laboratory parameters (for fasting 
see Section 8.1.2):
Glucose metabolism:
!
HbA1c
!
FPG (see Section 8.3.1.1)
Fasting lipid profile: 
!
Total cholesterol
!
LDL cholesterol
!
HDL cholesterol
!
Triglycerides
!
VLDL cholesterol
!
Free fatty acids
8.3.1.1
Fasting plasma glucose 
FPG is measured at the central laboratory in order to evaluate glycaemic control. The subject must 
attend these visits fasting (see Section 8.1.2).
A central FPG result ≤3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be 
reported as a hypoglycaemic episode but as a clinical laboratory adverse event (CLAE) at the 
discretion of the investigator (see Section 12.1.1).
8.3.2
Self-measured plasma glucose
At V1, subjects will be provided with a blood glucose meter (BG meter) including auxiliaries as 
well as instructions for use. The subjects will be instructed in how to use the device, and the 
instruction will be repeated as necessary during the trial. In case a hypoglycaemic episode is 
suspected, the provided BG meter should be used for SMPG measurement.
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. Only the BG meters provided by Novo Nordisk A/S should be used for the 
measurements required in the protocol.
Subjects should be instructed in how to record the results of the SMPG values in the diaries. The 
record of each SMPG value should include date, time and value. All data from the diary must be 
transcribed into the eCRF during or following the contact. If obtained via phone and a discrepancy 
is later detected, between the diary and the SMPG data obtained at the phone contact, the values in 
the eCRF must be corrected.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
50 of 132
Occasional review by the investigator of the values stored in the memory of the BG meter and 
correct reporting of these in the diary is advised in order to ensure adequacy of the data reported in 
the trial database.
The subject will be instructed to perform a 7-point SMPG profile three times during the trial period 
(see Section 2) using the BG meter provided for the trial. The 7-point SMPG profile should be 
performed on a day where the subject does not anticipate unusual strenuous exercise. The 7-point 
SMPG profile should preferably be taken within a week prior to the visit.
The record of each SMPG measurement should include the following seven time points:
!
before breakfast
!
90 minutes after start of breakfast
!
before lunch
!
90 minutes after start of lunch
!
before dinner
!
90 minutes after start of dinner
!
at bedtime
8.3.3
Body weight and height
Body weight must be measured and recorded in the eCRF in kilogram or pound (kg or lb), with one 
decimal (with an empty bladder, without shoes and only wearing light clothing). The body weight 
should be assessed on the same calibrated weighing scale equipment throughout the trial, if 
possible.
Height is measured without shoes in centimetres or inches and recorded in the eCRF to nearest ½ 
cm or ¼ inch.
8.3.4
Waist circumference
The waist circumference is defined as the minimal abdominal circumference located midway 
between the lower rib margin and the iliac crest.
The measurement of waist circumference must be performed and recorded in the eCRF. Waist 
circumference is measured in the horizontal plane and rounded up or down to the nearest ½ cm or ¼ 
inches using a non-stretchable measuring tape. The same measuring tape should be used throughout 
the trial.
The circumference should be measured when the subject is in a standing position, with an empty 
bladder and wearing light clothing. The subject should be standing, feet together with arms down 
their side and waist accessible. The tape should touch the skin but not compress soft tissue and 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
51 of 132
twists in the tape should be avoided. The subject should be asked to breathe normally and the 
measurement should be taken when the subject is breathing out gently.
8.3.5
Patient reported outcomes questionnaires
PRO will be assessed using the questionnaire:
Diabetes Treatment Satisfaction Questionnaire (DTSQ)35
The questionnaire must be completed by the subject as specified in the flow chart, see Section 2, 
preferably before any other trial-related activities for that visit. It takes approximately five minutes 
to complete the questionnaire. Subjects should be given the opportunity to complete the 
questionnaire by themselves without interruption. The completed questionnaires must be reviewed 
for potential adverse events and missing data while the subject is still at the site. All results from the 
PRO questionnaires must be transferred into the eCRF.
The questionnaire DTSQ is a commonly used instrument to evaluate PROs, also in the T2DM area. 
All the questionnaires will be translated to local languages, and also be linguistically validated 
before being handed out to the subjects participating in the trial.
The DTSQ questionnaire will be used to assess subject’s treatment satisfaction. This questionnaire 
contains 8 items that measures the treatment satisfaction for subjects’ diabetes treatment in terms of 
convenience, flexibility and general feelings regarding treatment.
8.4
Safety assessments
8.4.1
Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12 and appendix B.
8.4.1.1
Medication error 
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form (see Section 8.4.1.2, 
12.1.5 and appendix B): 
!
Trial product(s) involved 
!
Classification of medication error
!
Whether the subject experienced any hypoglycaemic episode and/or AE(s) as a result of the 
medication error 
!
Suspected primary reason for the medication error
For definition of medication errors, see Section 12.1.4 and appendix B.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
52 of 132
8.4.1.2
Adverse events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!
Acute coronary syndrome (myocardial infarction or hospitalisation for unstable angina)
!
Cerebrovascular event (stroke or transient ischaemic attack)
!
Heart failure
!
Pancreatitis
!
Neoplasm (excluding thyroid neoplasm)
!
Thyroid disease (including thyroid neoplasm)
!
Renal event
!
Hypersensitivity reaction
!
Acute gallstone disease
!
Medication error
!
Lactic acidosis
!
Creatine kinase (CK) > 10x UNL
!
Hepatic event defined as:
–
ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
–
ALT or AST > 3x UNL and total bilirubin > 2x UNL*
–
Hepatic event leading to trial product discontinuation.
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
See Section 12 and appendix B for details about the additional information to report.
Note that additional assessments will be required according to appendix B in case of: 
!
suspicion of acute pancreatitis
!
suspicion of hypersensitivity reaction
!
increased levels of creatine kinase
!
increased levels of aminotransferase
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
53 of 132
8.4.2
Physical examination
A physical examination will be performed by the investigator according to local procedure (see 
Section 2 and 8.1.8). A physical examination must include:
!
General appearance
!
Head, ears, eyes, nose, throat, neck
!
Thyroid gland
!
Respiratory system
!
Cardiovascular system
!
Gastrointestinal system including mouth
!
Musculoskeletal system
!
Central and peripheral nervous system
!
Skin
!
Lymph node palpation
8.4.3
Vital signs
Systolic and diastolic blood pressure
Systolic and diastolic blood pressure should be measured in a sitting position after the subject has 
been resting for at least 5 minutes and by using the standard clinical practice at the site. The data 
must be recorded in the eCRF. The actual value of the blood pressure measurement should be 
recorded in the eCRF (without rounding). The same equipment should be used throughout the trial.
Pulse
Pulse (beats per minute) must be recorded in the eCRF at site visits after resting for 5 minutes in a 
sitting position.
8.4.4
Eye examination 
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by the 
investigator or according to local practise. Results of the dilated fundoscopy/fundus photography 
will be interpreted by the investigator (see Section 8.1.8).
If dilated fundoscopy/fundus photography has been performed within 90 days prior to 
randomisation, the procedure does not need to be repeated, unless worsening of visual function 
since the last examination. The results must be available prior to randomisation.
If the dilated fundoscopy/fundus photography is performed before the subject has signed the 
informed consent form, it must be documented in the medical records that the reason for performing 
the procedure was not related to this trial.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
54 of 132
8.4.5
Electrocardiogram (12-lead)
12-lead ECG will be performed as per flowchart (see Section 2) and the assessment must be 
reviewed as described in Section 8.1.8 by the investigator. The ECGs will also undergo central 
assessment and the investigator must forward the ECGs to the central ECG reader as soon as 
possible.
If the central ECG evaluation of a baseline ECG is suggestive of a prior MI, the investigator will be 
notified. The investigator should consider if an update of the History of CVD form is required.
If the central ECG evaluation of a post-baseline ECG is suggestive of new MI, the investigator will 
be notified and a confirmatory ECG should be performed. Unless already done, the investigator 
should report this as an AE or a SAE at investigator’s discretion and according to Section 12.1. 
Additional ECG recordings can be performed at the investigator’s site at investigator’s discretion at 
other visits than the planned ECG visits. All these ECGs will undergo central assessment. The 
reason for additional ECG assessments should be documented and an AE should be reported if 
applicable.
All findings suggestive of new MI detected by the central ECG reading will be adjudicated by the 
event adjudication committee (EAC) (see Section 12.7.2).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
55 of 132
8.4.6
Laboratory assessments for safety
For overall laboratory process see Section 8.5.
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following safety laboratory parameters:
Haematology:
!
Haemoglobin
!
Haematocrit
!
Leucocytes
!
Thrombocytes
!
Differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
Biochemistry: 
!
Alanine aminotransferase (ALT)
!
Albumin
!
Alkaline phosphatase (ALP)
!
Amylase
!
Aspartate aminotransferase (AST)
!
Bilirubin, total
!
Calcium, total
!
Creatinine 
!
eGFR per CKD-EPI36
!
Creatine kinase (CK)
!
Lipase
!
Potassium
!
Sodium
!
Urea
Hormones:
!
Calcitonin
Other parameters:
!
Antibodies (see Section 8.4.8)
In case any calcitonin value at any time during the trial is ≥ 10 ng/L, the algorithm in appendix A
must be followed.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
56 of 132
8.4.7
Pregnancy testing
Females of childbearing potential will have a urine dip-stick pregnancy test performed at site as 
specified in Section 2 or as required by local law. For definition of female of non-childbearing 
potential and contraceptive methods, see Section 8.2.5.
In case a menstrual period is missed or if pregnancy is suspected between the scheduled visits, a 
urine pregnancy test should be performed. Investigator should instruct the subject to contact the site 
in case the pregnancy test is positive. At V2, females of childbearing potential will be provided with 
a urine dip-stick pregnancy test. 
8.4.8
Anti-semaglutide antibodies 
Blood samples will be drawn for measurement of antibodies against semaglutide at selected visits 
(see Section 2). Positive anti-semaglutide binding antibody samples will be further characterised for 
cross reactivity to native GLP-1. Samples which are positive for anti-semaglutide binding 
antibodies will be further characterised for in vitro neutralising effect towards semaglutide. In 
addition, samples which are positive for antibodies cross-reacting with native GLP-1 will be further 
analysed for in vitro neutralising effect towards native GLP-1.
Furthermore, samples drawn at randomisation may be used for calculations of the neutralising effect 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
Novo Nordisk.
At randomisation, the antibody sampling must be done pre-dose. 
Antibody samples will be stored as described in Section 24.2.
8.4.9
Hypoglycaemic episodes
Plasma glucose (PG) should always be measured and recorded when a hypoglycaemic episode is 
suspected. 
All PG values:
!
≤ 3.9 mmol/L (70 mg/dL) or 
!
> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the diary according to the instructions below throughout the trial from V1 to 
end of trial.
Upon onset of a hypoglycaemic episode, the subject is recommended to measure plasma glucose 
every 15 minutes until the SMPG value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been 
resolved in accordance to current guidelines37.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
57 of 132
A SMPG value ≤ 3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms must trigger a 
hypoglycaemic episode form to be completed by the subject. Repeated SMPG measurements and/or 
symptoms will per default be considered as one hypoglycaemic episode until a succeeding SMPG 
value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved. One hypoglycaemic 
episode form is to cover these measurements and/or symptoms.
In case of several low SMPG values within the hypoglycaemic episode, the lowest value is the one 
that will be reported as the SMPG value for the hypoglycaemic episode but the start time of the 
episode will remain as the time for the first SMPG value and/or symptom.
The record should include the following information: 
!
Start date and time of the hypoglycaemic episode.
!
Stop date and time of the hypoglycaemic episode (stop time is the first time the PG value is > 
3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved).
If a stop date and time is not reported, a hypoglycaemic episode will cover a period of 60 
minutes.
!
The PG level before treating the episode (if available) and any follow up measurements. 
The lowest value measured during the hypoglycaemic episode will be reported as the PG value 
for the episode, the remaining values will be kept as source data in the diary.
!
Whether the episode was symptomatic (Yes/No).
A hypoglycaemic episode starting without symptoms should be updated to symptomatic if the 
subject experiences symptoms later during the episode. 
!
Whether the subject was able to treat him/herself.
If the severity of a hypoglycaemic episode aggravates, only one hypoglycaemic episode should 
be reported reflecting the most severe degree of hypoglycaemia.
!
Date and time of last oral trial product administration, and for pen-injection and selected anti-
diabetic medications administered prior to the episode, date and time as well as dose must be 
collected.
!
Date and time of last main meal (not including snacks) prior to the episode.
!
Whether the episode occurred in relation to physical activity.
!
Change in any concomitant illness.
!
Any sign of fever and/or other acute disease.
!
Whether the subject was asleep when the episode occurred.
–
If yes, whether the symptoms of the episode woke up the subject.
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or 
take other corrective actions. PG concentrations may not be available during an event, but 
neurological recovery following the return of PG to normal is considered sufficient evidence that 
the event was induced by a low PG concentration37.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
58 of 132
Oral carbohydrates must not be given if the subject is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by the subject:
!
Who assisted in the treatment of the hypoglycaemic episode (i.e. medical person or non-medical 
person)?
!
Where the treatment was administered (in clinic/emergency room/ hospital or other. If the 
subject was treated in clinic/emergency room/hospital, whether they were transported in an 
ambulance or not)
!
Type of treatment provided by another person (i.e. oral carbohydrates, glucagon, IV glucose or 
other)
!
Were symptoms alleviated after administration of treatment?
!
Factors contributing to the episode (i.e. physical activity, missed meal, diet change, medication 
error (i.e. overdose, mix-up between products, incorrect use of device), miscalculation of dose 
of anti-diabetic medication, other factors not listed or unknown)
!
Did the subject experience seizure?
!
Was the subject unconscious/comatose?
!
Did the subject experience any of the following symptoms38
–
Autonomic: sweating, trembling, hunger or palpitations (rapid or irregular heart beat)
–
Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
–
General malaise: headache or malaise (feeling discomfort/unease)
!
Other symptoms
The Investigator must review the diary for low SMPG values not reported as hypoglycaemic 
episodes (see Section 2 for relevant visits). The subject must be questioned whether any of the low 
values were severe i.e. whether the subject was able to self-treat or not. If the subject was not able 
to self-treat, it has to be reported as a severe hypoglycaemic episode on a hypoglycaemic episode 
form.
Low SMPG values for non-severe hypoglycaemic episodes not having a hypoglycaemic episode 
form completed within 7 days since the SMPG measurement should be reported on a 
hypoglycaemic episode form with as much information as possible. Novo Nordisk will not query 
for additional data except for the start date, SMPG value and whether the subject was able to self-
treat due to decreased validity of such data39,40.
The subject must be re-trained in how to report hypoglycaemic episodes if the investigator identifies 
low SMPG values not reported as hypoglycaemic episodes.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
59 of 132
If the hypoglycaemic episode fulfils the criteria for an SAE, then an AE form and a safety 
information form (SIF) must also be filled in, see Section 12.
8.5
Laboratory assessments
The laboratory analyses will mainly be performed by a central laboratory. Anti-semaglutide 
antibodies, in vitro neutralising effect, and IgE anti-semaglutide antibodies will be analysed by a 
special laboratory and Novo Nordisk A/S (see Sections 8.4.8). For some of the analyses related to 
suspicion of acute pancreatitis and hypersensitivity reactions a local laboratory must be used (see 
appendix B). 
The handling, transportation and storage of biological samples are described in the laboratory 
manual (for central and special laboratory details see Attachment I).
Samples will be coded in order to keep subject identity anonymous.
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on another 
day within the visit window stated in the flow chart (see Section 2). Please note that a laboratory 
sample pertaining to a specific visit must always be reported to that visit.
For some of the samples drawn during the trial, subjects will be asked to attend the site visits fasting 
(fasting for blood sampling is defined in Section 8.1.2).
The central laboratory will provide laboratory results to the investigator on an ongoing basis. 
However, anti-semaglutide antibody results will not be available to the investigator during the trial. 
These results will be provided to the investigator upon request after the completion of the clinical 
trial report (CTR). The laboratory provides results to the trial sites in the units preferred by the trial 
sites while the results that are transferred to the trial database will always be in SI units.
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator.
The investigator must review all laboratory results for concomitant illnesses and AEs and report 
these according to Sections 8.2.4 and 12.
Laboratory samples will be destroyed at the latest at the completion of the CTR, or according to 
local regulations, except samples obtained for antibody analysis. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
60 of 132
8.6
Other assessments
8.6.1
Subject diary
The diaries should be handed out at the visits described in the flow chart Section 2. The recordings 
must be reviewed as described in Section 8.1.8 and transcribed to the eCRF at the following visit.
Entries in the diaries are only to be made by the subject, unless otherwise specified.
The investigator should instruct the subject in recording the following data in the diary:
!
date of first trial product administration
!
hypoglycaemic episodes
!
changes in concomitant medication
!
AEs
!
SMPG 7-point profile
8.6.2
Training in the injection pen
An injection pen is used for s.c. administration of liraglutide/liraglutide placebo. The subjects must 
be trained in how to handle the injection pen when handed out the first time. Training must be 
repeated during the trial at regular intervals in order to ensure correct use of the injection pen. The 
following should be emphasised:
!
Always use a new needle for each injection as this will prevent contamination and blocked 
needles
!
Priming the pen to ensure product flow 
!
The needle should be kept in the skin while counting slowly to 6 (or as described in the 
direction for use) after the dose counter has returned to zero after injection. If the needle is 
removed too early then the full dose may not have been delivered. Always remove the needle 
after each injection and store the pen-injector with no needle attached.
The investigator must document that direction for use (DFU) is given to the subject verbally and in 
writing at the first dispensing visit (V2).
8.7
Subject compliance
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure subject compliance. 
Treatment compliance: Will be assessed by monitoring of drug accountability. Prior to visits 
where drug accountability is performed, the subject will be asked to return all used, partly used and 
unused trial products. The investigator must assess the amount of trial products returned compared 
to what was dispensed at the last dispensing visit and, in case of discrepancies, question the subject.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
61 of 132
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed and should 
document this discussion in the subject’s medical record.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
62 of 132
9
Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM). 
Trial products must not be dispensed to any person not included in the trial. 
Liraglutide or liraglutide placebo must only be used, if it appear clear and colourless or almost 
colourless.
9.1
Trial products
The following trial products are considered as IMPs and will be provided by Novo Nordisk A/S, 
Denmark:
Table 9–1
Investigational medicinal products
Trial product
Strength
Dosage form
Route of 
administration
Container/
delivery device
Semaglutide 3 mg tablet
3 mg
Tablet
Oral
Blister carda
Semaglutide 7 mg tablet
7 mg
Semaglutide 14 mg tablet
14 mg
Placebo tablet
N/A
Liraglutide
6 mg/mL
Solution for
injection
Subcutaneous
injection (s.c.)
Pen-injector
Placebo injection
N/A
aOne dosepack contains one blister card with 7 tablets
Metformin, SGLT-2 inhibitors and rescue medication are considered NIMPs and will not be 
supplied by Novo Nordisk A/S. However, during the 52-weeks treatment period and the 5 weeks 
follow-up period; the patients de-facto cost (actual patient cost, not covered by the Health 
Authorities/any insurance) of SGLT-2-inhibitor and metformin (mono- or fixed dose combination 
products) will be reimbursed in accordance with local legislation and Ethics Committee approval.
For Japan only: During the treatment period, all anti-diabetic medication including pre-trial OADs 
will be reimbursed by Novo Nordisk Japan according to the local requirement.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
63 of 132
For both semaglutide and liraglutide, respectively, the active drug and the corresponding placebo 
are identical with regard to visual appearance. Furthermore, all semaglutide tablets are visually 
identical to each other, irrespective of the dose levels.
9.2
Labelling
The trial products will be labelled in accordance with Annex 1341, local regulations and trial 
requirements.
Each trial site will be supplied with sufficient trial product for the trial on an ongoing basis 
controlled by the IWRS. Trial products will be distributed to the trial sites according to enrolment 
and randomisation. 
The investigator must document that direction for use is given to the subject verbally and in writing 
at the first dispensing visit (V2). Directions for use should be given to the subject at subsequent 
visits when judged necessary by the investigator. The subjects must be trained in how to handle the 
injection pen when handed out the first time. Training must be repeated during the trial at regular 
intervals in order to ensure correct use of the injection pen.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
64 of 132
9.3
Storage 
Storage conditions of the trial products are outlined in Table 9–2.
Table 9–2
Storage conditions for investigational medicinal products
*In-use time starts when the product is taken out of the refrigerator at subjects home
The investigator must ensure that trial product is kept under proper storage conditions, and  record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by Novo Nordisk. The investigator must take 
appropriate action to ensure correct storage.
For Japan only: The head of the study site or the trial product storage manager if assigned by the 
head of the study site must ensure the availability of proper storage conditions, record and evaluate 
the temperature.
Trial product
Storage conditions
(not-in-use)
In-use conditions
In-use time*
Semaglutide 3 mg 
tablet
Do not store above 30ºC 
(86ºF)
Do not freeze
Do not refrigerate
Store in the original 
package
Take the tablet immediately 
after dispensation from blister 
card
Take the tablets whole: Do not 
break or chew
N/A
Semaglutide 7 mg 
tablet
Semaglutide 14 
mg tablet
Placebo tablet
Liraglutide 6
mg/mL
Store in a refrigerator
2°C to 8°C (36°F to 
46°F)
Protect from light
Do not freeze
At temperatures below 30°C 
or in a refrigerator 2°C to 8°C
US only: At room
temperature (59–86°F) or in a 
refrigerator (36°–46°F)
Protect from light
Do not freeze
Use within one month
US only: Use within 30
days
Placebo injections
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
65 of 132
9.4
Drug accountability and destruction
Drug accountability of all trial products received at site is the responsibility of the investigator.
For Japan only: Drug accountability is the responsibility of the head of the study site or the trial 
product storage manager if assigned by the head of the study site.
Subjects must be instructed to return all used, partly used and unused trial products including empty 
packaging material at each dispensing visit.
Returned trial product (used/partly used and/or unused, expired or damaged trial product) can be 
stored at room temperature and must be stored separately from non-allocated trial product. Non-
allocated trial product (including expired or damaged products) must be accounted for at the latest 
at closure of trial site.
Drug accountability is performed by using the IWRS. Drug accountability must be done on tablet 
and pen injection level.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by the monitor. Destruction of 
products must be documented in the IWRS.
9.5
Auxiliary supplies
The following will be provided by Novo Nordisk A/S in accordance with the TMM:
!
Direction For Use for pen-injector for trial product (liraglutide)
!
Needles for the device (needles longer than 8 mm must not be used)
!
BG meter and BG meter auxiliaries
For Japan only: The trial sites are allowed to purchase and supply themselves with auxiliary 
supplies, if possible. BG meters must be the same model as supplied by Novo Nordisk.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
66 of 132
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by authorised persons. 
IWRS is used for:
!
Screening
!
Screening failure
!
Randomisation
!
Medication arrival
!
Dispensing
!
Treatment discontinuation
!
Completion
!
Code break
!
Drug accountability
!
Data change
IWRS user manuals will be provided to each trial site. DUNs will be allocated using the IWRS. It is 
important to dispense the exact allocated DUNs to a subject.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
67 of 132
11 Randomisation procedure and breaking of blinded codes
The trial is a double-blinded trial. A randomisation session will be carried out for all subjects using 
the IWRS. 
At the randomisation visit (V2), subjects meeting all eligibility criteria will be randomised to one of 
three parallel treatment arms as described in Section 5.1.
Randomisation will be stratified based on:
!
Anti-diabetic background medication at screening (metformin alone, metformin in combination 
with SGLT-2 inhibitor)
!
Descent (Japanese subjects, non-Japanese subjects)
to ensure a 2:2:1 distribution of the three treatment arms within the four strata.
The aim is to randomise a minimum of 125 subjects on a background medication including SGLT-2 
inhibitor, and a minimum of 75 Japanese subjects.
11.1
Breaking of blinded codes
The IWRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person 
breaking the code must print the Code Break Confirmation Notification generated by the IWRS, 
record the reason, and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If the IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contacted. Contact details are listed in Attachment I. If the code has been 
broken the subject must discontinue treatment with trial product but be asked to continue in the trial 
(see Section 8.1.6). A treatment discontinuation session must be completed in the IWRS.
The laboratory responsible for antibody analysis and the responsible development bioanalysis 
scientist in Novo Nordisk will have access to the unblinding report in the IWRS.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
68 of 132
12 Adverse events, technical complaints and pregnancies
12.1
Definitions
12.1.1
Adverse event
An adverse event (AE) is any untoward medical occurrence in a subject administered or using a 
product, and which does not necessarily have a causal relationship with this treatment or usage. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!
A clinically significant worsening of a concomitant illness.
!
A CLAE: a clinical laboratory abnormality which is clinically significant, i.e. an abnormality 
that suggests a disease and/or organ toxicity and is of a severity that requires active 
management. Active management includes active treatment or further investigations, for 
example change of medicine dose or more frequent follow-up due to the abnormality.
The following should not be reported as AEs:
!
Pre-existing conditions, including those found as a result of screening or other trial procedures
performed before exposure to trial product (pre-existing conditions should be reported as 
medical history or concomitant illness).
!
Pre-planned procedures unless the condition for which the procedure was planned has worsened 
from the first trial related activity after the subject has signed the informed consent.
!
Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic episode form instead 
of on an AE form, see Section 8.4.9.
The following three definitions are used when assessing an AE:
!
Severity 
–
Mild – no or transient symptoms, no interference with the subject's daily activities.
–
Moderate – marked symptoms, moderate interference with the subject's daily activities.
–
Severe – considerable interference with the subject's daily activities; unacceptable.
!
Causality 
Relationship between an AE and the relevant trial product(s): 
–
Probable – Good reason and sufficient documentation to assume a causal relationship.
–
Possible – A causal relationship is conceivable and cannot be dismissed.
–
Unlikely – The event is most likely related to aetiology other than the trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
69 of 132
!
Final outcome
–
Recovered/resolved – The subject has fully recovered, or by medical or surgical treatment 
the condition has returned to the level observed at the first trial-related activity after the 
subject signed the informed consent.
–
Recovering/resolving – The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–
Recovered/resolved with sequelae – The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–
Not recovered/not resolved – The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–
Fatal – This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as ”recovered/resolved”, ”recovering/resolving”, ”recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an 
SAE.
–
Unknown – This term is only applicable if the subject is lost to follow-up.
12.1.2
Serious adverse event
An SAE is an experience that at any dose results in any of the following:
!
Death.
!
A life-threateninga experience.
!
In-patient hospitalisationb or prolongation of existing hospitalisation.
!
A persistent or significant disability or incapacityc.
!
A congenital anomaly or birth defect.
!
Important medical events that may not result in death, be life threateninga or require 
hospitalisationb may be considered an SAE when – based on appropriate medical judgement –
they may jeopardise the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in the definition of SAEd.  
a.
The term ”life threatening” in the definition of SAE refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it was more severe.
b. The term ”hospitalisation” is used when a subject: 
–
Is admitted to a hospital or in-patient, irrespective of the duration of physical stay, or 
–
Stays at the hospital for treatment or observation for more than 24 hours
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
70 of 132
Medical judgement must always be exercised, and when in doubt, the hospital contact should be 
regarded as a hospitalisation. Hospitalisations for administrative, trial related and social 
purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital 
admissions for surgical procedures, planned before trial inclusion, are not considered AEs or 
SAEs.
c.
A substantial disruption of a subject's ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospitalisation or development of drug 
dependency or drug abuse.
The following AEs must always be reported as an SAE using the important medical event criteria if 
no other seriousness criteria are applicable:
!
suspicion of transmission of infectious agents via the trial product
!
risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where no 
alternative aetiology exists (Hy's law).
Additional assessments should be made for events meeting the criterion of Hy’s law as stated above 
(see Appendix B). 
12.1.3
Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
71 of 132
12.1.4
Medication errors
A medication error concerning trial products is defined as:
!
Administration of wrong drug or use of wrong device. 
Note: Use of wrong DUN is not considered a medication error.
!
Wrong route of administration, such as intramuscular instead of s.c.
!
Administration of an overdose with the intention to cause harm (e.g. suicide attempt), misuse or 
abuse of trial product
!
Accidental administration of a higher dose than intended. A higher dose is a dose of at least one 
tablet more than the intended dose and for pen injection a higher dose than 1.8 mg/day; 
however, the administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial subject were likely to happen as judged by the investigator, although 
they did not necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section 8.4.1.1, 
12.1.5 and appendix B.
12.1.5
Adverse events requiring additional data collection
AEs requiring additional data collection are AEs where the additional data will benefit the 
evaluation of the product safety. A number of adverse events that always require additional data 
collection have been pre-specified. See appendix B for details about these events and the additional 
information to report.
Some events in this trial will be adjudicated by an independent external committee as described in 
Section 12.7.2.
Table 12-1 lists AEs that require completion of specific event forms in the eCRFs and/or are subject 
to event adjudication.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
72 of 132
Table 12–1
Adverse events requiring completion of specific event forms and/or are subject 
to event adjudication
Event
Specific event form
Event adjudication
Death
No
Yes
Acute coronary syndrome (myocardial infarction or 
hospitalisation for unstable angina)
Yes
Yes
Cerebrovascular event (stroke or transient ischaemic
attack)
Yes
Yes
Heart failure
Yes
Yes (only if requiring
hospitalisation)
Pancreatitis
Yes
Yes (only if acute pancreatitis)
Neoplasm (excluding thyroid neoplasm)
Yes
Yes (only if malignant)
Thyroid disease (including thyroid neoplasm)
Yes
Yes (only if malignant thyroid 
neoplasm or C-cell hyperplasia)
Renal event
Yes
Yes (only if acute kidney injury)
Hypersensitivity reaction
Yes
No
Acute gallstone disease
Yes
No
Medication error
Yes
No
Lactic acidosis
Yes
Yes
Creatine kinase (CK) > 10x UNL
Yes
No
Hepatic event defined as:
ALT or AST > 5 x UNL and total bilirubin ≤ 2 x UNL
ALT or AST > 3 x UNL and total bilirubin > 2 x UNL*
Hepatic event leading to trial product discontinuation.
Yes
No
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 
x UNL and total bilirubin > 2 x UNL, where no alternative aetiology exists (Hy's law), this must be reported as an SAE 
using the important medical event criterion if no other seriousness criteria are applicable.
For details about specific event forms, see appendix B.
12.1.6
Technical complaints
A technical complaint is any written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
73 of 132
Examples of technical complaints:
!
The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!
All packaging material including labelling
!
Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
Only technical complaints related to adverse events will be reported in the clinical trial report.  
12.2
Reporting of adverse events
All events meeting the definition of an AE must be collected and reported. This includes events
occurring from the first trial-related activity after the subject has signed the informed consent until
the end of the post-treatment follow-up period (V14) for subjects on trial product or until the end of 
trial (V13 or V14A, whichever comes last) for the subjects who have discontinued trial product 
prematurely. Events for withdrawn subjects will be collected and reported until last trial related 
contact with the subject. The events must be recorded in the applicable eCRF forms in a timely 
manner, see timelines below and Figure 12–1.
During each contact with the trial site staff, the subject must be asked about AEs and technical 
complaints, for example by asking: "Have you experienced any problems since the last contact?"
All AEs, either observed by the investigator or subject, must be reported by the investigator and 
evaluated. 
All AEs must be recorded by the investigator in the eCRF AE form. The investigator should report 
the diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms in the eCRF.
For SAEs, a safety information form (SIF) must be completed in addition to the AE form. A SIF is 
a form to collect supplementary clinical information. If several symptoms or diagnoses occur as part 
of the same clinical picture, one SIF can be used to describe all the SAEs. 
AEs requiring additional data collection must be reported using both the AE form and the specific 
event form. A specific event form is a form tailored to collect specific information related to the 
individual event. See appendix B for details about the events and the additional information to 
report. In case any of these events fulfil the criteria for seriousness in Section 12.1, then the event 
should be reported as serious.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
74 of 132
Some events will undergo event adjudication by the EAC, please refer to Section 12.7.2. For AEs 
qualifying for event adjudication, the adjudication form will also have to be completed in the eCRF. 
The adjudication form is a checklist of clinical data to be provided from the site.
For all non-serious AEs, the applicable forms should be signed when the event is resolved or at the 
end of the trial at the latest. 
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!
SAEs: The AE form within 24 hours and the SIF within 5 calendar days of the investigator's 
first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in 
the eCRF. 
For SAEs requiring reporting on a specific event form: In addition to the above, the specific 
event form within 14 calendar days from the investigators first knowledge of the AE.
!
Events for adjudication: The adjudication form should be completed within 14 calendar days
of the investigator’s first knowledge of the AE, see Section 12.7.2. The investigator should 
preferably provide the medical documentation within 4 weeks of event identification according 
to instructions in the event adjudication site manual. 
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by fax, e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact details (fax, telephone, e-mail and address) are provided in the investigator trial master file.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
75 of 132
AE identified
Does the AE require 
a specific event 
form?
Is the AE subject to 
adjudication and/or 
is the outcome 
fatal?
AE form < 24 hours
SIF < 5 calendar days
Specific event form 
For SAEs:
< 14 calendar days
Is the AE serious or 
non-serious?
AE form
Adjudication form
< 14 calendar days
Source data < 4 weeks
Non-serious
Serious
No
Yes
Yes
Queries and follow-up 
requests to be resolved 
< 14 calendar days
Timelines are for the completion of forms from the time of investigator’s awareness.
AEs requiring specific event forms are described in Section 12.1.4, 12.1.5 and appendix B.
AEs for adjudication are described in Section 12.7.2
AE: Adverse event  SAE: Serious adverse event  SIF: Safety Information form 
No additional action
No additional action
No
Figure 12–1
Reporting of AEs
Novo Nordisk A/S assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference
documents:
!
IB for oral Semaglutide (NN9924)24 and Victoza®; current versions and any updates 
thereto.
!
CCDS (Company Core Data Sheet) for Liraglutide ; current versions and any updates 
thereto.
Reporting of trial product-related SUSARs by Novo Nordisk A/S:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (SUSARs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including European Medicines Agency (EMA), of trial product-related SUSARs. In addition, Novo 
Nordisk will inform the IRBs/IECs of trial product-related SUSARs in accordance with local 
requirement and ICH GCP1, unless locally this is an obligation of the investigator.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
76 of 132
Novo Nordisk A/S products used as concomitant medication or non-investigational medicinal 
product:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product or concomitant medication in the trial, it is important that the 
suspected relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the 
SIF. Novo Nordisk may need to report this AE to relevant regulatory authorities.
12.3
Follow-up of adverse events
The investigator must record follow-up information by updating the medical records and the forms 
in the eCRF.
Follow up information must be reported to Novo Nordisk according to the following:
!
SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of 
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) 
may be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases 
can be closed with the outcome of “recovering/resolving” when the subject has completed the 
follow-up period and is expected by the investigator to recover.
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator's first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
!
Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the 
end of the follow-up period stated in the protocol, whichever comes first, and until all queries 
related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may be closed with the outcome 
“recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome 
of “recovering/resolving” when the subject has completed the follow-up period and is expected 
by the investigator to recover.
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within 14 calendar days
from the date of receipt of the request, unless otherwise specified in the follow-up request.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
77 of 132
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the IMP occurring to a subject after the subject has ended the trial, the investigator 
should report this SAE within the same timelines as for SAEs during the trial.
12.4
Technical complaints and technical complaint samples
12.4.1
Reporting of technical complaints
All technical complaints on any of the following products: 
!
semaglutide 3 mg/7 mg/14 mg or placebo tablets
!
liraglutide or placebo pre-filled pen-injector
!
Novo Nordisk needles
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to the Customer Complaint Center, Novo Nordisk.
Contact details (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs or SAEs.
Technical complaints must be reported on a separate technical complaint form. A technical 
complaint form for each code or lot number must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!
Technical complaint assessed as related to an SAE within 24 hours
!
All other technical complaints within 5 calendar days
If the eCRF is unavailable or when reporting a technical complaint that is not subject related, the 
information must be provided on a paper form by fax, e-mail or courier to the Customer Complaint 
Center, Novo Nordisk, within the same timelines as stated above. When the eCRF becomes 
available again, the investigator must enter the information on the technical complaint form in the 
eCRF.
12.4.2
Collection, storage and shipment of technical complaint samples
The investigator must collect the technical complaint sample and notify the monitor within 5 
calendar daysof obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included 
in the shipment of the sample. If several samples are returned in one shipment, the individual 
sample and the corresponding technical complaint form must be clearly separated.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
78 of 132
The investigator must ensure that the technical complaint sample contains the code or lot number 
and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
12.5
Pregnancies in female subjects
12.5.1
Pregnancies in female subjects
Female subjects must be instructed to notify the investigator immediately if they become pregnant 
during the trial. The investigator must report any pregnancy in subjects who have received trial 
product(s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant.
The following must be collected and reported by the investigator to Novo Nordisk – electronically 
(e.g. in PDF format), or by fax or courier:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to
be reported on Maternal Form 1A and 1B, respectively.
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further
information has to be reported for the female subject on Maternal Form 2. In addition,
information from the male partner has to be reported on the Paternal Form, after an informed
consent has been obtained from the male partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the
investigator's first knowledge of initial or follow-up information.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
79 of 132
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!
AE forma within 14 calendar days of the investigator's first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!
AE forma within 24 hours of the investigator's first knowledge of the SAE. 
!
SIF within 5 calendar days of the investigator's first knowledge of the SAE.
!
SAE follow-up information to the AE form and/or SIF within 24 hours of the 
investigator's first knowledge of the follow-up information.
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the 
subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE 
can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by the investigator within 14 calendar days from the date of receipt of 
the request, unless otherwise specified in the follow-up request.
12.6
Precautions and/or overdose
There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.
There is a potential risk of hypoglycaemia during dosing with semaglutide. The typical signs and 
symptoms of a non-severe hypoglycaemia include: hunger, slight headache, nausea, light-
headedness, palpitations and sweating. Symptoms of non-severe hypoglycaemia should be treated 
by ingestion of carbohydrates. 
Severe hypoglycaemia resulting in loss of consciousness should be treated according to best 
available medical practise. 
One case of accidental overdose of oral semaglutide was reported in the NN9924-3692 trial. The 
subject accidentally took the trial product
 and was thus treated with 20 mg of 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
80 of 132
oral semaglutide. The subject did not report any symptoms and treatment was continued without 
any change.
One case of accidental overdose has been reported in subjects treated with s.c. semaglutide once 
weekly. The subject inadvertently injected  mg of semaglutide instead of 0.4 mg, which 
corresponds to a 
-fold higher dose than the maximum dose included in that trial. After 
 hours 
the subject felt nauseated, vomited and had a headache. The subject was instructed to drink 
sufficient amounts of fluids. 
 and the subject 
wished to continue in the trial. No symptoms of hypoglycaemia or any other symptoms or signs 
were noted.  
For further details please see the current edition of the IB for oral administration of semaglutide 
(NN9924), edition 624, and any updates hereof.
12.7
Committees related to safety
12.7.1
Novo Nordisk safety committee
Novo Nordisk will constitute an internal oral semaglutide safety committee to perform ongoing 
safety surveillance. The oral semaglutide safety committee may recommend unblinding of any data 
for further analysis, and in this case an independent ad hoc group will be established in order to 
maintain the blinding of the trial personnel.
12.7.2
Event adjudication committee
An independent external event adjudication committee (EAC) is established to perform validation 
of selected AEs according to pre-defined diagnostic criteria. The validation is based on review of 
pre-defined clinical data related to the specific AE. Pre-defined clinical data consist of copies of 
source documents collected and delivered by the investigational sites.
The EAC is composed of permanent members covering required medical specialities. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk. 
The events are reviewed by the EAC in a blinded manner. The EAC will have no authorisations to 
impact on trial conduct, trial protocol or amendments.
The EAC works in accordance with written guidelines included in the EAC Charter describing in 
details the composition, tasks, responsibilities and work processes of the committee.
The events outlined in Table 12–2 have been selected for adjudication in order to obtain an external 
independent validation of the diagnosis. In addition, cardiovascular events are being adjudicated 
according to U.S. Food and Drug Administration (FDA) requirements42.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
81 of 132
The EAC will review copies in English (translated if necessary) of medical documentation received 
in the adjudication packages (e.g. x-rays, ECGs, ultrasound images, discharge summaries, 
pathology reports and death certificates). The investigator must provide medical documentation as 
soon as possible, when they receive the request from Novo Nordisk or the event adjudication 
vendor.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
82 of 132
The AEs for adjudication are listed in Table 12–2:
Table 12–2
Adverse events for adjudication
Events
Description
Adjudication outcome
Death*
! All-cause death
! Cardiovascular death 
(including undetermined 
cause of death)
! Non-cardiovascular death
Acute Coronary Syndrome
! Acute Coronary Syndrome conditions include: 
! ST-elevation acute myocardial infarction 
(STEMI)
! Non-ST elevation acute myocardial infarction 
(NSTEMI)
! Silent MI 
! Unstable angina pectoris (UAP)
! Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
! Unstable angina pectoris 
requiring hospitalisation
Cerebrovascular event
! Episode of focal or global neurological 
dysfunction caused by brain, spinal cord, or 
retinal vascular injury as a result of 
haemorrhage or infarction
! Transient Ischaemic Attack (TIA) is defined as 
a transient episode (< 24 hours) of focal 
neurological dysfunction caused by brain, spinal 
cord, or retinal ischaemia, without acute 
infarction
! Ischaemic stroke
! Haemorrhagic stroke
! Undetermined stroke
! TIA
Heart failure requiring 
hospitalisation
! Hospitalisation with a primary diagnosis of 
heart failure (new episode or worsening of 
existing heart failure)
! Heart failure requiring 
hospitalisation
Acute pancreatitis
The diagnosis of acute pancreatitis requires two of 
the following three features:
! Abdominal pain consistent with acute 
pancreatitis (acute onset of a persistent, severe, 
epigastric pain often radiating to the back)
! Serum lipase activity (and/or amylase activity) 
at least three times greater than the UNL
! Characteristic findings of acute pancreatitis on 
imaging
Acute pancreatitis
! Mild
! Moderately severe 
! Severe
Malignant neoplasm
Malignant neoplasms are defined as
! neoplasms in which abnormal cells divide 
without control and can invade nearby tissues 
and/or spread to other parts of the body through 
the blood and lymph systems
Thyroid neoplasms are excluded in this event 
category
! Malignant neoplasm
Thyroid disease, if malignant 
thyroid neoplasm or C-cell 
Malignant thyroid neoplasms are defined as 
! thyroid neoplasms in which abnormal cells 
! Malignant thyroid 
neoplasm
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
83 of 132
hyperplasia
divide without control and can invade nearby 
tissues and/or spread to other parts of the body 
through the blood and lymph systems
! C-cell hyperplasia, defined as hyperplasia of the 
parafollicular C-cells of the thyroid gland
! C-cell hyperplasia
Acute kidney injury
Acute kidney injury43 is defined as any of the 
following (not graded):
! Increase in serum creatinine by ≥ 0.3 mg/dL 
(≥26.5 μmol/L) within 48 hours, or
! Increase in serum creatinine to ≥ 1.5 times 
baseline, which is known or presumed to have 
occurred within the prior 7 days, or
! Urine volume < 0.5 mL/kg/h for 6 hours
! Acute kidney injury
Lactic acidosis
! Lactic acidosis is characterized by increased 
blood lactate level in association with metabolic 
acidosis
! Lactic acidosis
*Death is not a separate event, but an outcome
There are different processes for capturing events for adjudication:
!
Direct reporting by investigator:
o
All AEs need to be assessed by the investigator if any AE category is applicable. If the 
AE category selected is in scope for adjudication, the event specific adjudication form in 
the eCRF will be populated for sites to complete
o
AEs with fatal outcome
!
Screening: 
o
All AEs will be screened by NN for potential missed events for adjudication and if 
needed, the investigator will be asked to provide additional information such as an 
alternative aetiology, underlying cause(s) and/or clinical details.
o
All ECGs will be centrally read. If the central reading conclusion is suggestive of new 
MI, the ECG adjudication form will be populated for sites to complete for all post-
baseline ECGs.
!
EAC identified events:
o
The EAC can decide to have an AE adjudicated even if not initially reported as an event 
for adjudication by the investigator.
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date during the screening period. Event adjudication will not be performed for AEs in screening 
failures.
AEs for adjudication must be reported according to Section 12.2. In addition, the specific 
adjudication form should be completed within 14 calendar days of the investigator's first knowledge 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
84 of 132
of the AE and all relevant predefined documents provided within 4 weeks according to instructions 
in the event adjudication site manual.
The assessment made by the EAC will be included in the clinical trial report as well as the 
assessments made by the investigator. However, the adjudication made by an EAC, given its 
independent analysis of each event, will be attributed with greater importance of the two. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
85 of 132
13 Case report forms 
Novo Nordisk will provide a system for the eCRF. This system and support services to the system 
will be provided by an external supplier.
Ensure that all relevant questions are answered and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRF):
!
Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!
AE forms 
!
SIFs
!
Technical complaint forms (also to be used to report complaints that are not subject related (e.g. 
discovered at trial site before allocation)).
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by writing "ND" (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by writing "NA" (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
electronically signing the case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1
Corrections to case report forms 
Corrections to the eCRF data may be made by the investigator or the investigator's delegated staff.
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction. If corrections are made by the investigator's delegated staff after the date the investigator 
has signed the case book, the case book must be signed and dated again by the investigator.
13.2
Case report form flow 
The investigator must ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
86 of 132
At the end of the trial, the investigator must ensure that all remaining data have been entered into 
the eCRF no later than 3 days after LSLV at the site in order to ensure the planned lock of the 
database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site. When the final CTR is 
available, the data will be archived by Novo Nordisk A/S.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
87 of 132
14 Monitoring procedures
Monitoring will be conducted under a risk based approach.
During the course of the trial, the monitor will visit the trial site to ensure that the protocol is 
adhered to, that all issues have been recorded, to perform source data verification and to monitor 
drug accountability. The first monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and Good Clinical Practice (GCP), but will not exceed 12 weeks until 
LSLV at the trial site (for trial sites with active subjects (defined as subjects in screening, treatment 
or follow-up)).
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by telephone).
All data must be verifiable in source documentation other than the eCRF.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by the trial site can be corrected by another person than the person entering 
the source data if accepted by local regulations; any correction must be explained, signed and dated 
by the person making the correction.
The original of the completed diaries and/or PROs must not be removed from the trial site, unless 
they form part of the eCRF and a copy is kept at the site.
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures:
!
Date for obtaining informed consent.
!
Reason for screening failure
Monitors will review the subject's medical records and other source data (e.g. the diaries and PROs) 
to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, 
the investigator must be questioned about these.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
88 of 132
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
89 of 132
15 Data management
Data management is the responsibility of Novo Nordisk. Data management may be delegated under 
an agreement of transfer of responsibilities to a Contract Research Organisation (CRO). 
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks. 
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological material obtained from the subject will be identified by subject 
number and trial ID. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity of subjects in all presentations and publications as required by 
local, regional and national requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
90 of 132
16 Computerised systems
Novo Nordisk will capture and process clinical data using computerised systems that are described 
in Novo Nordisk Standard Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
91 of 132
17 Statistical considerations
General considerations
If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before 
database lock.
The blinding of the randomised treatments will be maintained until the database has been released 
for statistical analysis. Data from all sites will be analysed and reported together. 
In statistical analyses where stratification is included, the two combinations of anti-diabetic 
background medication at screening (metformin or metformin+SGLT-2 inhibitor) will be included 
based on the actual information collected through the eCRF. In case of missing eCRF information 
the information collected from the IWRS system will be used. The information regarding descent 
(Japanese subjects/non-Japanese subjects) will be included based on country details from the eCRF. 
In the statistical analyses the stratification factor will refer to anti-diabetic background medication
at screening. Descent (Japanese subjects/non-Japanese subjects) will be included in the statistical 
analyses as part of region.
The latest available measurement, at or prior to the randomisation visit, will be used as the baseline 
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline 
value will be left missing.
Laboratory values below the lower limit of quantification (LLoQ) will be set to ½LLoQ. Number of 
values below LLoQ by treatment and visit will be summarised if deemed relevant.
The primary and confirmatory efficacy endpoints will be evaluated at week 26. This approach is 
expected to result in a lower proportion of missing data, use of rescue medication and premature 
treatment discontinuations, compared to the expected proportion of missing data, use of rescue 
medication and premature treatment discontinuation at week 52, and therefore considered a 
meaningful representation and confirmation of the effect of oral semaglutide. 
Results from a statistical analysis will as a minimum be presented by the estimated treatment 
contrasts for the below two comparisons with associated two-sided 95% confidence intervals and p-
values corresponding to two-sided tests of no difference.
!
oral semaglutide 14 mg vs. placebo 
!
oral semaglutide 14 mg vs. liraglutide 1.8 mg 
If no statistical analysis is specified, data will be presented using relevant summary statistics.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
92 of 132
Primary and secondary estimands
Two estimands addressing different aspects of the trial objective will be defined; a primary de-facto 
(effectiveness) estimand and a secondary de-jure (efficacy) estimand: 
!
Primary estimand
–
de facto treatment difference (oral semaglutide versus placebo and oral semaglutide versus 
liraglutide) at week 26 for all randomised subjects regardless of adherence to randomised 
treatment and initiation of rescue medication
The primary de facto estimand assesses the expected glycaemic benefit in a future population that 
results from subjects initiating treatment with oral semaglutide including potential rescue 
medication(s) and the expected glycaemic benefit compared to initiating treatment with liraglutide 
including potential rescue medication(s). Generalisation of this estimand depends among other 
things on the extent to which the use of rescue medication in this trial reflects clinical practice and 
the adherence to trial product administration in this trial reflects the behaviour of the target 
population. Accordingly, data collected regardless of discontinuation of trial product or initiation of 
rescue medication(s) will be used to draw inference. 
!
Secondary estimand 
–
de-jure treatment difference (oral semaglutide versus placebo and oral semaglutide versus 
liraglutide) at week 26 for all randomised subjects if all subjects adhered to treatment and 
did not initiate rescue medication
The secondary de-jure estimand assesses the glycaemic benefit a future subject is expected to 
achieve if initiating and continuing treatment with oral semaglutide and the glycaemic benefit 
compared to liraglutide. It is considered a clinically relevant estimand as it provides information to 
treating clinicians about the expected glycaemic efficacy of oral semaglutide and the expected 
glycaemic efficacy compared to liraglutide for purposes of treating individual subjects. 
Generalisation of this estimand depends among other things on the extent to which the adherence to 
trial product administration in this trial reflects the behaviour of the target population. Accordingly, 
only data collected prior to discontinuation of trial product or initiation of rescue medication will be 
used to draw inference. This will avoid confounding from rescue medication. 
Missing data considerations at week 26
When estimating the primary estimand, the proportion of missing data, i.e., data that do not exist 
even though subjects are intended to stay in the trial regardless of treatment status and initiation of 
rescue medication(s), is expected to be maximum 10% based on the oral semaglutide phase 2 trial 
(NN9924-3790). Thus, missing data will be due to withdrawal from trial or lost to follow-up.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
93 of 132
When estimating the secondary estimand, the proportion of missing data is expected to be higher 
(20%) since data collected after discontinuation of trial product or initiation of rescue medication(s) 
will be set to missing. The 20% of missing data is based on the liraglutide phase 3 trial (NN2211-
1572), the oral semaglutide phase 2 trial (NN9924-3790) that indicates that a low starting dose with 
gradual dose escalation diminishes GI AEs compared with more aggressive dosing regimens. 
Across treatment arms the main reasons for missing data are expected to be early treatment 
discontinuation due to AEs (GI AEs for oral semaglutide and liraglutide) and initiation of rescue 
medication. Initiation of rescue medication is expected to be more frequent in the placebo arm than 
for the oral semaglutide and liraglutide arms. A higher proportion of subjects are expected to 
discontinue treatment due to AEs in the oral semaglutide and liraglutide arms, compared to the 
placebo arm. So overall the frequency of missing data is expected to be similar across treatment 
arms.
Descriptive summaries and graphical representation of extent, reason(s) for and pattern of missing 
data will be presented by treatment arm.
17.1
Sample size calculation
To assess the effect of liraglutide on glycaemic effect, a similar trial LEAD-2 (NCT00318461) 
where liraglutide was used as add on to metformin was reviewed. Based on this trials, the chosen 
margin of 0.4 provides assurance that oral semaglutide has a clinically relevant effect greater than 
zero. With regards to the constancy assumption, controlled clinical trials have consistently 
established that liraglutide is an effective anti-diabetic drug. Therefore, lack of trial sensitivity with 
liraglutide as comparator is not anticipated to be an issue in this trial. 
The primary endpoint is change from baseline to week 26 in HbA1c. For HbA1c, superiority of oral 
semaglutide vs. placebo and both non-inferiority and superiority of oral semaglutide vs. liraglutide 
are planned to be tested. The confirmatory secondary endpoint is change from baseline to week 26 
in body weight (kg). For body weight, superiority of oral semaglutide vs. placebo and oral 
semaglutide vs. liraglutide are planned to be tested. 
The sample size calculation is made to ensure a power of at least 90% for testing the below four out 
of the five pre-specified confirmatory hypotheses shown in Figure 17–1. The closed testing
procedure described in Bretz et al. (2011)44 is used to control the overall type I error at a nominal 
two-sided 5% level. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
94 of 132
The four hypotheses are
!
HbA1c superiority of oral semaglutide vs. placebo
!
HbA1c non-inferiority of oral semaglutide vs. liraglutide (margin 0.4%)
!
Body weight superiority of oral semaglutide vs. placebo 
!
Body weight superiority of oral semaglutide vs. liraglutide 
The statistical testing strategy is based on the following two principles:
!
To demonstrate glycaemic effect of oral semaglutide compared to placebo
!
Glycaemic effect compared to liraglutide must be established in terms of HbA1c non-inferiority 
before testing for added benefits in terms of HbA1c superiority and/or body weight superiority.
The sample size is calculated using the calcPower function in the R package, gMCP45 using 10000 
simulations. All of the five pre-specified confirmatory tests are assumed to be independent. Since 
some of the tests are positive correlated, the assumption of independence is viewed as conservative.
The sample size assumptions for treatment effects (TE), adjusted treatment effects and the standard 
deviations (SD) are given in Table 17–1.
These assumptions are primarily based on the oral semaglutide phase 2 results (NN9924-3790), 
liraglutide phase 3 trial results (Victoza® US prescribing information) and supported by results from 
the s.c. semaglutide phase 2 trial (NN9535-1821). 
Since the equalising effect of rescue medication will be included in the primary analysis as well as a 
conservative approach for handling of missing data will be performed, an adjustment in treatment 
effect will be implemented for the 10% of subjects who are expected to discontinue trial product or 
initiate rescue medication and for the 10% of subjects who are expected to have actual missing data. 
The treatment effects used in the sample size calculation will be adjusted according to a 75% 
smaller effect in these subjects. For the 10% of the subjects with missing data, the non-inferiority 
margin of 0.4% for HbA1c is added to the imputed values, when testing for non-inferiority. The 
adjusted treatment effects for testing non-inferiority (HbA1c oral semaglutide versus liraglutide 
only) and superiority are as described below:
!
Non-inferiority 
–
0.8×TE + 0.2×TE×0.25 + non-inferiority margin×0.1
!
Superiority
–
0.8×TE + 0.2×TE×0.25 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
95 of 132
Table 17–1
Assumptions used in the sample size calculation
Comparator
Parameter
Treatment effect 
(TE)
Adjusted TE, 
non-inferiority
Adjusted TE, 
superiority
Standard 
deviation 
Non-
inferiority 
margin
Placebo
HbA1c 
−1.0%
−0.85%
1.1%
Liraglutide
HbA1c
0%
+0.04%
0%
1.1%
0.4%
Placebo
Body weight
−3kg
−2.55kg 
4kg
Liraglutide
Body weight
−1.5kg
−1.275kg
4kg
With the above assumptions using a 2:2:1 randomisation, allocating 276 subjects to each of the oral 
semaglutide and the liraglutide arms and allocating 138 subjects to the placebo arm, provides 90% 
power to jointly confirm HbA1c superiority of oral semaglutide vs. placebo, HbA1c non-inferiority 
of oral semaglutide vs. liraglutide, body weight superiority of oral semaglutide vs. placebo and 
body weight superiority of oral semaglutide vs. liraglutide. In total 690 subjects are planned to be 
randomised. Calculated powers for individual hypotheses are presented in Table 17–2. 
Table 17–2
Calculated powers for individual hypotheses
Comparator:
placebo
liraglutide
Statistical test:
HbA1c
superiority
Body weight
superiority
HbA1c
non-inferiority
HbA1c superiority
Body weight
superiority
Power:
> 99%
97%
97%
2%
91%
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
96 of 132
Figure 17–1
Graphical illustration of the closed testing procedure
The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA1c superiority test vs. placebo. The 
local significance level (α-local) will be reallocated if a hypothesis is confirmed according to the weight given by the 
directed edges between nodes (hypotheses).The sample size is based on the hypotheses in the dark boxes.
17.2
Definition of analysis sets
The following analysis sets will be defined:
Full analysis set (FAS): Includes all randomised subjects. Subjects in the FAS will contribute to 
the evaluation “as randomised”.
Safety analysis set (SAS): Includes all subjects exposed to at least one dose of trial product. 
Subjects in the SAS will contribute to the evaluation “as treated”.
Per protocol (PP) analysis set: Includes all subjects in the FAS who fulfils the following criteria
!
have not violated any inclusion criteria
!
have not fulfilled any exclusion criteria
!
have a baseline HbA1c measurement
!
is exposed to trial product and have at least one HbA1c measurement at or after week 14
Subjects in the PP analysis set will, as in the SAS, contribute to the analysis “as treated”.
 = 0
HbA1c (%)
Non-inferiority vs. liraglutide
 = 0
HbA1c (%)
Superiority vs. liraglutide
 = 0
Body weight (kg)
Superiority vs. liraglutide
1
1 2

1
1
 = 0.05
HbA1c (%)
Superiority vs. placebo
1
 = 0
Body weight (kg)
Superiority vs. placebo
1 2

CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
97 of 132
Data selections and observation periods
Unless subjects withdraw their informed consent, data collection will continue for the full duration 
of the trial. The full duration of the trial is defined as up to and including
!
the follow-up visit (V14) for subjects on trial product
!
the latest occurring visit of the end-of-treatment visit (V13) or the follow-up premature 
discontinuation visit (V14A), for subjects who have discontinued trial product prematurely.
Subjects and data to be used in an analysis will be selected in a two-step manner.
!
Firstly, subjects will be selected based on the specified analysis set
!
Secondly, data points on the selected subjects from the first step will be selected based on the 
specified observation period
Definition of the observation periods:
In-trial: This observation period represents the time period where subjects are considered to be in 
the trial, regardless of discontinuation of trial product or initiation of rescue medication. The in-trial 
observation period starts at randomisation (as registered in the IWRS) and ends at the date of
!
the last direct subject-site contact, which is scheduled to take place 5 week after planned last 
dose of trial product at the follow-up visit. 
!
withdrawal for subjects who withdraw their informed consent
!
the last subject-investigator contact as defined by the investigator for subjects who are lost to 
follow-up
!
death for subjects who dies before any of the above 
On-treatment: This observation period represents the time period where subjects are considered 
treated with trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. For adjudicated events, ECGs, anti-semaglutide antibodies, and 
AEs including hypoglycaemic episodes, the observation period ends at the first date of any of the 
following:
!
the follow-up visit (V14)
!
the follow-up prematurely discontinuation visit (V14A)
!
the last date on trial product +38 days (5 weeks follow-up period + 3 days visit window)
!
the end-date for the in-trial observation period
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
98 of 132
The follow-up visit is scheduled to take place 5 weeks after the last date on trial product 
corresponding to approximately five half-lives of oral semaglutide. The visit window for the follow-
up visit is +3 days.
For efficacy and other safety assessments (laboratory assessments, physical examination and vital 
signs) the observation period ends at the last date on trial product +3 days. This will be used in 
order to ensure specificity to reversible effects of treatment
On-treatment without rescue medication: This observation period is a subset of the on-treatment 
observation period, where subjects are considered treated with trial product, but has not initiated 
any rescue medications. The on-treatment without rescue medication observation period starts at 
first date on trial product and the observation period ends at the first date of any of the following:
!
the last dose of trial product +3 days
!
initiation of rescue medication
The in-trial observation period will be the primary observation period when estimating the primary 
estimand. The on-treatment without rescue medication observation period will be the primary 
observation period when estimating the secondary estimand. The on-treatment observation period 
will be considered supportive for evaluating efficacy. Safety will be evaluated based on the in-trial 
and the on-treatment observation periods.
Data points collected outside an observation period will be treated as missing in the analysis. 
Baseline data will always be included in an observation period. For adjudicated events, the onset 
date will be the EAC adjudicated onset date. 
Before data are locked for statistical analysis and the randomisation code is broken, a review of all 
data will take place. Any decision to exclude either a subject or single observations from the 
statistical analysis is the joint responsibility of the members of the Novo Nordisk study group. 
Exclusion of data from analyses should be used restrictively, and normally no data should be 
excluded from the FAS. The subjects or observations to be excluded, and the reasons for their 
exclusion must be documented and signed by those responsible before database lock. The subjects 
and observations excluded from analysis sets, and the reason for this, will be described in the 
clinical trial report.
Confirmatory hypotheses 
For the primary HbA1c endpoint and the confirmatory secondary body weight endpoint the 
following confirmatory one-sided hypotheses are planned to be tested for oral semaglutide versus 
placebo (superiority) and oral semaglutide versus liraglutide (non-inferiority and superiority). Let 
the mean treatment difference be defined as μ = (oral semaglutide minus placebo or oral 
semaglutide minus liraglutide):
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
99 of 132
!
HbA1c non-inferiority, using a non-inferiority margin of 0.4% (only vs. liraglutide) 
o
H0: μ ≥ 0.4% against Ha: μ < 0.4%
!
HbA1c superiority
o
H0: μ ≥ 0.0% against Ha: μ < 0.0%
!
Body weight superiority
o
H0: μ ≥ 0.0kg against Ha: μ < 0.0kg
Operationally, the hypotheses will be evaluated by two-sided tests.  
Multiplicity and criteria for confirming hypotheses
The type I error for testing the five confirmatory hypotheses related to the HbA1c and body weight 
endpoints will be preserved in the strong sense at 5 % (two-sided) using the weighted Bonferroni-
based closed testing procedure described in Bretz et al. (2011)44 and outlined in Figure 17–1. 
The first hypothesis to be tested is superiority of HbA1c versus placebo. It will be tested at the 
overall significance level (5 %) while allocating 0 % local significance level to the remaining 
hypotheses. For this hypothesis, and in general, if a hypothesis is confirmed the significance level 
will be reallocated according to the weight and the direction of the edges going from the confirmed 
hypothesis to the next hypotheses as specified in Figure 17–1. Each of the following hypotheses 
will be tested at their local significance level (α-local). This process will be repeated until no further 
hypotheses can be confirmed. 
Non-inferiority and/or superiority will be considered confirmed if the mean treatment difference is 
supporting the corresponding alternative hypothesis and the two-sided p-value from the primary 
analysis of the primary estimand is strictly below its local two-sided significance level as defined by 
the closed testing procedure in Figure 17–1. This is equivalent to using a one-sided p-value 
(nominal α = 0.025) and a one-sided 2.5 % overall significance level in the closed testing procedure.
17.3
Primary endpoint
The primary endpoint is change from baseline to week 26 in HbA1c.
17.3.1
Primary analysis for the primary estimand 
The primary estimand will be estimated based on the FAS using week 26 measurements from the 
in-trial observation period. The primary statistical analysis will be a pattern mixture model using 
multiple imputation to handle missing data assuming that the missing data mechanism is missing at 
random (MAR) within the groups used for imputation. Imputation of missing data at week 26 will 
be done within 6 groups of subjects defined by randomised treatment arm, and whether subjects at 
week 26 (i) have discontinued treatment or initiated rescue medication or (ii) are still on treatment 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
100 of 132
and have not initiated rescue medication. It is hereby assumed that the likely values of what the 
missing data would have been if available are best described by information from subjects who at 
week 26 are similar in terms of randomised treatment arm and treatment adherence/rescue 
medication status.
Missing values for each group will be imputed as follows:
!
An analysis of covariance (ANCOVA) with stratification factor and region as categorical fixed 
effects and baseline HbA1c measurement as a covariate will be fitted to observed values of the 
change from baseline in HbA1c at week 26.
!
The estimated parameters for location and dispersion will be used to impute 100 values for each 
subject with missing week 26 data based on stratification factor and region as categorical and 
baseline HbA1c. Thus, 100 complete data sets will be generated including observed and imputed 
values.
Analysis used for confirming superiority versus placebo/liraglutide at week 26:
For each of the 100 (now complete) imputed data sets, the change from baseline to week 26 will be 
analysed using an ANCOVA with treatment, stratification factor and region as categorical fixed 
effects and baseline HbA1c as covariate. The results obtained from analysing the datasets will be 
combined using Rubin’s rule46 to draw inference.
Analysis used for confirming non-inferiority versus liraglutide at week 26:
Prior to analysing the data using the same model and approach as used for confirming superiority 
(see above), a value of 0.4% (the non-inferiority margin) will be added to imputed values at week 
26 for the oral semaglutide treatment arms only47. For evaluating non-inferiority versus liraglutide 
an unadjusted two sided p-value for testing no difference from the non-inferiority margin will be 
presented.
17.3.2
Primary analysis for the secondary estimand
The secondary estimand will be estimated based on the FAS using post-baseline measurements up
to and including week 26 from the on-treatment without rescue medication observation period. The 
primary analysis for the secondary estimand will be a Mixed Model for Repeated Measurements 
(MMRM). A restricted maximum likelihood (REML) will be used. The model will include all post 
baseline HbA1c measurements collected at scheduled visits up to and including week 26 as 
dependent variables. The independent effects included in the model will be treatment, stratification 
factor and region as categorical fixed effects and baseline HbA1c as a covariate, all nested within 
visit. An unstructured covariance matrix for HbA1c measurements within the same subject will be 
employed, assuming measurements from different subjects are independent. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
101 of 132
The MMRM is a well-established method that accounts for the uncertainty pertaining to missing 
data. This analysis assumes that the missing data mechanism is MAR. Under this assumption the 
statistical behaviour of the missing data (given the observed responses and model fixed effects and 
covariates) is assumed to be same as the observed data. 
17.3.3
Sensitivity analyses
To investigate the sensitivity of the primary analysis results, complementary and separate analyses 
will be performed for the primary and secondary estimand. In line with EMA recommendations48
and with a report from the US National Research Council49, these analyses will primarily evaluate 
the sensitivity of the results due to the impact of missing data. Since conservatism, i.e. avoiding bias 
in favour of oral semaglutide, depends on the context, separate sensitivity analyses will be made for 
non-inferiority and superiority testing.
The evaluation of the robustness of the primary analysis results will primarily be based on a pattern 
mixture model approach using multiple imputation. An overview of the sensitivity analyses for each 
of the estimands are specified below followed by a more detailed description of the three different 
pattern mixture models used. Finally, three additional sensitivity analyses for the primary analysis 
will be described that are not based on the pattern mixture model approach (see section 17.3.3.2).
Sensitivity analyses for the primary estimand
The estimation of the primary estimand will be repeated using the following sensitivity analyses: 
!
A comparator multiple imputation analysis based on FAS using the in-trial observation period 
(superiority).
!
A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the in-trial observation period (superiority).
!
A tipping-point multiple imputation analysis based on FAS using the in-trial observation period 
(non-inferiority and superiority).
!
A MMRM analysis (the primary analysis for the secondary estimand) based on FAS using the 
in-trial observation period (non-inferiority and superiority).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
102 of 132
Sensitivity analyses for the secondary estimand
The estimation of the secondary estimand will be repeated using the following sensitivity analyses:
!
A comparator multiple imputation analysis based on FAS using the on-treatment without rescue 
medication observation period (superiority).
!
A comparator multiple imputation analysis based on FAS using the on-treatment observation 
period (superiority). This sensitivity analysis aims to compare oral semaglutide versus placebo 
and versus liraglutide for subjects who adhere to treatment regardless of whether or not rescue 
medication has been initiated.
!
A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the on-treatment without rescue medication 
observation period (superiority).
!
A tipping-point multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period (non-inferiority and superiority).
17.3.3.1
Pattern mixture models
Common for the three pattern mixture model sensitivity analyses is that they all aim to stress-test 
the primary HbA1c results by changing the assumptions for part or all missing data in the oral 
semaglutide treatment arm, while maintaining the missing data assumption for the comparator 
(placebo or liraglutide depending on the hypothesis). 
!
Comparator multiple imputation analysis: In this sensitivity analysis missing data at week 
26 for all subjects will be imputed to resemble the distribution of the week 26 values 
observed in the comparator arm. In effect this imputation approach removes the treatment 
difference between oral semaglutide and comparator for all subjects randomised to oral 
semaglutide, given that oral semaglutide is better than the comparator. Due to the potential 
lack of sensitivity for testing non-inferiority this sensitivity analysis will only be used to 
evaluate the robustness of HbA1c superiority conclusion.
!
Comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely: In this sensitivity analysis missing data at week 26 for subjects who 
discontinue oral semaglutide treatment due to treatment related AE(s) will be imputed to 
resemble the distribution of the week 26 values observed in the comparator arm. Treatment 
related AEs are defined as AEs classified as possible or probable related to trial product as 
reported by the investigator. In effect this imputation approach removes the treatment 
difference between oral semaglutide and the comparator for this selected group of subjects 
randomised to oral semaglutide. This sensitivity analysis is less conservative as compared to 
the first sensitivity analysis. Due to the potential lack of sensitivity for testing non-inferiority 
this sensitivity analysis will only be used to evaluate the robustness of HbA1c superiority 
conclusion.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
103 of 132
!
Tipping-point multiple imputation analysis: In this sensitivity analysis, missing data will 
first be imputed according to the primary analysis. Secondly, for the oral semaglutide 
treatment arm a penalty will be added to the imputed values at week 26. The approach is to 
gradually increase this penalty until the HbA1c conclusion from the primary analysis is 
changed. The specific value of the penalty that changes the conclusion will be used to 
evaluate the robustness of the primary analysis result. This sensitivity analysis will be used 
for evaluating the robustness of the HbA1c non-inferiority and superiority conclusions.
17.3.3.2
Other sensitivity analyses
The following additional sensitivity analyses will be specified
!
Per-protocol analysis: This sensitivity will be based on the per-protocol analysis set. Data 
from the on-treatment without rescue medication observation period will be analysed using 
the primary analysis approach for the primary estimand. This sensitivity analysis will be 
used to evaluate the robustness of the HbA1c non-inferiority conclusions.
!
Complete case analysis: This sensitivity analysis will be based on the on-treatment without 
rescue medication observation period and include subjects in the FAS who have a valid 
HbA1c measurement at week 26. The change from baseline to week 26 in HbA1c will be 
analysed by a linear normal model (ANCOVA) with treatment, stratification factor and 
region as categorical fixed effects and baseline HbA1c as a covariate. This sensitivity 
analysis will be used to evaluate the robustness of the HbA1c non-inferiority conclusions. 
!
Last observation carried forward (LOCF) analysis: This sensitivity analysis will be based 
on the FAS using the on-treatment without rescue medication observation period. The 
change from baseline to week 26 in HbA1c will be analysed by a linear normal model 
(ANCOVA) with treatment, stratification factor and region as categorical fixed effects and 
baseline HbA1c as a covariate. This sensitivity analysis will be used for evaluating the 
robustness of the HbA1c non-inferiority and superiority conclusions. 
17.3.3.3
Assessment of sensitivity analyses
The results from the sensitivity analyses will be collectively used to interpret the robustness of the 
trial results for HbA1c. Due to the large number of sensitivity analyses and their inherent 
conservative nature, it will not be a requirement that all confirmatory hypotheses are consistently 
confirmed across the sensitivity analyses. Thus, no absolute success criteria will be pre-defined for 
each sensitivity analysis. The sensitivity results in totality will be used to substantiate the credibility 
of the trial results.
17.4
Secondary endpoints
17.4.1
Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) will be a confirmatory secondary endpoint. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
104 of 132
The primary and secondary estimands will be estimated using the same approaches as described for 
the primary HbA1c endpoint. Body weight will only be tested for superiority. Baseline body weight 
will be used as a covariate instead of baseline HbA1c in both the multiple imputation and analysis 
model.
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding hypothesis and the two-sided p-value from the analysis of the primary estimand is 
strictly below its local two-sided significance level resulting from the closed testing procedure in 
Figure 17–1. Sensitivity analyses similar to the ones pre-specified for testing superiority for the 
primary HbA1c endpoint will be made to evaluate the robustness of the body weight results.
17.4.2
Supportive secondary endpoints
17.4.2.1
Efficacy endpoints
The below supportive secondary efficacy endpoints will be evaluated for
!
the primary estimand based on FAS using the in-trial observation period
!
the secondary estimand based on FAS using the on-treatment without rescue medication 
observation period
No sensitivity analyses are planned for these. 
17.4.2.2
Continuous efficacy endpoints
Change from baseline to week 52 in:
!
HbA1c
!
Body weight (kg)
Change from baseline to week 26 and week 52 in:
!
Body weight (%)
!
FPG
!
BMI
!
Waist circumference
!
Fasting lipid profiles (total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, 
triglycerides, free fatty acids)
BMI will be calculated based on body weight and height based on the formulae:
BMI kg/m2 = body weight (kg)/(Height (m) x Height (m)) or (kg/m2 = [lb/in2 x 703])
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
105 of 132
Change from baseline to week 26 and week 52 in 7-point self-measured plasma glucose (SMPG) 
profile:
!
Mean 7-point profile; defined as the area under the profile, calculated using the trapezoidal 
method, divided by the measurement time
!
Mean postprandial increment (during all meals)
The above continuous endpoints will be analysed separately using similar model approaches as for 
the primary endpoint with the associated baseline response as a covariate. Fasting lipid profile 
endpoints will be log-transformed prior to analysis with the associated log-transformed baseline 
value as a covariate.
For evaluation of the primary estimand the analysis will be performed separately for week 26 and 
week 52. For the analysis at week 52, the imputation of missing data will be further differentiated 
by whether subjects have discontinued trial product or initiated rescue medication prior to week 26 
or at or after week 26. This will result in imputation of missing data within 12 groups of subjects 
instead of the 6 groups as described for the week 26 evaluation in Section 17.3.1. If less than 5 
subjects have available data in one of the 12 groups, the imputation will be made within the 6 
groups specified for the primary evaluation. The frequency of missing data is expected to be slightly 
larger at week 52 compared to week 26. The rate of missing data is expected to decline over time. 
For evaluation of the secondary estimand the MMRM based primary analysis will include all 
scheduled post-baseline measurement up to and including week 52. From this model the estimated 
treatment differences (ratios) will be presented at week 26 (except for HbA1c and body weight), and 
week 52 with 95 % confidence intervals and two-sided p-values for test of no difference.
Binary efficacy endpoints
If a subject after week 26 achieves (yes/no):
!
HbA1c < 7.0 % (53 mmol/mol) (ADA) target
!
HbA1c ≤ 6.5 % (48 mmol/mol) (AACE) target
!
HbA1c reduction ≥ 1 % (10.9 mmol/mol)
!
Weight loss ≥ 3 %
!
Weight loss ≥ 5 %
!
Weight loss ≥ 10 %
!
HbA1c < 7.0 % (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemia) and no weight gain
!
HbA1c reduction ≥ 1 % (10.9 mmol/mol) and weight loss ≥ 3 %
The above eight endpoints will also be evaluated after week 52.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
106 of 132
The above eight binary endpoints will be analysed using a logistic regression model with treatment 
and region as fixed effects and baseline response as covariate (i.e. baseline HbA1c for binary 
HbA1c endpoints, baseline weight for weight endpoints and both baseline HbA1c and baseline 
weight for the binary endpoint that combines both parameters). To account for missing data, the 
analysis will be made using a sequential multiple imputation approach as described below:
!
Multiple imputed data sets (100) will be created in which missing values for the underlying 
continuous assessments are imputed by treatment group and treatment adherence/rescue 
status assuming MAR and as described in section 17.3.1 for the primary estimand and by 
treatment group assuming MAR and as described in section 17.3.2 for the secondary 
estimand.
!
The binary endpoint will be created for each of the 100 complete data sets
Each of the created complete data set will be analysed with the logistic model and inference will be 
drawn using Rubin’s rule46.
Time to event endpoint
!
Time to rescue medication
Subjects completing the study without need for rescue medication will be censored at the time point 
of the (actual) last date on trial product. The start time is first date on trial product. Time to rescue 
medication will be described and compared for oral semaglutide versus placebo and oral 
semaglutide versus liraglutide using likelihood ratio tests obtained from a proportional Cox hazards 
model with treatment, stratification factor and region as categorical fixed effects and baseline 
HbA1c as covariate. From this analysis the estimated Hazard ratios between semaglutide and 
placebo and between semaglutide and liraglutide will be presented together with 95 % confidence 
intervals and two-sided p-values for test of no difference.
17.4.2.3
Safety endpoints
The safety endpoints will be evaluated based on SAS using the on-treatment observation period and 
the in-trial observation period unless otherwise stated. The following endpoints are used to support 
the safety objective:
Adverse events 
!
Number of TEAEs during exposure to trial product, assessed up to approximately 57 weeks
All AEs will be coded using the most recent version of the Medical Dictionary for Regulatory 
Activities (MedDRA) coding. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
107 of 132
A TEAE is defined as an AE with onset in the on-treatment observation period (see definition of 
observation periods in Section 12).
TEAEs will be summarised in terms of the number of subjects with at least one event (N), the 
percentage of subjects with at least one event (%), the number of events (E) and the event rate per 
100 patient years of observation time (R) for the on-treatment observation period. Supportive 
summaries of AEs will be made for the in-trial observation period. The development over time in 
gastrointestinal AEs will be presented graphically.
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!
Amylase
!
Lipase
!
Pulse
!
Systolic blood pressure
!
Diastolic blood pressure
The above safety endpoints will be evaluated using the primary analysis for the primary estimand 
based on SAS using the in-trial observation period and using the primary analysis for the secondary 
estimand based on SAS using the on-treatment observation period. Endpoints will be analysed 
separately as described above for continuous efficacy endpoints. Results will be presented at week 
26 and 52. Amylase and lipase endpoints will be log-transformed prior to analysis with the 
associated log-transformed baseline value as a covariate.
Change from baseline to week 26 and week 52 in:
!
Haematology 
!
Biochemistry (except for amylase and lipase)
!
Calcitonin
!
ECG evaluation
!
Physical examination (week 52 only)
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!
Anti-semaglutide binding antibodies
!
Anti-semaglutide neutralising antibodies
!
Anti-semaglutide binding antibodies cross reacting with native GLP-1
!
Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 57 weeks
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
108 of 132
!
Anti-semaglutide binding antibody levels
The above safety endpoints will be summarised descriptively by treatment arm and visit. The binary
safety endpoints will be summarised as counts and relative frequencies. Calcitonin will also be 
presented by gender. 
Hypoglycaemia
!
Number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic 
episodes during exposure to trial product, assessed up to approximately 57 weeks
!
Treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes during 
exposure to trial product, assessed up to approximately 57 weeks (yes/no) 
Classification of hypoglycaemia:
Hypoglycaemic episodes will be summarised for the SAS and the on-treatment observation period 
only.
Treatment-emergent: hypoglycaemic episodes will be defined as treatment-emergent if the onset of 
the episode occurs within the on-treatment observation period (see definition of observation periods 
in Figure 17–2).
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05.59 both inclusive.
Hypoglycaemic episodes are classified according to the Novo Nordisk classification of 
hypoglycaemia and the ADA classification of hypoglycaemia (see Figure 17–2).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L 
(56 mg/dL)50. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-
off point in the definition of BG-confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification:
Severe or BG-confirmed symptomatic hypoglycaemia: An episode that is severe according to the 
ADA classification37 or BG-confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with 
symptoms consistent with hypoglycaemia. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
109 of 132
ADA classification of hypoglycaemia37
!
Severe hypoglycaemia: An episode requiring assistance of another person to actively administer 
carbohydrate, glucagon, or take other corrective actions. PG concentrations may not be 
available during an event, but neurological recovery following the return of PG to normal is 
considered sufficient evidence that the event was induced by a low plasma glucose
concentration.
! Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
! Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured plasma glucose concentration ≤ 3.9 mmol/L 
(70 mg/dL).
! Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the 
typical symptoms of hypoglycaemia with a measured plasma glucose concentration > 3.9 
mmol/L (70 mg/dL) but approaching that level.
! Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia 
are not accompanied by a plasma glucose determination but that was presumably caused by a 
plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
110 of 132
Hypoglycaemic 
episode 
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
Asymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemia
No
Yes
No measurement 
with symptoms
PG > 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
No
Yes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 17–2
ADA classification of hypoglycaemia
PG: plasma glucose. SMPG: Self-measured plasma glucose
Data on treatment-emergent hypoglycaemic episodes will be presented in terms of the number of 
subjects with at least one episode, the percentage of subjects with at least one episode (%), the total 
number of episodes and the episode rate per 100 patient years of observation time.
Analysis of severe or BG-confirmed symptomatic hypoglycaemic endpoints
The number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes 
will be evaluated for the on-treatment period using a negative binomial regression model with a log-
link function and the logarithm of the duration of the subject’s on-treatment observation period as 
offset. The model will include treatment and region as fixed factors and baseline HbA1c as 
covariate.
The binary endpoint showing whether a subject has at least one treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemic episode will be analysed using a logistic regression model 
with treatment and region as fixed factors and baseline HbA1c as covariate.
17.5
Interim analysis 
No interim analyses will be performed before the database is locked.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
111 of 132
17.6
Health economics and/or patient reported outcomes (PROs)
Change from baseline to week 26 and week 52 in:
!
DTSQs: individual items and treatment satisfaction score (6 of the 8 items summed)
The PRO endpoint will be evaluated using the primary analysis for the primary estimand based on 
FAS using the in-trial observation period and using the primary analysis for the secondary estimand 
based on FAS using the on-treatment without rescue medication period. The individual items and 
the treatment satisfaction score will be analysed separately as the other continuous efficacy 
endpoints with the associated baseline response as a covariate.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
112 of 132
18 Ethics
18.1
Benefit-risk assessment of the trial
18.1.1
Risks and precautions
The nonclinical safety programme of oral semaglutide has not revealed any safety issues precluding 
use in humans. 
The sections below describe the important identified and potential risks and precautions associated 
with oral semaglutide treatment. These are based on findings in nonclinical studies and clinical 
trials with oral semaglutide as well as other GLP-1 RAs. For each of these risks and precautions, 
mitigating actions have been implemented to minimise the risks for subjects enrolled in this trial.
Identified risks
Gastrointestinal adverse events
Consistent with findings with other GLP-1 RAs, the most frequently reported AEs in clinical trials 
with oral semaglutide have been gastrointestinal disorders (nausea, vomiting, diarrhoea, dyspepsia 
and constipation). Clinical trials have indicated that a low starting dose and gradual dose escalation 
mitigates the risk of gastrointestinal AEs. Consequently, a low starting dose and dose escalation 
with 4 week dose-escalation steps have been implemented in the trial. 
Potential risks
Medullary thyroid cancer
The human relevance of the proliferative C-cell changes found in rodents treated with GLP-1 RAs 
is unknown, but data suggest that rodents are more sensitive to the mode of action of GLP-1 RAs 
for induction of C-cell tumours. However, as a precaution, subjects with a family or personal 
history of MEN 2 or MTC will not be enrolled in the trial. During the trial, calcitonin will be 
measured on a regular basis, and the guidance for investigators on further evaluation and action on 
elevated calcitonin concentrations is included in appendix A. 
Acute pancreatitis
Acute pancreatitis has been reported in subjects treated with GLP-1 RAs including oral 
semaglutide. As a precaution, subjects with a history of acute or chronic pancreatitis will not be 
enrolled in the trial. Also, subjects will be informed about the symptoms of acute pancreatitis and 
serum levels of lipase and amylase will be monitored throughout the trial.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
113 of 132
Pancreatic cancer
Patients with T2DM have an increased risk of certain types of cancer such as pancreatic cancer. 
There is currently no support from nonclinical studies or clinical trials or post-marketing data that 
GLP-1-based therapies increase the risk of pancreatic cancer. However, pancreatic cancer has been 
included as a separate potential risk due to the scientific debate surrounding a potential association 
to GLP-1-based therapies and the unknown long-term effects of stimulation of β-cells and 
suppression of α-cells. Pancreatic cancer has been classified as a potential class risk of GLP-1 RAs 
by EMA.
Allergic reactions
As in the case with all protein-based pharmaceuticals, treatment with oral semaglutide may evoke 
allergic reactions. These may include urticaria, rash, pruritus as well as anaphylactic reactions. As a 
precaution, subjects with known or suspected hypersensitivity to trial product(s) or related products 
will not be enrolled in the trial. In addition, subjects will be instructed to contact the site staff as 
soon as possible for further guidance if suspicion of a hypersensitivity reaction to the trial product 
occurs.
Hypoglycaemia
Based on current knowledge about the GLP-1 RA drug class, there is a risk of hypoglycaemic 
episodes. Hypoglycaemic episodes have mainly been observed when a GLP-1 RA is combined with 
sulphonylurea or insulin. The risk for development of hypoglycaemia with oral semaglutide in 
combination with sulphonylurea and insulin is currently unknown. 
Acute renal impairment
In subjects treated with GLP-1 RAs, including oral semaglutide, gastrointestinal AEs such as 
nausea, vomiting and diarrhoea may lead to significant dehydration and secondary acute renal 
impairment. Subjects with gastrointestinal AEs are recommended to drink plenty of fluids to avoid 
volume depletion. Also, serum creatinine and other markers of kidney function will be monitored 
throughout the trial.
SGLT-2 inhibitors, an allowed background medication, have also been associated with volume 
depletion. It is recommended to monitor renal function and for signs and symptoms of fluid loss 
during therapy. Severe dehydration may be a risk factor for ketoacidosis.
Impaired renal function may increase the risk of metformin associated lactic acidosis when GLP-1 
RAs are co-administered with metformin. As a precaution, serum creatinine will be measured 
regularly. In subjects treated with metformin who experience prolonged or severe nausea and 
vomiting, the investigator should monitor serum creatinine, and if clinically indicated, withhold 
metformin until resolution of renal dysfunction.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
114 of 132
The use of the background medication should be in accordance with the current, approved labels.
Other safety considerations
Teratogenicity (embryo-foetal development toxicity)
Semaglutide caused embryo-foetal malformations in the rat through a GLP-1 receptor mediated 
effect on the inverted yolk sac placenta leading to impaired nutrient supply to the developing 
embryo. Primates do not have an inverted yolk sac placenta which makes this mechanism unlikely 
to be of relevance to humans. However, as a precaution, females who are pregnant, breast-feeding 
or intend to become pregnant or are of childbearing potential and not using an adequate 
contraceptive method will not be enrolled in the trial. In addition, pregnancy tests will be performed 
at all visits, including screening and follow-up and at any time during the trial if a menstrual period
is missed, or as required by local law.
General precautions 
All subjects will be included after a thorough evaluation with regards to in- and exclusion criteria 
defined in order to ensure that subjects are eligible for trial treatment.
There are also strict glycaemic rescue criteria in place to ensure acceptable glycaemic control 
during the trial. If rescue medication is required, it should be in accordance with ADA/European 
Association for the Study of Diabetes27,28 (excluding GLP-1 RAs, DPP-4 inhibitors and amylin 
analogues).
It is the responsibility of the investigator to ensure the best possible care according to the principles 
outlined in Diabetes Care 2014 Standards of Medical Care in Diabetes51.
Further details with regards to safety of trial product are described in the current edition of the IB 
for oral semaglutide (NN9924)24 or any updates thereto or in the current approved label of 
Victoza®.
18.1.1.1
Liraglutide
The most commonly reported side effects associated with liraglutide are nausea, diarrhoea, 
vomiting, other GI symptoms, nasopharyngitis, hypoglycaemia (when combined with SU or 
insulin), anorexia, headache, increased heart rate, dizziness, rash and injection site reactions. Also, 
dehydration, renal impairment and pancreatitis have been reported52.
18.1.1.2
Placebo
There will be strict glycaemic rescue criteria in place to ensure acceptable glycaemic control for all 
treatment arms at all times during the trial. Subjects will in case of unacceptable, persistent 
hyperglycaemia be offered treatment intensification (rescue medication) at the discretion of the 
investigator. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
115 of 132
18.1.2
Benefits 
In this trial, subjects will be randomised in a 2:2:1 manner to either oral semaglutide, liraglutide or 
placebo as add-on to their current background medication (metformin alone or metformin in 
combination with a SGLT-2 inhibitor). Subjects will therefore, for the majority of the trial period, 
be treated with a regime anticipated to be better than or equal to the treatment they receive at the 
time of entry into the trial. Based on the results of the phase 2 dose finding trial, oral semaglutide is 
expected to provide clinically relevant improvements in glycaemic control and body weight in 
subjects with type 2 diabetes. Similarly, treatment with liraglutide is expected to provide clinically 
relevant improvements in glycaemic control52.  
In addition, it is expected that all subjects, including subjects randomised to placebo, will benefit 
from participation through close contact with the study site, with close follow-up of their T2DM 
and a careful medical examination, all of which will most likely result in an intensified management 
of their T2DM.
All subjects in this trial will receive trial products and auxiliary supplies free of charge. 
18.1.3
Risk and benefit conclusion 
The safety profile for oral semaglutide generated from the clinical and nonclinical development 
programme has not revealed any safety issues that would prohibit administration of oral 
semaglutide in accordance with the planned clinical trial. The phase 2 results indicate that oral 
semaglutide will provide clinically relevant improvements in glycaemic control and body weight.
Liraglutide is already a marketed drug approved for the use in subjects with T2DM.
Safety and efficacy will be monitored regularly and acceptable glycaemic control will be reinforced
at all times during the trial.
In conclusion, the potential risk to the subjects in this trial is considered low and acceptable in view 
of the anticipated benefits oral semaglutide would provide to patients with T2DM. 
18.2
Informed consent
In seeking and documenting informed consent, the investigator must comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1 and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
116 of 132
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.
A voluntary, signed and personally dated informed consent must be obtained from the subject 
before any trial-related activity.
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally dated by the person who 
seeks the informed consent before any trial-related activity.
If information becomes available that may be relevant to the subject’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner and a revised 
written subject information must be provided and a new informed consent must be obtained.
In order to avoid missing data, the subjects will be informed about the importance of completing the 
trial also if the subjects discontinue from trial product.
18.3
Data handling
If the subject withdraws from the trial or is lost to follow up, then the subject’s data will be handled 
as follows:
!
Data already collected and any data collected at the end-of-trial visit including follow-up visit 
will be retained by Novo Nordisk, entered into the database and used for the clinical trial report. 
!
Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.4
Information to subjects during trial
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notification according to local regulations.
18.5
Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
117 of 132
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
118 of 132
19 Protocol compliance
19.1
Protocol deviations
Deviations from the protocol should be avoided.
If deviations do occur, the investigator must inform the monitor and the implications of the 
deviation must be reviewed and discussed.
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database. 
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor
trial master file.
19.2
Prevention of missing data
The importance of subject retention will be addressed by Novo Nordisk in the training and 
communication with the trial sites. 
The subjects will be carefully informed about the trial procedures before signing informed consent, 
so that they know the implications of participating in the trial.  
Close surveillance of subject retention will be performed throughout the trial by Novo Nordisk with 
focus on reasons for premature discontinuation of trial product or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites. 
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by appropriate actions (e.g. re-training of site staff).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
119 of 132
20 Audits and inspections
Any aspect of the clinical trial may be subject to audits conducted by Novo Nordisk or inspections 
from domestic or foreign regulatory authorities or from IRBs/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
120 of 132
21 Critical documents
Before a trial site is allowed to start screening subjects, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
!
Regulatory approval and/or acknowledgement of notification as required 
!
Approval/favourable opinion from IRBs/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, any 
other written information to be provided to the subject and subject recruitment materials
!
List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!
Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must include 
documented GCP training or a certificate)
!
Signed receipt of IB for oral semaglutide and SmPC or similar product information for Victoza®
(liraglutide)
!
Signed and dated Agreement on Protocol
!
Signed and dated Agreement on Protocol Amendment, if applicable
!
Contract, signed by the investigator and/or appropriate parties on behalf of the investigator’s site 
and Novo Nordisk
For Japan only: A seal is accepted as signature
!
Source document agreement
!
Central laboratory certification and normal ranges
!
Insurance statement, if applicable
!
Financial disclosure form from investigator and sub-investigator(s)
!
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!
For US trial sites: FDA form 1572 must be completed and signed by the investigator at each site
FDA form 1572:
For US sites:
!
Intended for US sites
!
Conducted under the IND
!
All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!
Intended for participating sites outside of the US
!
Not conducted under the IND
!
All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
121 of 132
By signing the protocol agreement, each investigator agrees to comply fully with ICH GCP1, 
applicable regulatory requirements and the Declaration of Helsinki2.
By signing the protocol agreement, each investigator also agrees to allow Novo Nordisk to make
investigator's name and information about site name and address publically available if this is 
required by national or international regulations.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
122 of 132
22 Responsibilities
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator's responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
123 of 132
23 Reports and publications
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by Novo Nordisk in connection with this 
trial shall remain the sole property of Novo Nordisk and is to be considered confidential 
information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial. The information 
obtained during this trial may be made available to other physicians who are conducting other 
clinical trials with the trial product, if deemed necessary by Novo Nordisk. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One or two investigators will be appointed by Novo Nordisk to review and sign the clinical trial 
report (signatory investigator) on behalf of all participating investigators. The signatory investigator 
will be appointed based upon the criteria defined by the International Committee of Medical Journal 
Editors for research publications53.
23.1
Communication of results
Novo Nordisk commits to communicating, and otherwise making available for public disclosure, 
results of trials regardless of outcome. Public disclosure includes publication of a paper in a 
scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or 
disclosure by other means.
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations, as reflected in the Novo Nordisk Code of Conduct for 
Clinical Trial Disclosure4.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
124 of 132
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators' and Novo Nordisk opinions 
will be fairly and sufficiently represented in the publication.
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by the journal. 
Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to 
review any scientific paper, presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication. 
23.1.1
Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors53 (sometimes referred to as the Vancouver 
Criteria). Novo Nordisk will appoint investigator(s) to prepare publications in collaboration with 
Novo Nordisk.
23.1.2
Site-specific publication(s) by investigator(s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than 18 months after trial completion.
23.2
Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. 
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
125 of 132
24 Retention of clinical trial documentation and human biosamples
24.1
Retention of clinical trial documentation
Subject's medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copies or prints) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by Novo Nordisk. These data must be retained by the trial site. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by Novo Nordisk.
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least 20 years 
after discontinuation of the marketing authorisation, termination of the trial or cancellation of the 
research project, whichever is longest.
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by local regulations or Novo Nordisk. In any case trial files cannot 
be destroyed until the trial site/institution is notified by Novo Nordisk. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.2
Retention of human biosamples
Antibody samples may be retained for later analysis for further characterisation of antibody 
responses towards drug if required by health authorities or for safety reasons.
The samples will be stored at a central bio-repository after end of trial and until marketing 
authorisation approval or until the research project terminates, but no longer than 15 years from end 
of trial after which they will be destroyed.
The subject’s identity will remain confidential and the antibody samples will be identified only by 
subject number, visit number and trial identification number. No direct identification of the subject 
will be stored together with the samples.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
126 of 132
Only Novo Nordisk staff and bio-repository personnel will have access to the stored antibody 
samples. 
Subjects can contact the investigator if they wish to be informed about results derived from stored 
antibody samples obtained from their own body. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
127 of 132
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status, and other documents as required by the 
local IRB/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opinion according to 
local regulations, unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copies must be sent to 
Novo Nordisk.
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
128 of 132
26 Indemnity statement
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by persons for whom the said site or investigator are 
responsible.
Novo Nordisk accepts liability in accordance with:
German Drug Law dated August 24, 1976, last amended by article 3 of the law dated December 10, 
2015 (Federal Law Gazette I p. 2210).
For Poland only: Novo Nordisk carries liability for the trial exclusively in the scope defined by the
applicable laws and in particular by the Civil Code and the Pharmaceutical Law dated 6 September
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to
support potential claims for liability attributable to the trial, Novo Nordisk and the investigators
are covered by the insurance policy issued according to applicable Polish law.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
129 of 132
27 References
1.
International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. 
Guideline for Good Clinical Practice E6(R1), Step 4. 10 June 1996.
2.
World Medical Association. Declaration of Helsinki. Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3.
DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835, ix.
4.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
5.
Chuang LM, Tsai ST, Huang BY, Tai TY, Diabcare-Asia Study G. The status of diabetes 
control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. 
Diabet Med. 2002;19(12):978-85.
6.
Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults 
with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31(1):102-4.
7.
Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. 
Mol Cell Endocrinol. 2009;297(1-2):127-36.
8.
Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913.
9.
Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of 
the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(3):737-
45.
10.
Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-
insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
11.
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 
(GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-8.
12.
Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in 
normal and diabetic sujbjects. J Clin Invest. 1967;46(12):1954-62.
13.
Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-
normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and 
glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 
2009;52(2):199-207.
14.
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. 
Nat Rev Endocrinol. 2012;8(12):728-42.
15.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and 
suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-20.
16.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like 
peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy 
humans. Am J Physiol. 1997;273(5 Pt 1):E981-8.
17.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of 
fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-
insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-4.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
130 of 132
18.
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and 
clinical implications. Am J Med. 2011;124(1 Suppl):S3-18.
19.
Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. 
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic 
patients. J Clin Endocrinol Metab. 2001;86(8):3717-23.
20.
Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once 
weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a 
randomised, open-label study. Lancet. 2013;381(9861):117-24.
21.
European Medicines Agency. ICH Topic M 3 (R2): Non-Clinical Safety Studies for the 
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, Step 3. 
July 2008.
22.
Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 
receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 
2015;28(3):391-402.
23.
Novo Nordisk A/S. Investigators Brochure for s.c. Semaglutide (NN9535), Edition 10 or 
any updates hereof. 2015.
24.
Novo Nordisk A/S. Investigators Brochure for oral Semaglutide (NN9924), Edition 6 or any 
updates hereof. 2015.
25.
EU label information Victoza, current version and any updates hereof.
26.
US label information Victoza, current version and any updates hereof.
27.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position 
statement of the American Diabetes Association (ADA) and the European Association for 
the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
28.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. 
Update to a position statement of the American Diabetes Association and the European 
Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42.
29.
Novo Nordisk A/S. http://www.novonordisk-trials.com/website/content/how-we-disclose-
trial-information.aspx.
30.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
31.
U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007. 27 September 2007.
32.
The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 1 May 
2001.
33.
The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
131 of 132
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. 2004.
34.
The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. 
Official Journal of the European Communities. December 2006.
35.
Bradley C. Diabetes Treatment Satisfaction Questionnaire. In: Bradley C, editor. Handbook 
of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers; 1994. p. 
111-32.
36.
National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 
Update. Am J Kidney Dis. 2012;60(5):850-86.
37.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
38.
McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
39.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. December 2009.
40.
Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-
42.
41.
Commission E. The Rules Governing Medicinal Products in the European Union, Volume 4, 
Annex 13, Investigational Medicinal Products. Brussels, February 2010.
42.
Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Strockbridge NL, et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials 
(Draft). 20 Aug 2014.
43.
KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international 
supplements. 2012;2(1):1-138.
44.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical 
approaches for multiple comparison procedures using weighted Bonferroni, Simes, or 
parametric tests. Biometrical Journal. 2011;53(6):894-913.
45.
Rohmeyer K, Klinglmueller F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. 3 Oct 2014.
46.
Little RJA, Rubin DB. Statistical analysis with missing data: New York: John Wiley & 
Sons. 1987.
47.
Koch GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
48.
(CHMP) EMACfMPfHU. Guideline on Missing Data in Confirmatory Clinical Trials 
(EMA/CPMP/EWP/1776/99 Rev. 1). 7/2/2010 2010.
49.
National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press. 2010.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT no.: 2015-005210-30
Page:
132 of 132
50.
Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 
1987;79(3):777-81.
51.
Standards of medical care in diabetes--2015: summary of revisions. Diabetes Care. 2015;38 
Suppl:S4.
52.
Novo Nordisk A/S. Victoza® (liraglutide), EU Summary of product characteristics (SmPc) 
(last updated 24/11/2015).
53.
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 12/16/2014 
2014.
CONFIDENTIAL


Protocol - Appendix A
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT No.: 2015-005210-30
Page:
1 of 6
Appendix A
Monitoring of Calcitonin
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol - Appendix A
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT No.: 2015-005210-30
Page:
2 of 6
1
Background
Treatment with GLP-1 receptor agonists has been shown to be associated with thyroid C-cell 
changes in rodents but not in non-human primates. The human relevance of this finding is 
unknown. However, based on the findings in rodents, monitoring of serum calcitonin (a sensitive 
biomarker for C-cell activation) is currently being performed in clinical trials with semaglutide.
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (greater than 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is 
less clear with regards to indication of disease.
There are several known confounding factors affecting calcitonin levels, e.g.:
!
renal dysfunction
!
smoking
!
autoimmune thyroiditis
!
several drug classes (e.g. proton pump inhibitors, beta-blockers, H2-blockers and 
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various co-morbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.
CONFIDENTIAL


Protocol - Appendix A
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT No.: 2015-005210-30
Page:
3 of 6
2
Calcitonin monitoring
A blood sample will be drawn at pre-specified trial visits for measurement of calcitonin.
In case a subject has a calcitonin value ≥ 10 ng/L, the algorithm outlined in Figure 1 and described 
below should be followed. The algorithm applies for all calcitonin values in the trial.
Calcitonin < 10ng/L
Calcitonin  ≥ 10 ng/L and 
< 50 ng/L
Calcitonin  ≥ 50 ng/L and 
< 100 ng/L
Calcitonin  ≥ 100 ng/L
Evaluation of 
calcitonin results
Calcitonin  ≥ 10 ng/L and 
last measurement in the 
trial
No action
●Investigate potential confounding 
factors
●Continue sampling of calcitonin 
according to protocol
●Refer to thyroid specialist
●Discontinue trial product
●Refer to thyroid specialist
●Refer to thyroid specialist
Figure 1
Flow of calcitonin monitoring
2.1
Calcitonin ≥ 100 ng/L  
Action: The subject must immediately be referred to a thyroid specialist for further evaluation and 
the trial product must be discontinued (see protocol Section 6.5 premature discontinuation of trial 
CONFIDENTIAL


Protocol - Appendix A
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT No.: 2015-005210-30
Page:
4 of 6
product). The subject should remain in the trial; however, all medications suspected to relate to this 
condition must be discontinued until diagnosis has been established.
Background: These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease 1. All of these patients were diagnosed with MTC, resulting in a positive predictive 
value of 100 %.
Diagnostic evaluation should include:
!
thyroid ultrasound examination
!
fine needle aspiration of any nodules > 1 cm 
!
potentially, surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 and perform a genetic test for RET proto-oncogene mutation.
2.2
Calcitonin ≥ 50 and < 100 ng/L
Action: The subject should be referred to a thyroid specialist for further evaluation. The subject 
should remain in the trial and continuation on trial product should be based on the evaluation done 
by the thyroid specialist. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease 1. Two of these subjects were diagnosed with MTC and two were diagnosed with 
C-cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%.
Diagnostic evaluation should include: 
!
thyroid ultrasound examination 
!
if available, and if there are no contraindications, a pentagastrin stimulation test should be done. 
For subjects with positive pentagastrin stimulation test, surgery should be considered.
!
if pentagastrin stimulation test is not available, thyroid ultrasound and fine needle aspiration 
biopsy may add important clinical information about the need for surgery.
2.3
Calcitonin ≥ 10 and < 50 ng/L
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol.
If the value is from the last sample taken in the trial, the subject should be referred to a thyroid 
specialist for further evaluation.
CONFIDENTIAL


Protocol - Appendix A
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT No.: 2015-005210-30
Page:
5 of 6
Background: Calcitonin values from 20–50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease 1. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm 
with calcitonin in this range is extremely low.
For calcitonin values between 10-20 ng/L Costante et al. 1 identified 216 (3.7%) patients. One 
patient out of the 216 had a subsequent basal (unstimulated) calcitonin value of 33 ng/L, and had C-
cell hyperplasia at surgery. Two other studies used a cut-off of calcitonin > 10 ng/L to screen for C-
cell disease, but they do not provide sufficient information on patients with basal CT > 10 and < 20 
ng/L to allow conclusions 2, 3.
CONFIDENTIAL


Protocol - Appendix A
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029 
Status:
Final
EudraCT No.: 2015-005210-30
Page:
6 of 6
3
References
1.
Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive 
value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma 
in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 
2007;92(2):450-5.
2.
Scheuba C, Kaserer K, A m, drosten R. Sporadic hypercalcitoninemia: clinica and 
therapeutic consequences. Endocrine Related Cancer. 2009;16(1):243-53.
3.
Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M, et al. Histopathological 
and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic 
C-cell hyperplasia? Endocr Relat Cancer. 2007;14(2):393-403.
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
1 of 9
Appendix B
Adverse events requiring additional data collection
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
2 of 9
Adverse Events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!
Acute coronary syndrome (myocardial infarction or hospitalisation for unstable angina)
!
Cerebrovascular event (stroke or TIA)
!
Heart failure
!
Pancreatitis
!
Neoplasm (excluding thyroid neoplasm)
!
Thyroid disease (including thyroid neoplasm)
!
Renal event
!
Hypersensitivity reaction
!
Acute gallstone disease
!
Medication error (concerning trial products):
o
Administration of wrong drug. 
o
Note: Use of wrong DUN is not considered a medication error.
o
Wrong route of administration.
o
Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
o
Accidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however, the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen, as judged by the investigator, although they did not necessarily occur.
!
Lactic acidosis
!
Creatine kinase (CK) > 10 × UNL
!
Hepatic event:
o
ALT or AST > 5 × UNL and total bilirubin ≤ 2 × UNL
o
ALT or AST > 3 × UNL and total bilirubin > 2 × UNL*
o
Hepatic event leading to trial product discontinuation 
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 3 × UNL and total bilirubin > 2 × UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
In case any of these events fulfil the criteria for an SAE, please report accordingly, see Section 
12.1.2.
Some of these events will undergo event adjudication by the Event Adjudication Committee (EAC), 
please see Section 12.7.2 and Table 12-1.
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
3 of 9
Acute coronary syndrome
If an event of acute coronary syndrome (ranging from unstable angina pectoris to myocardial 
infarction) is observed during the trial, the following additional information must be reported if 
available: 
!
Duration of symptoms
!
Changes in ECG
!
Collection of cardiac biomarkers
!
Cardiac imaging
!
Cardiac stress testing
!
Angiography
!
Use of thrombolytic drugs
!
Revascularisation procedures 
Cerebrovascular event
If a cerebrovascular event (e.g. TIA, stroke) is observed during the trial, the following additional 
information must be reported if available: 
!
Type of event (e.g. TIA, stroke)
!
Contributing condition
!
Neurologic signs and symptoms
!
History of neurologic disease
!
Imaging supporting the condition
!
Treatment given for the condition
Heart failure
If an event of heart failure is observed during the trial, the following additional information must be 
reported if available: 
!
Signs and symptoms of heart failure
!
NYHA class
!
Supportive imaging
!
Supportive laboratory measurements
!
Initiation or intensification of treatment for this condition
Pancreatitis
For all confirmed events of pancreatitis the following additional information must be reported if 
available:
!
Signs and symptoms of pancreatitis
!
Specific laboratory test supporting a diagnosis of pancreatitis:
!
Imaging performed and consistency with pancreatic disease
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
4 of 9
!
Treatment for and complications of the event
!
Relevant risk factors for pancreatic disease
!
Family history of pancreatic disease
Assessments in case of suspicion of acute pancreatitis
Most patients with acute pancreatitis experience severe abdominal pain that is located generally in 
the epigastrium and radiates to the back. The onset of the pain may be swift, reaching maximum 
intensity within 30 min, is frequently unbearable, and characteristically persists for more than 24 
hours without relief 1.The pain is often associated with nausea and vomiting. Physical examination 
usually reveals severe upper abdominal tenderness at times associated with guarding. 
In general, both amylase and lipase are elevated during the course of acute pancreatitis. The serum 
lipase may remain elevated slightly longer than amylase. The level of the serum amylase and/or 
lipase does not correlate with the severity of acute pancreatitis 1. In general, serum lipase is thought 
to be more sensitive and specific than serum amylase in the diagnosis of acute pancreatitis. 
In case of suspicion of acute pancreatitis, the trial product should promptly be interrupted (no 
treatment discontinuation call should be made in IWRS before diagnosis of acute pancreatitis is 
confirmed). Appropriate additional examinations must be performed, including local measurement 
of amylase and lipase. 
The diagnosis of acute pancreatitis requires two of the following three features 2: 
!
abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric
pain often radiating to the back)
!
serum lipase activity (and/or amylase activity) at least three times greater than the upper normal 
limit
!
characteristic findings of acute pancreatitis on imaging.
If acute pancreatitis is ruled out, trial product should be re-initiated.
If acute pancreatitis is confirmed, appropriate treatment and careful monitoring of the subject 
should be initiated. The subject must be discontinued from trial product (treatment discontinuation 
call in IWRS), but should remain in the trial (see Section 6.5 and 8.1.5).
Neoplasm
All events of neoplasms (excluding thyroid neoplasms, which will be reported under thyroid 
disease) must be reported during the trial and the following additional information must be reported 
if available:
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
5 of 9
!
Type of neoplasm
!
Symptoms leading to identification of event
!
Diagnostic imaging
!
Pathological examination results
!
Treatment for the event
!
Participation in screening programs
!
Risk factors associated with the event
Thyroid disease
If an event of thyroid disease, including any thyroid neoplasms, is observed during the trial, the 
following additional information must be reported if available:
!
History of thyroid disease
!
Signs and symptoms leading to investigations of thyroid disease
!
Specific laboratory tests describing thyroid function
!
Diagnostic imaging performed and any prior imaging supporting the disease history 
!
Pathologic examinations
!
Treatment given for the condition
!
Risk factors identified
!
Family history of thyroid disease
Renal event 
If a renal event is observed during the trial, the following additional information must be reported if 
available:
!
Signs and symptoms of renal failure
!
Specific laboratory tests supporting the diagnosis 
!
Imaging performed supporting the diagnosis
!
Kidney biopsy results
!
Risk or confounding factors identified including exposure to nephrotoxic agents
Hypersensitivity reactions
All events of hypersensitivity reactions must be reported and the following additional information
must be reported if available:
!
Signs and symptoms associated with the event
!
Time of appearance after administration of trial drug
!
Relevant immunological tests performed
!
Treatment given for the reaction
!
Previous history of similar reactions
!
Risk or confounding factors identified
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
6 of 9
Assessments in case of suspicion of hypersensitivity reactions
In case of suspicion of a severe immediate systemic hypersensitivity reaction 3 to the trial product, 
the subject must be discontinued from trial product but should remain in the trial (see Section 6.5
and 8.1.5).
If suspicion of a hypersensitivity reaction occurs, the subjects should be instructed to contact the 
site staff as soon as possible for further guidance.
To assist in the diagnostic evaluation it is recommended to draw a blood sample for measurement of 
tryptase (total and/or mature tryptase, local assessment) within 3 hours of onset of the 
hypersensitivity reaction, and if this is achieved, a tryptase sample should also be drawn at V14A. 
Furthermore, a blood sample for assessment of anti-semaglutide IgE antibodies should be drawn as 
soon as possible after the event and at V14A and sent to the central laboratory. Tryptase 
concentrations, if available, should be included in the specific event form when reporting the AE.
In case of suspicion of immune complex disease 3, the subject must be discontinued from trial 
product but should remain in the trial (see Section 6.5 and 8.1.5). It is recommended to draw a 
blood sample for local assessment of complement levels (C3 and C4) to assist in the diagnostic 
evaluation. Complement level results should be included in the specific event form when reporting 
the AE.
Acute gallstone disease
If an event of acute gallstone disease or clinical suspicion of this is observed during the trial, the 
following additional information must be reported if available: 
!
Signs and symptoms of acute gallstone disease
!
Specific laboratory tests supporting a diagnosis of gallstone
!
Imaging performed and consistency with gallstone disease
!
Treatment given for the condition
!
Relevant risk factors for acute gallstone disease
!
Family history of gallstones
Medication error 
If a medication error is observed during the trial, the following additional information is required 
and must be reported: 
!
Trial product(s) involved 
!
Classification of medication error
o
Wrong drug(s) administered
o
Administration of an overdose
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
7 of 9
!
Whether the subject experienced any hypoglycaemic episode and/or AE(s) as a result of the 
medication error 
!
Suspected primary reason for the medication error 
For definition of medication error, see Section 12.1.4.
Lactic acidosis
If an event of lactic acidosis is observed during the trial, the following additional information must 
be reported if available:
!
Signs and symptoms of lactic acidosis
!
Specific laboratory tests describing the event 
!
Possible cause(s) of the event
Creatine kinase (CK) > 10 × UNL
If an event of CK > 10 × UNL is observed during the trial, the following additional information 
must be reported if available:
!
Signs and symptoms associated with the event 
!
Recent physical activity
!
Possible cause(s) of the event
Assessments in case of increased levels of creatine kinase
In case of CK > 10 × upper limit of normal (UNL), prompt repeat testing (at central laboratory) of 
CK should be done. Repeat testing (at central laboratory) should be done regularly until CK levels 
return to normal or baseline state. Additional clinical information should be gathered to seek the 
possible cause of the observed CK elevation. 
Hepatic event
!
ALT or AST > 5 × UNL and total bilirubin ≤ 2 × UNL
!
ALT or AST > 3 × UNL and total bilirubin > 2 × UNL*
!
Hepatic event leading to trial product discontinuation 
If one of the above events is observed during the trial, the following additional information must be 
reported if available:
!
Signs and symptoms associated with the event 
!
Risk factors
!
Relevant laboratory test results 
!
Diagnostic imaging performed 
!
Possible cause(s) of the event 
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
8 of 9
Assessments in case of increased levels of aminotransferases
Both events should prompt repeat testing (at the central laboratory) including ALT, AST, ALP and 
total bilirubin, and discontinuation of trial product should be considered. Thereafter, repeat testing 
(at the central laboratory) of ALT, AST, ALP and total bilirubin should be done regularly until the 
abnormalities return to normal or baseline state. Additional clinical information such as related 
symptoms, risk factors and contributing conditions (e.g. viral hepatitis, autoimmune hepatitis, 
alcoholic hepatitis, hepatobiliary or pancreatic disorders) should be gathered to seek a possible 
cause of the observed laboratory test abnormalities.
*Please note that risk of liver injury defined as ALT or AST > 3 × UNL and total bilirubin > 2 ×
UNL, where no alternative aetiology exits (Hy’s law), should also be reported as a SAE (important 
medical event, according to section 12.1.2).
CONFIDENTIAL


Protocol - Appendix B
CONFIDENTIAL
Date:
02 March 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
9 of 9
References: 
1.
Banks PA, Freeman ML, Practice Parameters Committee of the American College of G. 
Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379-400.
2.
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis-2012: revision of the Atlanta classification and definitions by 
international consensus. Gut. 2013;62(1):102-11.
3.
Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for 
Therapeutic Protein Products. August 2015.
CONFIDENTIAL


Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staff
CONFIDENTIAL
Date:
Novo Nordisk
Version:
Status:
Semaglutide
Trial ID: NN9924-4224
Clinical Trial Report
Appendix 16.1.1
29 October 2018
1.0
Final
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
1 of 21
Protocol Amendment
no 1
to Protocol, final version 1.0
dated 02 March 2016
Trial ID: NN9924-4224
PIONEER 4 – vs. GLP-1 RA
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects 
with Type 2 Diabetes Mellitus
Trial phase: 3a
Applicable to all countries 
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
2 of 21
Table of Contents   
Page
Table of Contents..............................................................................................................................................2
Table of Figures................................................................................................................................................3
Table of Tables..................................................................................................................................................3
1
Introduction including rationale for the protocol amendment.............................................................4
1.1
Additional eye examinations and additional data collection on diabetic retinopathy....................4
1.2
Addition of bicarbonate as a part of the biochemistry laboratory assessment...............................4
1.3
Investigator’s responsibility in ensuring evaluation and management of certain risk factors 
and complications ..........................................................................................................................4
1.4
Clarification of the criteria for completion, withdrawal and lost to follow-up..............................5
1.5
Minor adjustments, clarifications and correction of typographical errors.....................................5
1.5.1
Inclusion criteria ..........................................................................................................5
1.5.2
Statistical considerations..............................................................................................5
1.5.3
Adverse events for Adjudication .................................................................................5
1.5.4
Clarifications................................................................................................................6
2
Changes......................................................................................................................................................7
2.1
Section 2  Flow chart .....................................................................................................................7
2.2
Section 4.2.2.2 Supportive secondary safety endpoints.................................................................9
2.3
Section 6.2  Inclusion criteria ........................................................................................................9
2.4
Section 6.6 Withdrawal from trial .................................................................................................9
2.5
Section 8.1.3 Randomisation and trial product administration....................................................10
2.6
Section 8.1.4 Phone contacts .......................................................................................................10
2.7
Section 8.1.5 End-of-treatment (visit 13) and Follow-up (visit 14).............................................10
2.8
Section 8.1.6 Premature discontinuation of trial product and Follow-up (visits 13A and 
14A) .............................................................................................................................................11
2.9
Section 8.1.6.1 Lost to follow-up .................................................................................................11
2.10
Section 8.4.1.2 Adverse events requiring additional data collection...........................................12
2.11
Section 8.4.2   Physical examination ...........................................................................................13
2.12
Section 8.4.4  Eye examination....................................................................................................13
2.13
Section 8.4.6 Laboratory assessments for safety .........................................................................13
2.14
Section 8.4.8 Anti-semaglutide antibodies ..................................................................................14
2.15
Section 8.4.9  Hypoglycaemic episodes ......................................................................................14
2.16
Section 12.1.5 Adverse events requiring additional data collection............................................15
2.17
Section 12.2 Reporting of adverse events....................................................................................15
2.18
Section 12.7.2 Event adjudication committee..............................................................................15
2.19
Section 17.2  Definition of analysis sets......................................................................................15
2.20
Section 17.3.1 Primary analysis for the primary estimand ..........................................................16
2.21
Section 17.4.2.2 Continuous efficacy endpoints..........................................................................16
2.22
Section 17.4.2.3  Safety endpoints...............................................................................................17
2.23
Section 18.1.1  Risks and precautions .........................................................................................17
2.24
Section 18.1.1  Risks and precautions .........................................................................................18
2.25
Section 27  References.................................................................................................................18
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
3 of 21
2.26
Appendix B, Section 1 Adverse Events requiring additional data collection..............................19
2.27
Appendix B  New Section to be added to the appendix: .............................................................21
Table of Figures   
Page
No table of figures entries found.
Table of Tables   
Page
No table of figures entries found.
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
4 of 21
1
Introduction including rationale for the protocol amendment
This protocol amendment introduces:
1. Additional eye examinations and additional data collection on diabetic retinopathy 
2. Addition of bicarbonate as a part of the biochemistry laboratory assessment
3. Investigator’s responsibility in ensuring evaluation and management of certain risk factors and 
complications
4. Clarification of the criteria for completion, withdrawal and lost to follow-up
5. Other minor corrections and clarifications
1.1
Additional eye examinations and additional data collection on diabetic retinopathy 
Updated protocol Sections: 2, 4.2.2.2, 8.4.1.2, 8.4.4, 12.1.5, 17.2, 17.3.1, 17.4.2.2, 18.1.1 and 
Appendix B.
Transient worsening of diabetic retinopathy is a recognised complication in selected patients with 
diabetes after initiation of intensive antidiabetic treatment51. Risk factors for these events include 
long-standing poor glycaemic control and presence of proliferative retinopathy, and initial large 
improvements in blood glucose may be an additional aggravating factor. In a recently completed 
cardiovascular outcomes trial with s.c. semaglutide, results indicate an increased risk of events 
related to diabetic retinopathy in subjects treated with semaglutide compared to placebo56. The 
majority of the related adverse events were moderate in severity and did not lead to premature 
discontinuation of trial product. 
, additional eye examinations have 
been implemented in all trials in the PIONEER programme. Also, to further understand this safety 
signal, additional information will be collected for all diabetic retinopathy events reported during 
the trial. The information will be collected not only from new subjects enrolled by the time of this 
amendment, but also from already enrolled subjects to the extent that the information is available. 
Furthermore, information to the investigators and subjects related to diabetic retinopathy has been 
added to the protocol (see Section 18) and the subject information. 
1.2
Addition of bicarbonate as a part of the biochemistry laboratory assessment
Updated protocol Section: 8.4.6
 that bicarbonate is added as a routine laboratory test in trials where SGLT2-
inhibitors are used as background medication, because SGLT2-inhibitors have been associated with 
a risk for metabolic acidosis.
1.3
Investigator’s responsibility in ensuring evaluation and management of certain risk 
factors and complications
Updated protocol Section: 8.4.2
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
5 of 21
 text is added to highlight the investigator’s responsibility in 
relation to further evaluation of potential incidental thyroid nodules discovered at the physical 
examination.
In addition, text is added to highlight the investigator’s responsibility in ensuring evaluation and 
management of cardiovascular risk factors and microvascular complications such as diabetic kidney 
disease and diabetic retinopathy.
1.4
Clarification of the criteria for completion, withdrawal and lost to follow-up
Updated protocol Sections: 6.6, 8.1.5, 8.1.6 and 8.1.6.1.
The criteria for subject completion, -withdrawal and -lost to follow-up respectively are clarified and 
have been made consistent across Sections. Lost to follow-up is considered a subcategory to 
withdrawal from trial. In addition, it is emphasised that as soon as contact to a subject is lost, efforts 
must be made to regain contact and the efforts must continue until the subjects last planned visit.
Only if contact is not regained at that time point can the subject be considered lost to follow up. 
Because this trial is not an outcome trial the terminology ‘health status’ is replaced with “relevant 
safety information”- the purpose of which is to follow up on any adverse events or pregnancy, and 
not to determine if a subject completes the trial or not.
1.5
Minor adjustments, clarifications and correction of typographical errors
1.5.1
Inclusion criteria
Updated protocol Section: 6.2
The wording of Inclusion criterion no. 5 in Section 6.2 will be aligned with the wording in the 
summary section.
1.5.2
Statistical considerations
Updated protocol Sections: 17.3.1 and 17.4.2.2.
For the pattern mixture model using multiple imputations, the number of imputations will be 
increased from 100 to 1000 data sets, to ensure a greater precision of the estimates. In addition, an 
error in the number of groups used for imputations is corrected.
1.5.3
Adverse events for Adjudication
Updated protocol Section: 12.7.2
Table 12-2 has been aligned with Table 12-1 reflecting that unstable angina pectoris (UAP) requires
hospitalisation to qualify for Event Adjudication.
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
6 of 21
1.5.4
Clarifications
Updated protocol Sections: 8.1.3, 8.1.4, 8.4.9 and 12.2
Clarifications added regarding phone contact.
Wording deleted regarding hypoglycaemic episodes, as it is included in “medication errors”.
In this protocol amendment:
!
Any new text is written in italics.
!
Any text deleted from the protocol is written using strike through.
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
7 of 21
2
Changes
2.1
Section 2 
Flow chart
Trial Periods
Scree
ninga
Randomisa-
tion
Treatment
End-of-
treatment 
(EoT)
Follow-upb
EoT 
premature 
disconti-
nuationc
Follow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P)
V1
V2
P3
V4
P5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V13A
V14A
Visit number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Timing of visit (weeks)
Up to 
−2 
weeks 
0
2
4
6
8
14
20
26
32
38
45
52
57  
Day of 
discontinu
ation of 
trial
product
5 weeks 
after
discontinuati
on
of trial 
product (last 
dose) 
Visit window (days)
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+3
+3
+3
SUBJECT RELATED
INFO/ASSESSMENTS
PRO questionnaire
x
x
x
x
SAFETY
Eye examination
xd
xd
xd


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
8 of 21
Footer
Description
xd
Dilated fundoscopy/fundus photography performed within 90 days prior to randomisation is acceptable if results are 
available for evaluation at V2, unless worsening of visual function since last examination.
Dilated fundoscopy/fundus photography must be performed again:
!
at V13 or within 5 weeks thereafter for subjects completing treatment
!
at V13A or within 5 weeks thereafter, and again within 5 weeks prior to V13, for subjects who have prematurely 
discontinued trial product


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
9 of 21
2.2
Section 4.2.2.2
Supportive secondary safety endpoints
Change from baseline to week 26 and 52 in:
!
Haematology
!
Biochemistry
!
Calcitonin
!
Pulse
!
Systolic blood pressure
!
Diastolic blood pressure
!
Electrocardiogram (ECG) category
!
Physical examination (week 52 only)
!
Eye examination category (week 52 only)
2.3
Section 6.2 
Inclusion criteria
5. Stable daily dose of metformin (≥1500 mg or maximum tolerated dose as documented in the 
subject medical record) alone or in combination with a stable daily dose of a SGLT-2 inhibitor (all 
doses approved as maintenance therapy) ≥for at least 90 days prior to the day of screening (fixed-
dose combinations are allowed).
2.4
Section 6.6
Withdrawal from trial
The subject may withdraw consent at will at any time. The subject’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered as 
withdrawn from trial. A subject who does not complete the trial is also considered withdrawn from 
the trial. Hence a subject is considered withdrawn if the following applies: 
!
Subject withdrew consent
!
Subject is lost to follow up (only to be used if there is no contact with the subject by the time 
of the subject’s last scheduled visit, see Sections 8.1.7 and 8.1.8
!
Other (subject deceased or closure of trial site)
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
10 of 21
2.5
Section 8.1.3
Randomisation and trial product administration
Eligible subjects will be randomised into one of three treatment arms. The randomisation session
must be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial 
product to be dispensed to the subject.
All V2 assessments must be performed before administration of first dose of trial product.
Instruct and remind the subject to escalate the dose of liraglutide/placebo after week 1.
2.6
Section 8.1.4
Phone contacts
The phone contacts should be conducted as outlined in the flowchart (see Section 2).
At V2, the investigator should instruct the subject to dose escalate liraglutide/liraglutide placebo to 
1.2 mg once-daily after the first week of treatment. At the planned phone contact (P3), the 
investigator should follow-up on compliance and potential technical issues regarding the dose 
escalation that was done by subject after the first week of treatment. At P3, the subject will be 
instructed to dose escalate to 1.8 mg once-daily. At P5, the investigator should follow-up on 
compliance and reporting of adverse events (AEs) with special focus on preventing dehydration in 
case of severe gastrointestinal AEs.
2.7
Section 8.1.5
End-of-treatment (visit 13) and Follow-up (visit 14)
At V13 the subject should be reminded about the importance of attending the follow-up visit (V14). 
If the subject, nonetheless, does not attend V14, the site should make efforts to obtain contact with 
the subject within the visit window. 
A trial completer is defined as a subject who attends, or is in contact with the site, at the subject’s 
last scheduled visit. For subjects who complete treatment, the last scheduled visit is V14. (For 
subjects who discontinue trial product, see Section 8.1.6).
In case the subject cannot be reached (by clinic visit or phone contact) at the scheduled visit 14, the 
site should consult the contacts provided by the subject (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow up and this should 
be specified in the end-of-trial form.
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
11 of 21
2.8
Section 8.1.6
Premature discontinuation of trial product and Follow-up (visits 
13A and 14A)
Subjects should continue with the originally scheduled site contacts after V134A and up to and 
including V13. If necessary, in order to retain the subject in the trial, site visits can be replaced by 
phone contacts after V14A. However, if a subject is unable or unwilling to attend all subsequent 
visit(s), the investigator should at least aim to have the subject attend V9 (week 26) and the End-of-
treatment visit (V13) (week 52) as these visits should be performed for all subjects, if at all possible 
(except subjects who withdraw informed consent, see Section 8.1.7). 
Subjects, who only agree to attend or provide health status at the planned V12, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by clinic visit or phone 
contact) at the scheduled V12, the site should consult the contacts provided by the subject (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow-up and this should be specified in the end of trial form.
A subject who prematurely discontinued trial product is still considered a trial completer if the 
subject attends or is in contact with the site, at the subject’s last scheduled visit. For subjects who 
prematurely discontinue trial product, the last scheduled visit is V13 (or V14A if it is scheduled 
after V13). The site should in due time prepare for establishing contact with the subject within the 
visit window of the scheduled V9 and V13, respectively if the subject has agreed to attend these 
visits. 
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact with the site in relation to the trial 
should be considered as having withdrawn from the trial consent (for withdrawal procedures, see 
Section 8.1.7).
2.9
Section 8.1.6.1
Lost to follow-up
In case contact to the subject is lost during the trial, the site should immediately undertake efforts to 
re-establish contact. If the subject cannot be reached (by clinic visit or phone contact) and the 
subject has consented to it, the site should consult the contacts provided by the subject (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local 
law) in an attempt to regain contact with the subject or to obtain relevant safety information from 
other sources. Efforts to regain contact should continue until the end of the subject’s last scheduled 
visit: V14 for subjects who have completed treatment, whereas for subjects who have discontinued 
trial product prematurely the last visit is V13 (or V14A if it is scheduled after V13). Only if contact 
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
12 of 21
with the subject is not regained by the end of the visit window of the last scheduled visit can the 
subject be considered lost to follow up (see Section 6.6).
2.10
Section 8.4.1.2
Adverse events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!
Acute coronary syndrome (myocardial infarction or hospitalisation for unstable angina 
pectoris)
!
Cerebrovascular event (stroke or transient ischaemic attack)
!
Heart failure 
!
Pancreatitis
!
Neoplasm (excluding thyroid neoplasm)
!
Thyroid disease (including thyroid neoplasm)
!
Renal event
!
Hypersensitivity reaction
!
Acute gallstone disease
!
Medication error
!
Lactic acidosis
!
Creatine kinase (CK) > 10x UNL
!
Hepatic event defined as:
-
ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
-
ALT or AST > 3x UNL and total bilirubin > 2x UNL*
-
Hepatic event leading to trial product discontinuation.
!
Diabetic retinopathy and related complications
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 3x UNL and total bilirubin > 2x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
13 of 21
2.11
Section 8.4.2
Physical examination
A physical examination will be performed by the investigator according to local procedure (see 
Section 2 and 8.1.8). A physical examination must include:
!
General appearance
!
Head, ears, eyes, nose, throat, neck
!
Thyroid gland*
!
Respiratory system
!
Cardiovascular system
!
Gastrointestinal system including mouth
!
Musculoskeletal system
!
Central and peripheral nervous system
!
Skin
!
Lymph node palpation
*Please note that the diagnostic evaluation of thyroid nodules should be in accordance with the 
American Thyroid Association Management Guidelines or any updates hereof 35, and adapted to 
local treatment guidelines if applicable.
2.12
Section 8.4.4
Eye examination 
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by the 
investigator or according to local practice. Fundoscopy requires pharmacological dilation of both 
pupils. Results of the dilated fundoscopy/fundus photography will be interpreted by the investigator 
(see Section 8.1.8).
2.13
Section 8.4.6
Laboratory assessments for safety
Biochemistry:
!
Alanine aminotransferase (ALT)
!
Albumin
!
Alkaline phosphatase (ALP)
!
Amylase
!
Aspartate aminotransferase (AST)
!
Bilirubin, total
!
Calcium, total
!
Creatinine
!
eGFR per CKD-EPI36
!
Creatine kinase (CK)
!
Lipase
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
14 of 21
!
Potassium
!
Sodium
!
Urea
!
Bicarbonate
2.14
Section 8.4.8
Anti-semaglutide antibodies
Furthermore, samples drawn at randomisation may be used for calculations of the neutralising effect 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
Novo Nordisk or the special laboratory responsible for antibody binding analysis.
2.15
Section 8.4.9 
Hypoglycaemic episodes
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by the subject:
!
Who assisted in the treatment of the hypoglycaemic episode (i.e. medical person or non-
medical person)?
!
Where the treatment was administered (in clinic/emergency room/ hospital or other. If the 
subject was treated in clinic/emergency room/hospital, whether they were transported in an 
ambulance or not)
!
Type of treatment provided by another person (i.e. oral carbohydrates, glucagon, IV glucose 
or other)
!
Were symptoms alleviated after administration of treatment?
!
Factors contributing to the episode (i.e. physical activity, missed meal, diet change, 
medication error (i.e. overdose, mix-up between products, incorrect use of device), 
miscalculation of dose of anti-diabetic medication, other factors not listed or unknown)
!
Did the subject experience seizure?
!
Was the subject unconscious/comatose?
!
Did the subject experience any of the following symptoms38
-
Autonomic: sweating, trembling, hunger or palpitations (rapid or irregular heart beat)
-
Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
-
General malaise: headache or malaise (feeling discomfort/unease)
!
Other symptoms
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
15 of 21
2.16
Section 12.1.5
Adverse events requiring additional data collection
Table 12-1
Adverse events requiring completion of specific event forms and/or are subject to 
event adjudication
Event
Specific event form
Event adjudication
Diabetic retinopathy and related complications
Yes
No
2.17
Section 12.2
Reporting of adverse events
Novo Nordisk A/S assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference
documents: 
!
IB for oral Semaglutide (NN9924)24 and Victoza®; current versions and any updates 
thereto.
!
CCDS (Company Core Data Sheet) for Victoza® Liraglutide; current versions and any 
updates thereto. 
2.18
Section 12.7.2
Event adjudication committee
Table 12 2
Adverse events for adjudication
Events
Description
Adjudication outcome
Acute Coronary Syndrome
! Acute Coronary Syndrome conditions include: 
! ST-elevation acute myocardial infarction 
(STEMI)
! Non-ST elevation acute myocardial infarction 
(NSTEMI)
! Silent MI 
! Unstable angina pectoris (UAP) requiring 
hospitalisation
! Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
! Unstable angina pectoris 
requiring hospitalisation
2.19
Section 17.2 
Definition of analysis sets
On-treatment: This observation period represents the time period where subjects are considered 
treated with trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. For adjudicated events, ECGs, eye examination category, anti-
semaglutide antibodies, and AEs including hypoglycaemic episodes, the observation period ends at 
the first date of any of the following:
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
16 of 21
!
the follow-up visit (V14)
!
the follow-up prematurely discontinuation visit (V14A)
!
the last date on trial product +38 days (5 weeks follow-up period + 3 days visit window)
!
the end-date for the in-trial observation period
2.20
Section 17.3.1
Primary analysis for the primary estimand 
Missing values for each group will be imputed as follows:
!
An analysis of covariance (ANCOVA) with stratification factor and region as categorical fixed 
effects and baseline HbA1c measurement as a covariate will be fitted to observed values of the 
change from baseline in HbA1c at week 26.
!
The estimated parameters for location and dispersion will be used to impute 100 1000 values for 
each subject with missing week 26 data based on stratification factor and region as categorical 
and baseline HbA1c. Thus, 100 1000 complete data sets will be generated including observed 
and imputed values.
Analysis used for confirming superiority versus placebo/liraglutide at week 26:
For each of the 100 1000 (now complete) imputed data sets, the change from baseline to week 26 
will be analysed using an ANCOVA with treatment, stratification factor and region as categorical 
fixed effects and baseline HbA1c as covariate. The results obtained from analysing the datasets will 
be combined using Rubin’s rule46 to draw inference.
2.21
Section 17.4.2.2 Continuous efficacy endpoints
For evaluation of the primary estimand the analyses will be performed separately for week 26 and 
week 52. For the analysis at week 52, the imputation of missing data will be further differentiated 
by whether subjects have discontinued trial product or initiated rescue medication prior to week 26 
or at/or after week 26. This will result in imputation of missing data within 12 9 groups of subjects 
instead of the 6 groups as described for the week 26 evaluation in Section 17.3.1. If less than five 
subjects have available data in one of the 12 9 groups, the imputation will be made within the 6
groups specified for the primary evaluation. The frequency of missing data is expected to be slightly 
larger at week 52 compared to week 26. The rate of missing data is expected to decline over time.
Binary efficacy endpoints
The above eight binary endpoints will be analysed using a logistic regression model with treatment,
stratification factor and region as fixed effects and baseline response as covariate (i.e. baseline 
HbA1c for binary HbA1c endpoints, baseline weight for weight endpoints and both baseline HbA1c 
and baseline weight for the binary endpoint that combines both parameters). To account for missing 
data, the analysis will be made using a sequential multiple imputation approach as described below:
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
17 of 21
!
Multiple imputed data sets (100 1000) will be created in which missing values for the 
underlying continuous assessments are imputed by treatment group and treatment 
adherence/rescue status assuming MAR and as described in Section 17.3.1 for the primary 
estimand and by treatment group assuming MAR and as described in Section 17.3.2 for the 
secondary estimand.
!
The binary endpoint will be created for each of the 100 1000 complete data sets
Each of the created complete data set will be analysed with the logistic model and inference will be 
drawn using Rubin’s rule46.
2.22
Section 17.4.2.3
Safety endpoints
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!
Haematology 
!
Biochemistry (except for amylase and lipase)
!
Calcitonin
!
ECG evaluation
!
Physical examination (week 52 only)
!
Eye examination category (week 52 only) 
2.23
Section 18.1.1 
Risks and precautions
Other safety considerations
Diabetic retinopathy complications
A transient worsening of diabetic retinopathy is a recognised complication in selected patients with 
diabetes after initiation of intensive antidiabetic treatment51-53. Risk factors for these events include 
long-standing poor glycaemic control and presence of proliferative retinopathy, and initial large 
improvements in blood glucose may be an additional aggravating factor. Several studies have, 
however, documented long-term beneficial effects of intensive glycaemic treatment in reducing 
retinopathy progression54,55 even in intensively treated patients who experienced early worsening52. 
In a cardiovascular outcomes trial with s.c. semaglutide, results indicate an increased risk of events 
related to diabetic retinopathy in subjects treated with semaglutide compared to placebo56. As a 
precaution in this trial, all subjects are required to have a fundus photography or dilated 
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
18 of 21
fundoscopy performed before enrolment into the trial; moreover, subjects with proliferative 
retinopathy or maculopathy requiring acute treatment will be excluded. As part of good diabetes 
management the investigator is encouraged to ensure adequate monitoring and treatment of
diabetic retinopathy in subjects enrolled into the trial57.
2.24
Section 18.1.1 
Risks and precautions
It is the responsibility of the investigator to ensure the best possible care off the subject. This 
includes adequate glycaemic control, appropriate risk factor modification such as optimal 
treatment of hypertension, dyslipidaemia and other cardiovascular risk factors, as well as regular 
monitoring and treatment of diabetic kidney disease and diabetic retinopathy 57. 
2.25
Section 27
References
The reference numbers will change throughout the updated protocol when below new references are 
introduced
35.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 
American Thyroid Association Management Guidelines for Adult Patients with Thyroid 
Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines 
Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-
133.
51.
Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid 
tightening of blood glucose control leads to transient deterioration of retinopathy in insulin 
dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811-
5.
52.
The Diabetes Control and Complications Trial Research Group. Early worsening of 
diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 
1998;116(7):874-86.
53.
Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic 
control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin 
Pract. 2014;103(3):e37-9.
54.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53, Erratum 
1999; 354: 602.
55.
The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye 
Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On 
(ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on 
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
19 of 21
Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) Follow-On Study. Diabetes Care. 2016;39(7):1089-100.
56.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
57.
American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes 
Care. 2016;39 (Suppl. 1):S1-S109. 
2.26
Appendix B, Section 1 Adverse Events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!
Acute coronary syndrome (myocardial infarction or hospitalisation for unstable angina)
!
Cerebrovascular event (stroke or TIA)
!
Heart failure
!
Pancreatitis
!
Neoplasm (excluding thyroid neoplasm)
!
Thyroid disease (including thyroid neoplasm)
!
Renal event
!
Hypersensitivity reaction
!
Acute gallstone disease
!
Medication error (concerning trial products):
o
Administration of wrong drug. 
o
Note: Use of wrong DUN is not considered a medication error.
o
Wrong route of administration.
o
Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
o
Accidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however, the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen, as judged by the investigator, although they did not necessarily occur.
!
Lactic acidosis
!
Creatine kinase (CK) > 10 × UNL
!
Hepatic event:
o
ALT or AST > 5 × UNL and total bilirubin ≤ 2 × UNL
o
ALT or AST > 3 × UNL and total bilirubin > 2 × UNL* 
o
Hepatic event leading to trial product discontinuation 
!
Diabetic retinopathy and related complications
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
20 of 21
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
15 November 2016
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT No.: 2015-005210-30
Page:
21 of 21
2.27
Appendix B
New Section to be added to the appendix:
Diabetic retinopathy and related complications
If an event of diabetic retinopathy or related complications is observed during the trial the 
following additional information must be reported, if available:
!
Signs and symptoms associated with the event
!
Results of the eye examination 
!
Treatment for and complications of the event
!
Contributing conditions
CONFIDENTIAL

SAP_001.pdf: 
Cover Page for Statistical analysis plan 
 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT02863419 
Sponsor trial ID: 
NN9924-4224 
Official title of study: 
PIONEER 4 – vs. GLP-1 RA 
Efficacy and safety of oral semaglutide versus liraglutide and 
versus placebo in subjects with type 2 diabetes mellitus 
A 52-week randomised, double-blind, active- and placebo- 
controlled trial 
Document date: 
29 October 2018 
 


Link
Link
List of contents
Statistical analysis plan......................................................................................................................
Pre-defined MedDRA search –list of preferred terms.....................................................
CONFIDENTIAL
Date:
Novo Nordisk
Version:
Status:
Semaglutide
Trial ID: NN9924-4224
Clinical Trial Report
Appendix 16.1.9
29 October 2018
1.0
Final
16.1.9 Documentation of statistical methods
CONFIDENTIAL
Redacted VWDWLVWLFDODQDO\VLVSODQ 
Includes redaction of personal identifiable information only. 
. 


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
1 of 30
Statistical Analysis Plan
Trial ID: NN9924-4224
PIONEER 4 – vs. GLP-1 RA
Efficacy and Safety of Oral Semaglutide versus Liraglutide
and versus Placebo in Subjects with Type 2 Diabetes Mellitus
A 52-week randomised, double-dummy, double-blind, active- and placebo-controlled trial
Author:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
2 of 30
Table of contents   
Table of contents.........................................................................................................................................2
List of abbreviations ...................................................................................................................................3
1
Introduction .........................................................................................................................................6
1.1
Trial information.......................................................................................................................6
1.2
Scope of the statistical analysis plan..........................................................................................6
2
Statistical considerations .....................................................................................................................7
2.1
Sample size calculation .............................................................................................................9
2.2
Definition of analysis sets........................................................................................................12
2.3
Primary endpoint.....................................................................................................................15
2.3.1
Primary analysis for the primary estimand..............................................................15
2.3.2
Primary analysis for the secondary estimand ..........................................................16
2.3.3
Sensitivity analyses................................................................................................17
2.3.3.1
Pattern mixture models.....................................................................18
2.3.3.2
Other sensitivity analyses .................................................................18
2.3.3.3
Assessment of sensitivity analyses....................................................19
2.4
Secondary endpoints ...............................................................................................................19
2.4.1
Confirmatory secondary endpoints.........................................................................19
2.4.2
Supportive secondary endpoints .............................................................................19
2.4.2.1
Efficacy endpoints............................................................................19
2.4.2.2
Safety endpoints...............................................................................23
2.5
Interim analysis.......................................................................................................................27
2.6
Patient reported outcomes .......................................................................................................27
2.6.1
Diabetes Treatment Satisfaction Questionnaire – status version (DTSQs)...............27
2.6.2
Responder analyses................................................................................................28
3
Changes to the statistical analyses planned in the protocol..............................................................28
4
References ..........................................................................................................................................30
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
3 of 30
List of abbreviations
AACE
American Association of Clinical Endocrinologists
ADA
American Diabetes Association
AE
adverse event
ALP
Alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
Analysis of covariance
AST
aspartate aminotransferase
AUC
Area under the curve
BG
blood glucose
BG meter
blood glucose meter
BMI
body mass index
CLAE
clinical laboratory adverse event
CK
creatine kinase
CKD-EPI
Chronic Kidney Disease Epidemiology collaboration
CRF
case report form
CRO
contract research organisation
CVD
cardiovascular disease
DFU
direction for use
DPP-4
dipeptidyl peptidase-4
DTSQ
diabetes treatment satisfaction questionnaire
DUN
dispensing unit number
EAC
event adjudication committee
ECG
electrocardiogram
eCRF
electronic case report form
EDC
electronic data capture
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EOT
end of treatment
FAS
full analysis set
FDA
U.S. Food and Drug Administration
FDAAA
U.S. Food and Drug Administration Amendment Act
FPG
fasting plasma glucose
FSFV
first subject first visit
GCP
Good Clinical Practice
GLP-1
glucagon-like peptide-1
GLP-1 RA
glucagon-like peptide-1 receptor agonist
HbA1c
glycosylated haemoglobin
HDL
high density lipoprotein
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
4 of 30
HOMA-B
homeostatic model assessment index of beta-cell function
HOMA-IR
homeostatic model assessment index of insulin resistance
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation
ICMJE
International Committee of Medical Journal Editors
IEC
independent ethics committee
IMP
investigational medicinal product
IRB
institutional review board
IWRS
interactive web response system
LDL
low density lipoprotein
LLoQ
lower limit of quantification 
LSFV
last subject first visit
LSLV
last subject last visit
MAR
missing at random
MedDRA
Medical Dictionary for Regulatory Activities
MEN 2
Multiple Endocrine Neoplasia Type 2
MI
Multiple Imputation
MTC
Medullary Thyroid Carcinoma
NIMP
non-investigational medicinal product
NYHA
New York Heart Association
OAD
oral antidiabetic drug
PG
plasma glucose
PK
pharmacokinetics
PP
per protocol
PRO
patient reported outcome
SAE
serious adverse event
SAP
statistical analysis plan
s.c.
subcutaneous(ly)
SGLT-2
sodium-glucose co-transporter-2
SIF
safety information form
SMPG
self-measured plasma glucose
SmPC
summary of product characteristics
SNAC
sodium N-[8-(2-hydroxybenzoyl) amino] caprylate
STEMI
ST-elevation acute myocardial infarction
SUSAR
suspected unexpected serious adverse reaction
T2DM
type 2 diabetes mellitus
TEAE
treatment-emergent adverse events 
TIA
transient ischaemic attack
TMM
Trial Materials Manual
UNL
Upper Normal Limit
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
5 of 30
UTN
Universal Trial Number
VLDL
very low density lipoprotein
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
6 of 30
1
Introduction
1.1
Trial information
This is a 52-week, randomised, double-blind, double-dummy, active- and placebo-controlled, 
parallel-group, multicentre, multinational trial with 3 arms comparing the efficacy and safety of 
once-daily dosing of oral semaglutide vs. liraglutide and vs. placebo in subjects with T2DM.
Primary objective
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on glycaemic control in subjects with type 2 diabetes mellitus (T2DM).
Secondary objectives
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on body weight in subjects with T2DM.
To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus 1.8 
mg liraglutide subcutaneous and versus placebo, all in combination with metformin with or without 
a SGLT-2 inhibitor, in subjects with T2DM.
Trial design
Subjects will be randomised in a 2:2:1 manner to receive one of the following treatments:
!
14 mg oral semaglutide once-daily
!
1.8 mg liraglutide subcutaneous (s.c.) injection once-daily
!
placebo once-daily 
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks. For further details, see the trial protocol.
1.2
Scope of the statistical analysis plan
This statistical analysis plan (SAP) is based on the protocol for trial NN9924-4224 “Efficacy and 
Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes 
Mellitus”, version 2.0 (17 November 2016), and includes more detailed procedures for executing 
the statistical analyses of the primary and secondary endpoints. Statistical analyses and a number of 
clarifications additional to those specified in the trial protocol are pre-specified with this SAP. All 
changes to the statistical analyses planned in the trial protocol are documented in Section 3.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
7 of 30
Novo Nordisk will be responsible for the statistical analyses and reporting. 
2
Statistical considerations
General considerations
The blinding of the randomised treatments will be maintained until the database has been released 
for statistical analysis. Data from all sites will be analysed and reported together. 
In statistical analyses where stratification is included, the two combinations of anti-diabetic 
background medication at screening (metformin or metformin+SGLT-2 inhibitor) will be included 
based on the actual information collected through the eCRF. In case of missing eCRF information 
the information collected from the IWRS system will be used. The information regarding descent 
(Japanese subjects/non-Japanese subjects) will be included based on country details from the eCRF. 
In the statistical analyses the stratification factor will refer to anti-diabetic background medication 
at screening. Descent (Japanese subjects/non-Japanese subjects) will be included in the statistical 
analyses as part of region.
The latest available measurement, at or prior to the randomisation visit, will be used as the baseline 
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline 
value will be left missing.
Laboratory values below the lower limit of quantification (LLoQ) will be set to ½LLoQ. Number of 
values below LLoQ by treatment and visit will be summarised if deemed relevant.
The primary and confirmatory efficacy endpoints will be evaluated at week 26. This approach is 
expected to result in a lower proportion of missing data, use of rescue medication and premature 
treatment discontinuations, compared to the expected proportion of missing data, use of rescue 
medication and premature treatment discontinuation at week 52, and therefore considered a 
meaningful representation and confirmation of the effect of oral semaglutide. 
Results from a statistical analysis will as a minimum be presented by the estimated treatment 
contrasts for the below two comparisons with associated two-sided 95% confidence intervals and p-
values corresponding to two-sided tests of no difference.
!
oral semaglutide 14 mg vs. placebo
!
oral semaglutide 14 mg vs. liraglutide 1.8 mg
If no statistical analysis is specified, data will be presented using relevant summary statistics.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
8 of 30
Primary and secondary estimands
Two estimands addressing different aspects of the primary trial objective will be defined as follows: 
!
Primary estimand – ‘Treatment policy’
!
treatment difference (oral semaglutide versus placebo and oral semaglutide versus 
liraglutide) at week 26 for all randomised subjects regardless of adherence to 
randomised treatment and initiation of rescue medication
The treatment policy estimand assesses the expected glycaemic benefit in a future population that 
results from subjects initiating treatment with oral semaglutide including potential rescue 
medication(s) and the expected glycaemic benefit compared to initiating treatment with liraglutide 
including potential rescue medication(s). Generalisation of this estimand depends among other 
things on the extent to which the use of rescue medication in this trial reflects clinical practice and 
the adherence to trial product administration in this trial reflects the behaviour of the target 
population. Accordingly, data collected regardless of discontinuation of trial product or initiation of 
rescue medication(s) will be used to draw inference. 
!
Secondary estimand – ‘Hypothetical’
!
treatment difference (oral semaglutide versus placebo and oral semaglutide versus 
liraglutide) at week 26 for all randomised subjects if all subjects adhered to treatment 
and did not initiate rescue medication
The hypothetical estimand assesses the glycaemic benefit a future subject is expected to achieve if 
initiating and continuing treatment with oral semaglutide and the glycaemic benefit compared to 
liraglutide. It is considered a clinically relevant estimand as it provides information to treating 
clinicians about the expected glycaemic efficacy of oral semaglutide and the expected glycaemic 
efficacy compared to liraglutide for purposes of treating individual subjects. Generalisation of this 
estimand depends among other things on the extent to which the adherence to trial product 
administration in this trial reflects the behaviour of the target population. Accordingly, only data 
collected prior to discontinuation of trial product or initiation of rescue medication will be used to 
draw inference. This will avoid confounding from rescue medication.
Analogously, two estimands will be pre-defined for the remaining secondary endpoints.
Missing data considerations at week 26
When estimating the primary estimand, the proportion of missing data, i.e., data that do not exist 
even though subjects are intended to stay in the trial regardless of treatment status and initiation of 
rescue medication(s), is expected to be maximum 10% based on the oral semaglutide phase 2 trial 
(NN9924-3790). Thus, missing data will be due to withdrawal from trial or lost to follow-up.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
9 of 30
When estimating the secondary estimand, the proportion of missing data is expected to be higher 
(20%) since data collected after discontinuation of trial product or initiation of rescue medication(s) 
will be set to missing. The 20% of missing data is based on the liraglutide phase 3 trial (NN2211-
1572), the oral semaglutide phase 2 trial (NN9924-3790) that indicates that a low starting dose with 
gradual dose escalation diminishes GI AEs compared with more aggressive dosing regimens. 
Across treatment arms the main reasons for missing data are expected to be early treatment 
discontinuation due to AEs (GI AEs for oral semaglutide and liraglutide) and initiation of rescue 
medication. Initiation of rescue medication is expected to be more frequent in the placebo arm than 
for the oral semaglutide and liraglutide arms. A higher proportion of subjects are expected to 
discontinue treatment due to AEs in the oral semaglutide and liraglutide arms, compared to the 
placebo arm. So overall the frequency of missing data is expected to be similar across treatment 
arms.
Descriptive summaries and graphical representation of extent, reason(s) for and pattern of missing 
data will be presented by treatment arm.
2.1
Sample size calculation
To assess the effect of liraglutide on glycaemic effect, a similar trial LEAD-2 (NCT00318461) 
where liraglutide was used as add on to metformin was reviewed. Based on this trials, the chosen 
margin of 0.4 provides assurance that oral semaglutide has a clinically relevant effect greater than 
zero. With regards to the constancy assumption, controlled clinical trials have consistently 
established that liraglutide is an effective anti-diabetic drug. Therefore, lack of trial sensitivity with 
liraglutide as comparator is not anticipated to be an issue in this trial. 
The primary endpoint is change from baseline to week 26 in HbA1c. For HbA1c, superiority of oral 
semaglutide vs. placebo and both non-inferiority and superiority of oral semaglutide vs. liraglutide 
are planned to be tested. The confirmatory secondary endpoint is change from baseline to week 26 
in body weight (kg). For body weight, superiority of oral semaglutide vs. placebo and oral 
semaglutide vs. liraglutide are planned to be tested.
The sample size calculation is made to ensure a power of at least 90% for testing the below four out 
of the five pre-specified confirmatory hypotheses shown in Figure 2–1. The closed testing 
procedure described in Bretz et al. (2011)1 is used to control the overall type I error at a nominal 
two-sided 5% level. 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
10 of 30
The four hypotheses are
!
HbA1c superiority of oral semaglutide vs. placebo
!
HbA1c non-inferiority of oral semaglutide vs. liraglutide (margin 0.4%)
!
Body weight superiority of oral semaglutide vs. placebo 
!
Body weight superiority of oral semaglutide vs. liraglutide 
The statistical testing strategy is based on the following two principles:
!
To demonstrate glycaemic effect of oral semaglutide compared to placebo
!
Glycaemic effect compared to liraglutide must be established in terms of HbA1c non-inferiority 
before testing for added benefits in terms of HbA1c superiority and/or body weight superiority.
The sample size is calculated using the calcPower function in the R package, gMCP2 using 10000 
simulations. All of the five pre-specified confirmatory tests are assumed to be independent. Since 
some of the tests are positive correlated, the assumption of independence is viewed as conservative.
The sample size assumptions for treatment effects (TE), adjusted treatment effects and the standard 
deviations (SD) are given in Table 2–1.
These assumptions are primarily based on the oral semaglutide phase 2 results (NN9924-3790), 
liraglutide phase 3 trial results (Victoza® US prescribing information) and supported by results 
from the s.c. semaglutide phase 2 trial (NN9535-1821). 
Since the equalising effect of rescue medication will be included in the primary analysis as well as a 
conservative approach for handling of missing data will be performed, an adjustment in treatment 
effect will be implemented for the 10% of subjects who are expected to discontinue trial product or 
initiate rescue medication and for the 10% of subjects who are expected to have actual missing data. 
The treatment effects used in the sample size calculation will be adjusted according to a 75% 
smaller effect in these subjects. For the 10% of the subjects with missing data, the non-inferiority 
margin of 0.4% for HbA1c is added to the imputed values, when testing for non-inferiority. The 
adjusted treatment effects for testing non-inferiority (HbA1c oral semaglutide versus liraglutide 
only) and superiority are as described below:
!
Non-inferiority 
–
0.8×TE + 0.2×TE×0.25 + non-inferiority margin×0.1
!
Superiority
–
0.8×TE + 0.2×TE×0.25
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
11 of 30
Table 2–1
Assumptions used in the sample size calculation
Comparator
Parameter
Treatment effect 
(TE)
Adjusted TE, 
non-inferiority
Adjusted TE, 
superiority
Standard 
deviation 
Non-
inferiority 
margin
Placebo
HbA1c 
−1.0%
−0.85%
1.1%
Liraglutide
HbA1c
0%
+0.04%
0%
1.1%
0.4%
Placebo
Body weight
−3kg
−2.55kg 
4kg
Liraglutide
Body weight
−1.5kg
−1.275kg
4kg
With the above assumptions using a 2:2:1 randomisation, allocating 276 subjects to each of the oral 
semaglutide and the liraglutide arms and allocating 138 subjects to the placebo arm, provides 90% 
power to jointly confirm HbA1c superiority of oral semaglutide vs. placebo, HbA1c non-inferiority 
of oral semaglutide vs. liraglutide, body weight superiority of oral semaglutide vs. placebo and 
body weight superiority of oral semaglutide vs. liraglutide. In total 690 subjects are planned to be 
randomised. Calculated powers for individual hypotheses are presented in Table 2–2. 
Table 2–2
Calculated powers for individual hypotheses
Comparator:
placebo
liraglutide
Statistical test:
HbA1c
superiority
Body weight
superiority
HbA1c
non-inferiority
HbA1c superiority
Body weight
superiority
Power:
> 99%
97%
97%
2%
91%
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
12 of 30
Figure 2–1
Graphical illustration of the closed testing procedure
The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA1c superiority test vs. placebo. The 
local significance level (α-local) will be reallocated if a hypothesis is confirmed according to the weight given by the 
directed edges between nodes (hypotheses).The sample size is based on the hypotheses in the dark boxes.
2.2
Definition of analysis sets
The following analysis sets will be defined:
Full analysis set (FAS): Includes all randomised subjects. Subjects in the FAS will contribute to 
the evaluation “as randomised”.
Safety analysis set (SAS): Includes all subjects exposed to at least one dose of trial product. 
Subjects in the SAS will contribute to the evaluation “as treated”.
Per protocol (PP) analysis set: Includes all subjects in the FAS who fulfils the following criteria
!
have not violated any inclusion criteria
!
have not fulfilled any exclusion criteria
!
have a baseline HbA1c measurement
!
is exposed to trial product and have at least one valid HbA1c measurement while on treatment 
without rescue medication at or after week 14
Subjects in the PP analysis set will, as in the SAS, contribute to the analysis “as treated”.
 = 0
HbA1c (%)
Non-inferiority vs. liraglutide
 = 0
HbA1c (%)
Superiority vs. liraglutide
 = 0
Body weight (kg)
Superiority vs. liraglutide
1
1 2

1
1
 = 0.05
HbA1c (%)
Superiority vs. placebo
 = 0
Body weight (kg)
Superiority vs. placebo
1 2

1
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
13 of 30
Data selections and observation periods
Unless subjects withdraw their informed consent, data collection will continue for the full duration 
of the trial. The full duration of the trial is defined as up to and including
!
the follow-up visit (V14) for subjects on trial product
!
the latest occurring visit of the end-of-treatment visit (V13) or the follow-up premature 
discontinuation visit (V14A), for subjects who have discontinued trial product prematurely.
Subjects and data to be used in an analysis will be selected in a two-step manner.
!
Firstly, subjects will be selected based on the specified analysis set
!
Secondly, data points on the selected subjects from the first step will be selected based on the 
specified observation period
Definition of the observation periods:
In-trial: This observation period represents the time period where subjects are considered to be in 
the trial, regardless of discontinuation of trial product or initiation of rescue medication. The in -trial 
observation period starts at randomisation (as registered in the IWRS) and ends at the date of
!
the last direct subject-site contact, which is scheduled to take place 5 week after planned last 
dose of trial product at the follow-up visit. 
!
withdrawal for subjects who withdraw their informed consent
!
the last subject-investigator contact as defined by the investigator for subjects  who are lost 
to follow-up
!
death for subjects who dies before any of the above 
On-treatment: This observation period represents the time period where subjects are considered 
treated with trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. For adjudicated events, ECGs, eye examination category, anti-
semaglutide antibodies, and AEs including hypoglycaemic episodes, the observation period ends at 
the first date of any of the following:
!
the follow-up visit (V14)
!
the follow-up prematurely discontinuation visit (V14A)
!
the last date on trial product +38 days (5 weeks follow-up period + 3 days visit window)
!
the end-date for the in-trial observation period
The follow-up visit is scheduled to take place 5 weeks after the last date on trial product 
corresponding to approximately five half-lives of oral semaglutide. The visit window for the follow-
up visit is +3 days.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
14 of 30
For efficacy and other safety assessments (laboratory assessments, physical examination and vital 
signs) the observation period ends at the last date on trial product +3 days. This will be used in 
order to ensure specificity to reversible effects of treatment
On-treatment without rescue medication: This observation period is a subset of the on-treatment 
observation period, where subjects are considered treated with trial product, but has not initiated 
any rescue medications. The on-treatment without rescue medication observation period starts at 
first date on trial product and the observation period ends at the first date of any of the following:
!
the last dose of trial product +3 days
!
initiation of rescue medication
The in-trial observation period will be the primary observation period when estimating the primary 
estimand. The on-treatment without rescue medication observation period will be the primary 
observation period when estimating the secondary estimand. The on-treatment observation period 
will be considered supportive for evaluating efficacy. Safety will be evaluated based on the in-trial 
and the on-treatment observation periods.
Data points collected outside an observation period will be treated as missing in the analysis.
Baseline data will always be included in an observation period. For adjudicated events, the onset 
date will be the EAC adjudicated onset date. 
Before data are locked for statistical analysis and the randomisation code is broken, a review of all 
data will take place. Any decision to exclude either a subject or single observations from the 
statistical analysis is the joint responsibility of the members of the Novo Nordisk study group. 
Exclusion of data from analyses should be used restrictively, and normally no data should be 
excluded from the FAS. The subjects or observations to be excluded, and the reasons for their 
exclusion must be documented and signed by those responsible before database lock. The subjects 
and observations excluded from analysis sets, and the reason for this, will be described in the 
clinical trial report.
Confirmatory hypotheses  
For the primary HbA1c endpoint and the confirmatory secondary body weight endpoint the 
following confirmatory one-sided hypotheses are planned to be tested for oral semaglutide versus 
placebo (superiority) and oral semaglutide versus liraglutide (non-inferiority and superiority). Let 
the mean treatment difference be defined as μ = (oral semaglutide minus placebo or oral 
semaglutide minus liraglutide):
!
HbA1c non-inferiority, using a non-inferiority margin of 0.4% (only vs. liraglutide) 
o
H0: μ ≥ 0.4% against Ha: μ < 0.4%
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
15 of 30
!
HbA1c superiority
o
H0: μ ≥ 0.0% against Ha: μ < 0.0%
!
Body weight superiority
o
H0: μ ≥ 0.0kg against Ha: μ < 0.0kg
Operationally, the hypotheses will be evaluated by two-sided tests.
Multiplicity and criteria for confirming hypotheses
The type I error for testing the five confirmatory hypotheses related to the HbA1c and body weight 
endpoints will be preserved in the strong sense at 5 % (two-sided) using the weighted Bonferroni-
based closed testing procedure described in Bretz et al. (2011)1 and outlined in Figure 2–1. 
The first hypothesis to be tested is superiority of HbA1c versus placebo. It will be tested at the 
overall significance level (5 %) while allocating 0 % local significance level to the remaining 
hypotheses. For this hypothesis, and in general, if a hypothesis is confirmed the significance level 
will be reallocated according to the weight and the direction of the edges going from the confirmed 
hypothesis to the next hypotheses as specified in Figure 2–1. Each of the following hypotheses will 
be tested at their local significance level (α-local). This process will be repeated until no further 
hypotheses can be confirmed. 
Non-inferiority and/or superiority will be considered confirmed if the mean treatment difference is 
supporting the corresponding alternative hypothesis and the two-sided p-value from the primary 
analysis of the primary estimand is strictly below its local two -sided significance level as defined by 
the closed testing procedure in Figure 2–1. This is equivalent to using a one-sided p-value (nominal 
α = 0.025) and a one-sided 2.5 % overall significance level in the closed testing procedure.
2.3
Primary endpoint
The primary endpoint is change from baseline to week 26 in HbA1c.
2.3.1
Primary analysis for the primary estimand 
The primary estimand will be estimated based on the FAS using week 26 measurements from the 
in-trial observation period. The primary statistical analysis will be a pattern mixture model using 
multiple imputation to handle missing data assuming that the missing data mechanism is missing at 
random (MAR) within the groups used for imputation. Imputation of missing data at week 26 will 
be done within 6 groups of subjects defined by randomised treatment arm, and whether subjects at 
week 26 (i) have discontinued treatment or initiated rescue medication or (ii) are still on treatment 
and have not initiated rescue medication. It is hereby assumed that the likely values of what the 
missing data would have been if available are best described by information from subjects who at 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
16 of 30
week 26 are similar in terms of randomised treatment arm and treatment adherence/rescue 
medication status.
Missing values for each group will be imputed as follows:
!
An analysis of covariance (ANCOVA) with stratification factor and region as cate gorical fixed 
effects and baseline HbA1c measurement as a covariate will be fitted to observed values of the 
change from baseline in HbA1c at week 26.
!
The estimated parameters for location and dispersion will be used to impute 1000 values for 
each subject with missing week 26 data based on stratification factor and region as categorical 
and baseline HbA1c. Thus, 1000 complete data sets will be generated including observed and 
imputed values.
In the statistical analysis models the variable region is included as a categorical fixed effect. The 
regions to be used in the statistical analyses are defined as Europe, North America, South America 
and Asia. When addressing the treatment policy estimand, the imputation is to be done within 
groups defined by randomised treatment and treatment adherence at time of evaluation. The number 
of subjects in the groups who at time of evaluation (week 26 and 52) have discontinued trial product 
or initiated rescue medication are expected to be relatively low. Therefore, t he region variable 
included in the imputation model will be reduced in levels avoiding estimation problems due to 
sparse data. The regions to be used in these imputations are defined as North America and Other 
regions.
Analysis used for confirming superiority versus placebo/liraglutide at week 26:
For each of the 1000 (now complete) imputed data sets, the change from baseline to week 26 will 
be analysed using an ANCOVA with treatment, stratification factor and region as categorical fixed 
effects and baseline HbA1c as covariate. The results obtained from analysing the datasets will be 
combined using Rubin’s rule3 to draw inference.
Analysis used for confirming non-inferiority versus liraglutide at week 26:
Prior to analysing the data using the same model and approach as used for confirming superiority 
(see above), a value of 0.4% (the non-inferiority margin) will be added to imputed values at week 
26 for the oral semaglutide treatment arms only4. For evaluating non-inferiority versus liraglutide an 
unadjusted two sided p-value for testing no difference from the non-inferiority margin will be 
presented.
2.3.2
Primary analysis for the secondary estimand
The secondary estimand will be estimated based on the FAS using post-baseline measurements up 
to and including week 26 from the on-treatment without rescue medication observation period. The 
primary analysis for the secondary estimand will be a Mixed Model for Repeated Measurements 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
17 of 30
(MMRM). A restricted maximum likelihood (REML) will be used. The model will include all post 
baseline HbA1c measurements collected at scheduled visits up to and including week 26 as 
dependent variables. The independent effects included in the model will be treatment, stratification 
factor and region as categorical fixed effects and baseline HbA1c as a covariate, all nested within 
visit. An unstructured covariance matrix for HbA1c measurements within the same subject will be 
employed, assuming measurements from different subjects are independent. 
The MMRM is a well-established method that accounts for the uncertainty pertaining to missing 
data. This analysis assumes that the missing data mechanism is MAR. Under this assumption the
statistical behaviour of the missing data (given the observed responses and model fixed effects and 
covariates) is assumed to be same as the observed data.
For subjects who do not have post-baseline assessments for planned visits available in the on-
treatment without rescue medication period, the baseline value will be carried forward to the first 
planned visit to ensure that all randomised subjects will contribute to the statistical analysis.
2.3.3
Sensitivity analyses
To investigate the sensitivity of the primary analysis results, complementary and separate analyses 
will be performed for the primary and secondary estimand. In line with EMA recommendations5
and with a report from the US National Research Council6, these analyses will primarily evaluate 
the sensitivity of the results due to the impact of missing data. Since conservatism, i.e. avoiding bias 
in favour of oral semaglutide, depends on the context, separate sensitivity analyses will be made for 
non-inferiority and superiority testing.
The evaluation of the robustness of the primary analysis results will primarily be based on a pattern 
mixture model approach using multiple imputation. An overview of the sensitivity analyses for each 
of the estimands are specified below followed by a more detailed description of the three different 
pattern mixture models used. Finally, three additional sensitivity analyses for the primary analysis 
will be described that are not based on the pattern mixture model approach (see section 2.3.3.1).
Sensitivity analyses for the primary estimand
The estimation of the primary estimand will be repeated using the following sensitivity analyses: 
!
A comparator multiple imputation analysis based on FAS using the in-trial observation period 
(superiority).
!
A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the in-trial observation period (superiority).
!
A tipping-point multiple imputation analysis based on FAS using the in-trial observation period 
(non-inferiority and superiority).
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
18 of 30
Sensitivity analyses for the secondary estimand
The estimation of the secondary estimand will be repeated using the following sensitivity analyses:
!
A tipping-point multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period (non-inferiority and superiority).
2.3.3.1
Pattern mixture models
Common for the three pattern mixture model sensitivity analyses is that they all aim to stress-test 
the primary HbA1c results by changing the assumptions for part or all missing data in the oral 
semaglutide treatment arm, while maintaining the missing data assumption for the comparator 
(placebo or liraglutide depending on the hypothesis). 
!
Comparator multiple imputation analysis: In this sensitivity analysis missing data at week 
26 for all subjects will be imputed to resemble the distribution of the week 26 values 
observed in the comparator arm. In effect this imputation approach removes the treatment 
difference between oral semaglutide and comparator for all subjects randomised to oral 
semaglutide, given that oral semaglutide is better than the comparator. Due to the potential 
lack of sensitivity for testing non-inferiority this sensitivity analysis will only be used to 
evaluate the robustness of HbA1c superiority conclusion.
!
Comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely: In this sensitivity analysis missing data at week 26 for subjects who 
discontinue oral semaglutide treatment due to treatment related AE(s) will be imputed to 
resemble the distribution of the week 26 values observed in the comparator arm. Treatment 
related AEs are defined as AEs classified as possible or probable related to trial product as 
reported by the investigator. In effect this imputation approach removes the treatment 
difference between oral semaglutide and the comparator for this selected group of subjects 
randomised to oral semaglutide. This sensitivity analysis is less conservative as compared to 
the first sensitivity analysis. Due to the potential lack of sensitivity for testing non-inferiority 
this sensitivity analysis will only be used to evaluate the robustness of HbA1c superiority 
conclusion.
!
Tipping-point multiple imputation analysis: In this sensitivity analysis, missing data will 
first be imputed according to the primary analysis. Secondly, for the oral semaglutide 
treatment arm a penalty will be added to the imputed values at week 26. The approach is to 
gradually increase this penalty until the HbA1c conclusion from the primary analysis is 
changed. The specific value of the penalty that changes the conclusion will be used to 
evaluate the robustness of the primary analysis result. This sensitivity analysis will be used 
for evaluating the robustness of the HbA1c non-inferiority and superiority conclusions.
2.3.3.2
Other sensitivity analyses
The following additional sensitivity analys is will be specified
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
19 of 30
Per-protocol analysis: This sensitivity analysis will be based on the per-protocol analysis set. Data 
from the on-treatment without rescue medication observation period will be analysed using the 
primary analysis approach for the secondary estimand. This sensitivity analysis will be used to 
evaluate the robustness of the HbA1c non-inferiority conclusions.
2.3.3.3
Assessment of sensitivity analyses
The results from the sensitivity analyses will be collectively used to interpret the robustness of the 
trial results for HbA1c. Due to the large number of sensitivity analyses and their inherent 
conservative nature, it will not be a requirement that all confirmatory hypotheses are consistently 
confirmed across the sensitivity analyses. Thus, no absolute success criteria will be pre-defined for 
each sensitivity analysis. The sensitivity results in totality will be used to substantiate the credibility 
of the trial results.  
2.4
Secondary endpoints
2.4.1
Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) will be a confirmatory secondary endpoint. 
The primary and secondary estimands will be estimated using the same approaches as described for 
the primary HbA1c endpoint. Body weight will only be tested for superiority. Baseline body weight 
will be used as a covariate instead of baseline HbA1c in both the multiple imputation and analysis 
model.
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding hypothesis and the two-sided p-value from the analysis of the primary estimand is 
strictly below its local two -sided significance level resulting from the closed testing procedure in 
Figure 2–1. Sensitivity analyses similar to the ones pre-specified for testing superiority for the 
primary HbA1c endpoint will be made to evaluate the robustness of the body weight results.
2.4.2
Supportive secondary endpoints
2.4.2.1
Efficacy endpoints
The below supportive secondary efficacy endpoints will be evaluated for
!
the primary estimand based on FAS using the in-trial observation period
!
the secondary estimand based on FAS using the on-treatment without rescue medication 
observation period
No sensitivity analyses are planned for these. 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
20 of 30
Continuous efficacy endpoints
Change from baseline to week 52 in:
!
HbA1c
!
Body weight (kg)
Change from baseline to week 26 and week 52 in:
!
Body weight (%)
!
FPG
!
BMI
!
Waist circumference
!
Fasting lipid profiles (total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, 
triglycerides, free fatty acids)
BMI will be calculated based on body weight and height based on the formulae:
BMI kg/m2 = body weight (kg)/(Height (m) x Height (m)) or (kg/m2 = [lb/in2 x 703])
Change from baseline to week 26 and week 52 in 7-point SMPG profile:
!
Mean 7-point profile; defined as the area under the profile, calculated using the trapezoidal 
method, divided by the measurement time
!
Mean postprandial increment (over all meals)
The above continuous endpoints will be analysed separately using similar model approaches as for 
the primary endpoint with the associated baseline response as a covariate. Fasting lipid profile 
endpoints will be log-transformed prior to analysis with the associated log-transformed baseline 
value as a covariate.
For evaluation of the primary estimand the analysis will be performed separately for week 26 and 
week 52. For the analysis at week 52, the imputation of missing data will be further differentiated 
by whether subjects have discontinued trial product or initiated rescue medication prior to week 26 
or at/after week 26. This will result in imputation of missing data within 9 groups of subjects 
instead of the 6 groups as described for the week 26 evaluation in Section 2.3.1. If less than 5 
subjects have available data in one of the 9 groups, the imputation will be made within the 6 groups 
specified for the primary evaluation. The frequency of missing data is expected to be slightly larger 
at week 52 compared to week 26. The rate of missing data is expected to decline over time. 
For evaluation of the secondary estimand the MMRM based primary analysis will include all 
scheduled post-baseline measurement up to and including week 52. From this model the estimated 
treatment differences (ratios) will be presented at week 26 (except for HbA1c and body weight), and 
week 52 with 95 % confidence intervals and two-sided p-values for test of no difference. The 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
21 of 30
baseline will not be carried forward to first planned visit if the first planned visit falls later than 8 
weeks after randomisation.
Binary efficacy endpoints
If a subject after week 26 achieves (yes/no):
!
HbA1c < 7.0% (53 mmol/mol) (ADA) target
!
HbA1c ≤ 6.5% (48 mmol/mol) (AACE) target
!
Weight loss ≥ 5%
!
Weight loss ≥ 10%
!
HbA1c < 7.0% (53 mmol/mol) without hypoglycaemia (severe or BG-confirmed symptomatic 
hypoglycaemic episodes) and no weight gain
!
HbA1c reduction ≥ 1%-point (10.9 mmol/mol) and weight loss ≥ 3%
When addressing the treatment policy estimand the ‘no hypoglycaemia’ component of the 
composite endpoint will also include non-treatment-emergent events of severe or BG-confirmed 
symptomatic hypoglycaemia as data collected regardless of discontinuation of trial product or 
initiation of rescue medication(s) is used. The above six binary endpoints will also be evaluated 
after week 52.
Missing data for the above six binary endpoints will be accounted for using multiple imputation 
techniques. For the treatment policy estimand the binary endpoints will be calculated as 
dichotomisations of the 1000 multiple imputations underlying the primary MI analysis. For the 
hypothetical estimand the model will be implemented using a sequential imputation approach 
assuming MAR. The imputation will be done as described below:
!
Intermittent missing values in the on-treatment without rescue observation period will be
imputed using a Markov Chain Monte Carlo (MCMC) method, in order to obtain a monotone 
missing data pattern. This imputation is done for each treatment group separately and a 1000 
copies of the data set will be generated.
!
A sequential regression approach for imputing monotone missing values at planned visits will 
be implemented starting with the first visit after baseline and sequentially continuing to the 
planned end of treatment visit. For each treatment group an analysis of covariance model will be 
used to impute missing values at each planned visit. The model will include stratification factor  
and region as categorical effect and baseline and post-baseline values prior to the visit in 
question as covariates.
The binary endpoints will be derived as dichotomisations of the 1000 multiple imputations from the 
sequential imputation.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
22 of 30
For both estimands, each of the 1000 data sets will be analysed using a logistic regression model 
with treatment, stratification factor and region as fixed effects and baseline value as covariate (i.e. 
baseline HbA1c for binary HbA1c endpoints, baseline body weight for body weight endpoints and 
both HbA1c and baseline body weight for the composite endpoints that comprises both parameters). 
The results will be combined using Rubin’s rule3 to draw inference.
For the composite endpoints involving both HbA1c and body weight the imputed data sets will be 
combined by imputation number.
Time to event endpoints
!
Time to additional anti-diabetic medication (to support the treatment policy estimand)
!
Time to rescue medication (to support the hypothetical estimand)
Definition of additional anti-diabetic medication: New anti-diabetic medication and/or 
Intensification of anti-diabetic medication initiated at or after randomisation and before (planned) 
end-of-treatment.
Definition of rescue medication: New anti-diabetic medication and/or Intensification of anti-
diabetic medication initiated at or after randomisation and before last date on trial product. This is a 
subset of the additional anti-diabetic medication. 
The following rules will be applied based on the concomitant medication data reported by the 
investigator, to determine whether or not the recorded anti-diabetic medication is 1. New anti-
diabetic medication or 2. Intensification of anti-diabetic medication
1. New anti-diabetic medication: Anti-diabetic medication (4th-level ATC code) that is initiated 
after randomisation and is new compared to the anti-diabetic background medication at 
randomisation (see above) and with a dosing duration of more than 21 days 
2. Intensification of anti-diabetic medication: A more than 20% increase in the dose of anti-
diabetic medication after randomisation as compared to the anti-diabetic medication dose at 
randomisation (5th-level ATC code not changed) and with a dosing duration of more than 21 
days.
More than 21 days is chosen as a minimum duration for the medication to be considered as ‘anti-
diabetic medication’. This threshold is set to ensure that the short -term durations (i.e. ≤ 21 days) of 
anti-diabetic medication (e.g. in connection with concurrent illnesses) are not included because such 
intensifications are not likely to affect the effect endpoints.
Treatment policy estimand: Time to additional anti-diabetic medication
The treatment policy estimand is addressed for the FAS using the in-trial observation period and 
additional anti-diabetic medication will be considered an event regardless of treatment adherence. 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
23 of 30
Time from randomisation to additional anti-diabetic medication will be analysed using a Cox 
proportional hazards model with treatment, stratification factor and region as categorical fixed 
effects and baseline HbA1c as a covariate. From this analysis the estimated Hazard ratios between 
oral semaglutide versus placebo and oral semaglutide vs liraglutide together with associated two-
sided 95% CIs and unadjusted two-sided p-values will be presented. The analysis aims to address 
the need of additional anti-diabetic medication regardless of this is due to lack of effect or 
tolerability. Switch to other anti-diabetic treatment is therefore also considered an event and 
withdrawn subjects or subject lost to follow-up will be considered as having an event on the day of 
withdrawal. Subjects will be censored on the day before planned end of treatment visit. 
Hypothetical estimand: Time to rescue medication
The hypothetical estimand is addressed for the FAS using the on-treatment without rescue 
medication observation period. Time from first dose of trial product to initiation of rescue 
medication will be analysed using the same model as described above. The analysis aims to address 
lack of effect and only initiation of rescue medication as add-on to randomised treatment is 
considered an event. Switch to other anti-diabetic treatment is not considered an event and as a 
consequence subjects will be censored on the day before date of last trial product. Potential events 
occurring between randomisation and first date on trial product will be included in the analysis as 
events at day 0, in order to count all events of rescue medication.
2.4.2.2
Safety endpoints
The safety endpoints will be evaluated based on SAS using the on-treatment observation period and 
the in-trial observation period unless otherwise stated. The following endpoints are used to support 
the safety objective:
Adverse events 
!
Number of treatment emergent adverse events (TEAEs) during exposure to trial product, 
assessed up to approximately 57 weeks
All AEs will be coded using version 20.1 of the Medical Dictionary for Regulatory Activities 
(MedDRA) coding. 
A treatment-emergent AE is defined as an AE with onset in the on-treatment observation period 
(see definition of observation periods in Section 2.2).
TEAEs will be summarised in terms of the number of subjects with at least one event (N), the 
percentage of subjects with at least one event (%), the number of events (E) and the event rate per 
100 patient years of observation time (R) for the on-treatment observation period. Supportive 
summaries of AEs will be made for the in-trial observation period. The development over time in 
gastrointestinal AEs will be presented graphically.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
24 of 30
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!
Amylase
!
Lipase
!
Pulse
!
Systolic blood pressure
!
Diastolic blood pressure
The above safety endpoints will be evaluated using the primary analysis for the primary estimand 
based on SAS using the in-trial observation period and using the primary analysis for the secondary 
estimand based on SAS using the on-treatment observation period. Endpoints will be analysed 
separately as described above for continuous efficacy endpoints. Results will be presented at week 
26 and at week 52. Amylase and lipase endpoints will be log-transformed prior to analysis with the 
associated log-transformed baseline value as a covariate.
Change from baseline to week 26 and week 52 in:
!
ECG evaluation
!
Physical examination (week 52 only)
!
Eye examination category (week 52 only)
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!
Anti-semaglutide binding antibodies
!
Anti-semaglutide neutralising antibodies
!
Anti-semaglutide binding antibodies cross reacting with native GLP-1
!
Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 57 weeks:
!
Anti-semaglutide binding antibody levels
Other safety assessments
Change from baseline to week 26 and week 52 in:
!
Haematology 
!
Biochemistry (except for amylase and lipase)
!
Calcitonin
The above safety endpoints and assessments will be summarised descriptively by treatment arm and 
visit. Categorical safety endpoints and assessments will be summarised as counts and relative 
frequencies. Calcitonin will also be presented by gender. 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
25 of 30
Hypoglycaemia
!
Number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes 
during exposure to trial product, assessed up to approximately 57 weeks
!
Treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes during 
exposure to trial product, assessed up to approximately 57 weeks (yes/no) 
Classification of hypoglycaemia:
Hypoglycaemic episodes will be summarised for the SAS and the on-treatment observation period 
only.
Treatment-emergent: hypoglycaemic episodes will be defined as treatment-emergent if the onset of 
the episode occurs within the on-treatment observation period (see definition of observation periods 
in Section 2.2).
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05.59 both inclusive.
Hypoglycaemic episodes are classified according to the Novo Nordisk classification of 
hypoglycaemia and the ADA classification of hypoglycaemia (see Figure 2–2).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L 
(56 mg/dL)7. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-
off point in the definition of BG-confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification:
Severe or BG-confirmed symptomatic hypoglycaemia: An episode that is severe according to the 
ADA classification8 or BG-confirmed by a PG value < 3.1 mmol/L (56 mg/dL) with symptoms 
consistent with hypoglycaemia. 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
26 of 30
ADA classification of hypoglycaemia8
!
Severe hypoglycaemia: An episode requiring assistance of another person to actively administer 
carbohydrate, glucagon, or take other corrective actions. PG concentrations may not be 
available during an event, but neurological recovery following the return of PG to normal is 
considered sufficient evidence that the event was induced by a low PG concentration.
!
Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!
Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!
Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the 
typical symptoms of hypoglycaemia with a measured PG concentration > 3.9 mmol/L 
(70 mg/dL) but approaching that level.
!
Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia 
are not accompanied by a PG determination but that was presumably caused by a PG 
concentration ≤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
episode 
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
Asymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemia
No
Yes
No measurement 
with symptoms
PG > 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
No
Yes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 2–2
ADA classification of hypoglycaemia
PG: plasma glucose. SMPG: Self-measured plasma glucose
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
27 of 30
Data on treatment-emergent hypoglycaemic episodes will be presented in terms of the number of 
subjects with at least one episode, the percentage of subjects with at least one episode (%), the total 
number of episodes and the episode rate per 100 patient years of observation time.
Analysis of severe or BG-confirmed symptomatic hypoglycaemic endpoints
Due to the sparse data the pre-specified analyses of severe or BG-confirmed symptomatic 
hypoglycaemia will not be performed.
2.5
Interim analysis 
No interim analyses will be performed before the database is locked.
2.6
Patient reported outcomes
Change from baseline to week 26 and week 52 in:
!
DTSQs: individual items and treatment satisfaction score (6 of the 8 items summed)
The PRO endpoint will be evaluated using the primary analysis for the primary estimand based on 
FAS using the in-trial observation period and using the primary analysis for the secondary estimand 
based on FAS using the on-treatment without rescue medication period. The individual items and 
the treatment satisfaction score will be analysed separately as the other continuous efficacy 
endpoints with the associated baseline response as a covariate.
2.6.1
Diabetes Treatment Satisfaction Questionnaire – status version (DTSQs)
The DTSQs questionnaire will be used to assess subject’s treatment satisfaction. This questionnaire 
contains 8 items that measures the treatment satisfaction for subjects’ diabetes treatment in terms of 
convenience, flexibility and general feelings regarding treatment.
The DTSQs items are scored on a 7-point graded response scale ranging from 6 to 0. Higher scores 
indicate higher levels of treatment satisfaction for DTSQs items 1, 4 -8. For items 2 and 3 a higher 
score indicates a higher patient perceived experience of hyperglycaemia and hypoglycaemia,
respectively. Thus, lower scores indicate a perception of blood glucose levels being “none of the 
time” unacceptably high (item 2) or low (item 3). If data are missing for an item, the item score is 
treated as missing. No reversal of item scores will be done.
The domain score of total treatment satisfaction (total treatment satisfaction score) is computed by 
adding the six items scores 1, 4-8. The score has a minimum of zero and a maximum of 36. A 
higher treatment satisfaction score indicates a higher level of treatment satisfaction. No reversals of 
items are necessary prior to computing the treatment satisfaction score.
Missing data at instrument level will be handled in the following way. For computing the total 
treatment satisfaction score consisting of six items, missing data from one item is allowed. 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
28 of 30
Scoring algorithm:
!
Step 1: Sum the existing item scores (i.e. either 5 or 6 item scores)
!
Step 2: Divide this sum by the number of existing item scores
!
Step 3: Multiply by 6 (the number of items in the total treatment satisfaction scale)
Half of a standard deviation (SD) of the baseline DTSQs item and domain scores were used as 
distribution-based approach defining the responder thresholds. The thresholds are derived from 
baseline DTSQs data across trial arms. Responder analyses will be based on the responder threshold 
values and are described in section 2.6.2.
2.6.2
Responder analyses
Responder analyses will be conducted for both estimands, for the same time points that are defined 
for the analyses of PRO endpoint (see protocol) and separately for each score.
For descriptive statistics the following subject responder categorization is applied for all relevant 
time points and scores:
!
Responder - improvement: Individual change from baseline in score ≥ positive responder 
threshold 
!
Non-responder - no change: Individual change from baseline in score  > negative responder 
threshold value and < positive responder threshold value
!
Non-responder - worsening: Individual change from baseline in score  ≤ negative responder 
threshold value
The following binary subject responder definition is applied for all relevant time points and scores:
!
Responder: Individual change from baseline in score ≥ positive responder threshold
!
Non-responder: Individual change from baseline in score < positive responder threshold
The binary responder endpoints will be analysed as the other supportive secondary binary efficacy 
endpoints. Estimated proportions and differences in proportions will be reported in addition to odds 
and odds ratios.
The responder analyses will not be included in the CTR, but in a separate PRO report.
3
Changes to the statistical analyses planned in the protocol
The main analyses were described in the protocol for the trial NN9924-4224. However, 
clarifications, more detailed descriptions of endpoints and analyses are provided in this SAP. The 
changes from the protocol of NN9924-4224 are summarised below:
!
‘On-treatment without rescue medication’ added to the criteria ‘is exposed to trial product 
and have at least one HbA1c measurement at or after week 14’ for Per protocol analysis set.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
29 of 30
!
The primary and secondary estimands have changed names from de-facto and de-jure to 
treatment policy and hypothetical, respectively.
!
The MMRM sensitivity analysis of the primary estimand has been omitted in section 2.3.3. 
It is considered sufficient to keep the three current sensitivity analyses to stress test the 
primary results.
!
For the MMRM analyses, it is specified that for subjects who do not have post-baseline 
assessments for planned visits available in the on-treatment without rescue medication 
period, the baseline value will be carried forward to the first planned visit, if the first 
planned visit do not fall later than 8 weeks after randomisation, to ensure that all randomised 
subjects will contribute to the statistical analyses. 
!
The three MI sensitivity analyses of the secondary estimand have been omitted in section 
2.3.3. It is considered sufficient to keep the tipping point sensitivity analysis for the 
secondary hypothetical estimand as it can be considered as a progressive stress-testing to 
assess how severe departures from MAR must be in order to reverse the conclusions from 
the primary MMRM analysis used to address the hypothetical estimand.
!
The LOCF sensitivity analysis specified in the trial protocol (section 17.3.3.2) has been 
omitted, as it is not realistic that subjects with missing data would have had stable results 
from the point of drop out to trial completion.
!
The complete case analysis is based on the assumption that missing data are MCAR, this 
assumption seem questionable and since a per-protocol analysis is performed, this extra 
sensitivity analysis is excluded.
!
The statistical analyses of the two binary effect endpoints (HbA1c reduction ≥ 1%-point 
(10.9 mmol/mol) and body weight loss ≥ 3%) have been omitted, because they are being 
analysed as a part of the two composite binary effect endpoints.
!
For the binary efficacy endpoints, it has been specified how missing data in the analyses for 
the hypothetical estimand will be imputed using a sequential imputation approach assuming 
MAR.
!
A clarification of the ‘without hypoglycaemia’ component in composite binary endpoints 
has been added.
!
The definitions of initiation of rescue medication and additional anti -diabetic medication 
used for the time-to-event endpoints as well as the accompanying statistical analyses have 
been further clarified.
!
Standard laboratory parameters have been downgraded from ‘endpoints’ to ‘assessments’ 
because these parameters are included to ensure that the investigator can monitor the 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
25 May 2018
Novo Nordisk
Trial ID: NN9924-4224
Version:
1.0
UTN: U1111-1176-6029
Status:
Final
EudraCT no.: 2015-005210-30
Page:
30 of 30
individual subject and to allow for detection of potential safety signal on a trial-level that is 
not reflected in adverse event reporting.
!
In section 2.6 details on the analyses of DTSQs endpoints have been included.
4
References
1. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches 
for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. 
Biometrical Journal. 2011;53(6):894-913.
2. Rohmeyer K, Klinglmueller F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. 3 Oct 2014.
3. Little RJA, Rubin DB. Statistical analysis with missing data: New York: John Wiley & Sons. 
1987.
4. Koch GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
5. Committee for Medicinal Products for Human Use (CHMP). Guideline on Missing Data in 
Confirmatory Clinical Trials. EMA/CPMP/EWP/1776/99 Rev. 1. 2 Jul 2010.
6. National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press. 2010.
7. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose 
counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 
1987;79(3):777-81.
8. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and 
diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine 
Society. Diabetes Care. 2013;36(5):1384-95.
9. Bradley C. Diabetes Treatment Satisfaction Questionnaire. In: Bradley C, editor. Handbook of 
Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers; 1994. p. 111-32
CONFIDENTIAL